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ABSTRACT 
Carbonyl groups of reducing sugars or several dicarbonyl compounds 
can nonenzymatically react with the free amino groups of biomolecules, in a 
Maillard-type reaction, to form a polymorphic group of compounds referred to 
as advanced glycation end products (AGEs). It has been known since 
several decades that DNA and its nucleobases also undergo similar 
reactions leading to the generation of DNA-advanced glycation endproducts 
(DNA-AGEs). Several DNA-AGEs have been isolated from incubation 
mixtures of DNA with sugars and dicarbonyl compounds and their structures 
identified. Amongst them N -(1-carboxyethyl)-2'- deoxyguanosine (CEdGA.s) 
has been identified as the major marker for glycation in DNA. Furthermore it 
was shown that DNA-AGEs are also formed in cultured cells and thus, in 
vitro experiments revealed their mutagenic potential. DNA is also known to 
be glycated in vivo and DNA-glycation products such as CEdGA.e have been 
detected in human tissues and urine. 
Although the nonenzymatic glycation of biomolecules occurs under 
normal conditions, in some metabolic disorders such as diabetes and 
uraemia, enhanced formation and accumulation of AGEs occurs and 
contributes to many of the long-term complications associated with the 
diseases. The rapid formation and accumulation of AGEs is caused not only 
by D-glucose, but also by other more potent glycators like fructose and 
ribose as well as certain sugar-derived dicarbonyl intermediates such as 
glyoxal and methyglyoxal (MG). 
Thus, in the present study a comparison of the glycation potential of 
reducing sugars such as fructose and ribose with glucose has been made. In 
vitro incubations conducted with pBr322 plasmid DNA showed that both 
fructose and ribose induce transformation of the plasmid from the. 
supercoiled forni to the open circular and linear forms wherein ribose was 
found to be the most active. In case of ribose, the transformation to linear 
form was visible as early as 3 days and the super coiled fomn completely 
disappeared when the incubation was extended to seven days. When DNA-
sugar incubations were carried out in the presence of EDTA, the extent of 
plasmid transformation was reduced. The metal ion chelator, Diethylene 
triamine penta-acetic acid (DETAPAC), was more effective in restricting DNA 
damage induced by various sugars. 
In agreement with the studies of Khalifah et al.(1996;1999), it was 
observed that pBr322 samples subjected to interrupted incubation, in 
absence of the sugar showed more marked plasmid transformation as 
compared to those incubated in presence of sugar. Similarly, DNA samples 
incubated with ribose-exposed BSA showed more rapid transformation in 
absence of sugar than in its presence. Glucose- and fructose-exposed BSA 
were less effective in this regard. 
pBr322 DNA incubated with various sugars was moderately resistant 
to digestion by restriction enzymes. DNA incubated with sugar-exposed BSA 
in absence of the sugar, showed greater resistance to digestion by Bam HI, 
Eco Rl and Hinf I as compared to those incubated with sugar-exposed BSA 
in presence of the sugar. 
In vitro incubations of 2'-deoxyguanosine (2'-dG) with 5 and 20 mM 
glucose, fructose and ribose, at pH 7.4 and 37°C resulted in the formation of 
various DNA-AGEs. Ribose produced highest levels of the AGEs followed by 
fructose and then glucose. The nucleoside-sugar incubations, revealed the 
formation of MG and glyoxal leading to MG derived 3-(2'-deoxy-p-D-erythro-
pentofuranosyl)-6, 7-dihydro-6, 7-dihydroxy-6-methyl-imidazo [2, 3-p] purin-9 
(8) one (MGdG) and glyoxal derived 3-(2'-deoxy-p-D-erythro-
pentofuranosyl)-6,7-dihydro-6, 7-dihydroxy-imidazo [2, 3-p] purin-9 (8) one 
(GdG) adducts along with the oxidation marker- 8-oxo-7,8-dihydro-2'-
deoxyguanosine (8-oxodG), which were quantified using isotopic dilution 
tandem mass spectrometry. The order of adduct formation by all the three 
sugars was GdG> 8-oxodG> CEdGA,B>MGdG. 
Further in vitro studies using the anti-glycating agents-
Aminoguanidine (AG) and DETAPAC confirmed the occurrence of the 
glycation reaction and DNA-AGE formation. AG effectively inhibited 8-oxodG 
formation by the sugars upto 14 days of incubation. However, the efficacy of 
inhibition of CEdGAB and MGdG was lost at the end of 7 days in case of 
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fructose and 2 days for ribose treated samples. AG also inhibited GdG 
formation upto 14 days in case of fructose and glucose and upto only 2 days 
in case of ribose. DETAPAC inhibited the formation of 8-oxodG and GdG 
most effectively besides inhibiting MGdG and CEdGA.B formation. This 
suggested that free radicals produced by metal-catalysed oxidation reactions 
contribute significantly towards the glycation of DNA. 
The study with calf thymus DNA showed greater formation of glycation 
adducts - MGdG, CEdGAB and GdG in samples incubated continuously with 
the sugar as compared to those subjected to interrupted incubation in 
absence of the sugar. ELISA studies using a monoclonal antibody against 
CEdGA,B showed that CEdGA,B showed a concentration and time dependent 
rise in its levels in DNA during incubation with ribose and fructose. 
A novel procedure for the concurrent synthesis of both the MG 
derived DNA-AGEs, namely MGdG and CEdGA,B was developed, which 
allowed isolation of the labile MGdG adduct alongwith the known major DNA 
glycation marker, CEdGA.e- It was demonstrated for the first time that the 
labile Schiff base molecule, MGdG persists upto 4 days of incubation. This 
facilitated its isolation and purification by anion-exchange chromatography 
and further characterization using LC-MS/MS, ^^ C and ^H-NMR. Column 
temperature had a significant effect on the elution profile of the adducts and 
the LC-MS/MS procedure was optimized for column temperature. A broad 
MGdG peak was seen at 30°C, whereas at 10°C the MGdG peak was 
effectively split into three distinct peaks. Similar, improvement in the elution 
behavior of the GdG peak was also seen at 10°C. 
Isotopic dilution tandem mass spectrometry using stable isotopic 
standards was carried out to quantify the various DNA-AGEs (MGdG, 
CEdGA.B, GdG) alongwith the oxidation marker- 8-oxodG in enzymatically 
digested DNA samples obtained from human promyelocytic leukaemia (HL-
60) cells and human mononuclear lymphocytes (MNLs) obtained from 
healthy human subjects. The level of AGEs was as follows, MGdG>8-
oxodG>GdG>CEdGA,B. 
Further studies were carried out to quantify the DNA-AGE levels in 
plasma and urine from type-2 diabetics with and without nephropathy as well 
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as in plasma of patients of End Stage Renal Disease (ESRD). This study is 
the first of its kind in which the DNA glycation and oxidation adduct levels 
have been measured in samples obtained from diabetics and ESRD patients 
using the gold standard method of isotopic dilution mass spectrometry. The 
plasma samples from type-2 diabetics showed highest MGdG levels followed 
by GdG, 8-oxodG and CEdGA,B, whereas the urinary levels were 8-
oxodG>MGdG>GdG>CEdGA,B- The adducts levels in plasma from ESRD 
patients showed a trend quite similar to that observed in plasma from Type-2 
diabetics. 
Glyoxalase enzymatic machinery is employed as a defense tool by 
various cells to protect against the damaging effect of the glycation reaction 
by oxoaldehydes. Many multidrug resistant (MDR) tumours however 
overexpress Glyoxalase I (Glo-I) to their advantage in evading anti-tumour 
drug induced apoptosis. Therefore, the effect of the cell permeable Glo-I 
inhibitor, S-p-bromobenzylglutathione cyclopentyl diester (BBGC) in inducing 
DNA-glycation in the four MDR tumour cell types was investigated. Cell 
types with Glo-I overexpression, NCI-H522 and MG63 tumour cells, were 
found to be more sensitive to the inhibitor treatment. GdG nucleotide adduct 
levels in cell line with Glo-I gene amplification (NCI-H522) and CEdGA.e 
levels in A549 (cell type without amplification) were significantly elevated 
after inhibitor treatment, but no significant increase in MGdG levels was 
evident. GdG levels in MG63 cells exposed to BBGC were also higher but 
not statistically significant. This suggested that MG adducts of proteins rather 
than DNA may trigger apoptosis and cell death in tumour cells with elevated 
Glo-I levels. 
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ABSTRACT 
Carbonyl groups of reducing sugars or several dicarbonyl compounds 
can nonenzymatically react with the free amino groups of biomolecules, in a 
Maillard-type reaction, to fonn a polymorphic group of compounds referred to 
as advanced glycation end products (AGEs). It has been known since 
several decades that DNA and its nucleobases also undergo similar 
reactions leading to the generation of DNA-advanced glycation endproducts 
(DNA-AGEs). Several DNA-AGEs have been isolated from incubation 
mixtures of DNA with sugars and dicarbonyl compounds and their structures 
identified. Amongst them N^-(1-carboxyethyl)-2'- deoxyguanosine (CEdGA,B) 
has been identified as the major marker for glycation in DNA. Furthermore it 
was shown that DNA-AGEs are also formed in cultured cells and thus, in 
vitro experiments revealed their mutagenic potential. DNA is also known to 
be glycated in vivo and DNA-glycation products such as CEdGA.e have been 
detected in human tissues and urine. 
Although the nonenzymatic glycation of biomolecules occurs under 
normal conditions, in some metabolic disorders such as diabetes and 
uraemia, enhanced formation and accumulation of AGEs occurs and 
contributes to many of the long-term complications associated with the 
diseases. The rapid formation and accumulation of AGEs is caused not only 
by D-glucose, but also by other more potent glycators like fructose and 
ribose as well as certain sugar-derived dicarbonyl intermediates such as 
glyoxal and methyglyoxal (MG). 
Thus, in the present study a comparison of the glycation potential of 
reducing sugars such as fructose and ribose with glucose has been made, in 
vitro incubations conducted with pBr322 plasmid DNA showed that both 
fructose and ribose induce transfomnation of the plasmid from the 
supercoiled forni to the open circular and linear fonns wherein ribose was 
found to be the most active. In case of ribose, the transformation to linear 
form was visible as early as 3 days and the super coiled form completely 
disappeared when the incubation was extended to seven days. When DNA-
sugar incubations were carried out in the presence of EDTA, the extent of 
plasmid transformation was reduced. The metal ion chelator, Diethylene 
triamine penta-acetic acid (DETAPAC), was more effective in restricting DNA 
damage induced by various sugars. 
In agreement with the studies of Khalifah et al.(1996; 1999), it was 
observed that pBr322 samples subjected to interrupted incubation, in 
absence of the sugar showed more marked plasmid transformation as 
compared to those incubated in presence of sugar. Similarly, DNA samples 
incubated with ribose-exposed BSA showed more rapid transformation in 
absence of sugar than in its presence. Glucose- and fructose-exposed BSA 
were less effective in this regard. 
pBr322 DNA incubated with various sugars was moderately resistant 
to digestion by restriction enzymes. DNA incubated with sugar-exposed BSA 
in absence of the sugar, showed greater resistance to digestion by Bam HI, 
Eco Rl and Hinf I as compared to those incubated with sugar-exposed BSA 
in presence of the sugar. 
In vitro incubations of 2'-deoxyguanosine (2'-dG) with 5 and 20 mM 
glucose, fructose and ribose, at pH 7.4 and 37°C resulted in the fomnation of 
various DNA-AGEs. Ribose produced highest levels of the AGEs followed by 
fructose and then glucose. The nucleoside-sugar incubations, revealed the 
formation of MG and glyoxal leading to MG derived 3-{2'-deoxy-p-D-erythro-
pentofuranosyl)-6, 7-dihydro-6, 7-dihydroxy-6-methyl-imidazo [2, 3-p] purin-9 
(8) one (MGdG) and glyoxal derived 3-(2'-deoxy-p-D-erythro-
pentofuranosyl)-6,7-dlhydro-6, 7-dihydroxy-imidazo [2, 3-p] purin-9 (8) one 
(GdG) adducts along with the oxidation mariner- 8-oxo-7,8-dihydro-2'-
deoxyguanoslne (8-oxodG), which were quantified using isotopic dilution 
tandem mass spectrometry. The order of adduct formation by all the three 
sugars was GdG> 8-oxodG> CEdGA,B>MGdG. 
Further in vitro studies using the anti-glycating agents-
Aminoguanidine (AG) and DETAPAC confirmed the occun-ence of the 
glycation reaction and DNA-AGE formation. AG effectively inhibited 8-oxodG 
formation by the sugars upto 14 days of incubation. However, the efficacy of 
inhibition of CEdGA.e and MGdG was lost at the end of 7 days in case of 
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fructose and 2 days for ribose treated samples. AG also inhibited GdG 
formation upto 14 days in case of fructose and glucose and upto only 2 days 
in case of ribose. DETAPAC inhibited the formation of 8-oxodG and GdG 
most effectively besides inhibiting MGdG and CEdGA.e formation. This 
suggested that free radicals produced by metal-catalysed oxidation reactions 
contribute significantly towards the glycation of DNA. 
The study with calf thymus DNA showed greater formation of glycation 
adducts - MGdG, CEdGA,B and GdG in samples incubated continuously with 
the sugar as compared to those subjected to interrupted incubation in 
absence of the sugar. ELISA studies using a monoclonal antibody against 
CEdGA.B showed that CEdGA,B showed a concentration and time dependent 
rise in its levels in DNA during incubation with ribose and fructose. 
A novel procedure for the concurrent synthesis of both the MG 
derived DNA-AGEs, namely MGdG and CEdGA,B was developed, which 
allowed isolation of the labile MGdG adduct alongwith the known major DNA 
glycation marker, CEdGA,B- It was demonstrated for the first time that the 
labile Schiff base molecule, MGdG persists upto 4 days of incubation. This 
facilitated its isolation and purification by anion-exchange chromatography 
and further characterization using LC-MS/MS, ^^ C and ^H-NMR. Column 
temperature had a significant effect on the elution profile of the adducts and 
the LC-MS/MS procedure was optimized for column temperature. A broad 
MGdG peak was seen at 30°C, whereas at 10°C the MGdG peak was 
effectively split into three distinct peaks. Similar, improvement in the elution 
behavior of the GdG peak was also seen at 10°C. 
Isotopic dilution tandem mass spectrometry using stable isotopic 
standards was carried out to quantify the various DNA-AGEs (MGdG, 
CEdGA,B, GdG) alongwith the oxidation marker- 8-oxodG in enzymatically 
digested DNA samples obtained from human promyelocytic leukaemia (HL-
60) cells and human mononuclear lymphocytes (MNLs) obtained from 
healthy human subjects. The level of AGEs was as follows, MGdG>8-
oxodG>GdG>CEdGA,B-
Further studies were carried out to quantify the DNA-AGE levels in 
plasma and urine from type-2 diabetics with and without nephropathy as well 
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as in plasma of patients of End Stage Renal Disease (ESRD). This study is 
the first of its kind in which the DNA glycation and oxidation adduct levels 
have been measured in samples obtained from diabetics and ESRD patients 
using the gold standard method of isotopic dilution mass spectrometry. The 
plasma samples from type-2 diabetics showed highest MGdG levels followed 
by GdG, 8-oxodG and CEdGA,B, whereas the urinary levels were 8-
oxodG>MGdG>GdG>CEdGA,B- The adducts levels in plasma from ESRD 
patients showed a trend quite similar to that observed in plasma from Type-2 
diabetics. 
Glyoxalase enzymatic machinery is employed as a defense tool by 
various cells to protect against the damaging effect of the glycation reaction 
by oxoaldehydes. Many multidrug resistant (MDR) tumours however 
overexpress Glyoxalase I (Glo-I) to their advantage in evading anti-tumour 
drug induced apoptosis. Therefore, the effect of the cell permeable Glo-I 
inhibitor, S-p-bromobenzylglutathione cyclopentyl diester (BBGC) in inducing 
DNA-glycation in the four MDR tumour cell types was investigated. Cell 
types with Glo-I overexpression, NCI-H522 and MG63 tumour cells, were 
found to be more sensitive to the inhibitor treatment. GdG nucleotide adduct 
levels in cell line with Glo-I gene amplification (NCI-H522) and CEdGA,8 
levels in A549 (cell type without amplification) were significantly elevated 
after inhibitor treatment, but no significant increase in MGdG levels was 
evident. GdG levels in MG63 cells exposed to BBGC were also higher but 
not statistically significant. This suggested that MG adducts of proteins rather 
than DNA may trigger apoptosis and cell death in tumour cells with elevated 
Glo-I levels. 
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m a iTiycTiON 
1. GENERAL INTRODUCTION 
1.1 Glycation, the non-enzymatic glycosylation. 
The term glycation is used to describe the non-enzymatic reactions of 
glucose and other reducing sugars, a-oxoaldehydes and other saccharide 
derivatives with proteins, DNA and lipids. The process involves a complex 
series of parallel and sequential reactions, often referred collectively as the 
Maillard reactions, which generate a variety of stable adducts. In the early 
1900s, Maillard and associates while studying foods exposed to high 
temperature, described a non-enzymatic browning reaction taking place 
between sugars and amino acids (Maillard and Gautier, 1912; Kaanane and 
Labuza, 1989). It however took several decades before the significance of 
the reactions in human health was recognized. Koenig et al. (1976) were the 
first to study in vivo glycation of hemoglobin and could correlate the 
circulating level of glucose with that of hemoglobinic-
It was not until 1980 that the pathophysiological relevance of the 
Maillard reaction was recognized in complications associated with diabetes, 
aging, Alzheimer's disease (Monnier et al., 1981; Munch et al., 1998; Baynes 
et al., 1999; Basta et al., 2002; Bucciarelli et a!., 2002), cataracts (Singh et 
al., 2001), uraemia (Miyata et al., 1999), atherosclerosis (Li et al., 1996), 
arthritis (Thornalley, 1999), osteoarthritis (DeGroot et al., 2004) and cancer 
(Stopper et al., 2003). A plethora of researches on the in vivo and in vitro 
modifications of proteins caused by various sugars followed. It is now widely 
recognized that glycation is an omnipotent process taking place in nearly all 
organisms and tissues. 
1.1.1 The overall chemistry of glycation. 
Reducing sugars react rapidly and reversibly with the amino- and 
other nucleophilic groups of proteins/nucleic acids and fomn Schiff bases. 
The aldose derived Schiff base undergoes rearrangement to the Amadori 
adducts while those fonned with ketoses cause fomiation of Heyns adducts. 
This intermediate stage of the reaction is slow and may require a few days 
for completion. The Amadori/Heyns product maybe degraded further into a 
variety of carbonyl compounds like MG, glyoxal or deoxyglucosones that 
further propagate the reaction (Thornalley et al., 1999; Glomb and Monnier, 
1995). Both the Amadori and Heyns adducts also undergo further complex 
transformations including oxidation and fragmentation, to yield yellow-brown, 
heterogenous AGEs (Fig. 1.1). The reactions are accompanied by the 
formation of a variety of reactive oxygen species (ROS). 
1.2DNAglycation. 
Till lately studies on the in vivo Maillard reaction focused almost 
exclusively on the chemical modification of proteins and DNA has been 
greatly neglected because Maillard adducts in DNA did not appear to 
increase with age or in disease. However, with the availability of exquisitely 
sensitive, high-resolution technologies, such as microbore HPLC and 
capillary electrophoresis interfaced to electrospray ionization tandem mass 
spectrometry, it has now become possible to detect modified nucleotides 
formed during the Maillard reaction. Studies on Maillard reaction damage to 
DNA and the effects of AGE / Advanced lipoxidation endproduct (ALE) 
inhibitors on the modification of DNA are likely to provide critical information 
for assessing the role of the Maillard reaction in aging and diabetes (Baynes, 
2002). 
1.2.1 Protection against DNA glycation. 
DNA is clearly the most precious molecule of the cell and is among 
the long lived molecules in eukaryotes. Organisms have evolved a number 
of mechanisms for protection of biomolecules against the Maillard reaction. 
These include transport and storage proteins that restrict the availability of 
free metal ion catalysts of Maillard reactions; metabolic pathways that 
reduce, oxidize, or othenwise inactivate or detoxify reactive intermediates 
and anti-oxidant systems that limit the propagation of oxidative damage 
induced by the Maillard reaction. In addition, mammals have metabolic 
pathways that limit the free concentrations of reactive sugars. The 
evolutionary selection of glucose as blood sugar has also been ascribed to 
the fact that glucose, among all sugars, exists to the greatest extent in the 
cyclic conformation, so it is least reactive with the proteins (and DNA) and is 
also the most resistant to oxidative degradation (Bunn and Higgins, 1981). 
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Fig.1.1 - The reactions of DNA with glucose and fructose. 
The concentration of metabolic intermediates, such as sugar 
phosphates and dehydroascorbate, which are more reactive than glucose 
with proteins, are also maintained at micromolar, rather than millimolar 
concentrations in cells. Moreover a large fraction of these metabolites may 
exist primarily in protein-bound forms, focusing their nonenzymatic reactivity 
on enzymes with relatively rapid turnover and restricting their reactivity with 
DNA (Baynes, 2002). A special level of protection is afforded to eukaryotic 
DNA, in addition to its histone and polyamine shields, its localization in the 
nucleus protects it from Maillard reaction intermediates and ROS. The 
protection of DNA in the cell nucleus may have been important in the 
evolution of rapidly dividing, short-lived prokaryotes to more slowly dividing, 
long lived eukaryotic species. Limiting the influx of glucose into the cells by 
development of insulin resistance, either with age or in diabetes, may also 
be a mechanism for limiting Maillard reaction damage to DNA of post mitotic 
cells in long lived organisms (Baynes, 2002). 
Several enzymes and pathways also exist that detoxify the 
compounds with potential glycation mediated toxicity. These include Glo-I, 
aldehyde reductases and aldehyde dehydrogenases that serve to protect 
against nucleotide glycation and resulting mutations. But a study by 
Thornalley (2003b) suggested that some anticancer agents work by utilizing 
DNA glycation to induce cytotoxicity of cancer cells. On the other hand too 
much protection from glycation also proved harmful. Tumors that 
overexpress Glo-I turn multidrug resistant. 
1.2.2 DNA glycation adducts/AGEs. 
Although early researches focused on protein glycation reactions and 
the related AGE associated complications, Krymkiewicz (1973) showed for 
the first time that in vitro incubation of labeled MG with DNA, led to 
incorporation of radioactivity into the DNA. In similarity to proteins the 
reaction of reducing sugars with DNA also resulted in characteristic browning 
(Bucala et al., 1984). The sites of glycation in DNA are amino groups of the 
nucleobases and amongst them guanine and its derivatives react most 
readily with sugars and carbonyls (Papoulis et al., 1995). 
This was followed by studies in which in vitro incubations of free 
guanine, guanosine or 2'-deoxyguanosine (2'-dG) with reducing sugars were 
performed and the DNA-AGEs isolated. At elevatejd temperatures, the 
glucosyiamine of 2'-dG and D^glucose was the main product (Knerr et a!., 
1994). However, at physiological temperatures, the formation of (2/?, 4S, 
5R)-2-(A/^ -2'-deoxyguanosyl)-4, 5, 6-trihydroxyhexanoate [A/^ -(1-carboxy-3, 
4, 5-trihydroxypentyl)-2'-deoxyguanosine] (CTPdG) predominated (Ochs and 
Severin, 1995; Knerr and Severin, 1993). 
Intracellular glucose exists primarily as glucose-6-phosphate and 
when the reaction of 2'-dG with glucose-6-phosphate was studied such a 
reaction led to the formation of a CTPdG derivative, phosphorylated at 
position 5 (NissI et al., 1996). CEdGA.s was the other AGE, which was first 
Isolated as a reaction product of glyceraldehyde with 2'-dG (Ochs and 
Severin, 1994). Later, it was shown that CEdGAB or the analogous 
derivatives from guanosine, guanine or 9-methylguanine - CEG, CEguanine 
and CEmG were also formed from various sugars, sugar phosphates and 
sugar degradation products, such as glucose, ribose, glucose-6-phosphate, 
dihydroxyacetone, or ascorbic acid (Papoulis et al., 1995; NissI et al., 1996; 
Seidel and Pischetsrieder, 1998a; Larisch et al., 1997). The various DNA-
AGEs known to be formed from carbohydrates derived metabolites are 
detailed in Fig. 1.2. The reducing sugars glucose/ fructose are themselves 
potent sources of nucleotide AGE formation by reacting with 2'-dG. In the 
presence of oxygen and glucose, low concentration of W -^carboxymethyl-
guanosine (CMG) was additionally detectable (Seidel and Pischetsrieder, 
1998b; Al-Abed et al., 1998). a-dicarbonyls may also react with the 
nucleotide to produce similar nucleotide AGEs. A similar reaction has also 
been studied in case of deoxycytidine that forms the AGE- 5'-glycolylcytidine 
(Barea and Bonatto, 2008). 
CEdGA.B appears to be the major adduct formed during glycation 
reaction of DNA/nucleotides. However, as observed in case of protein 
glycation, a-dicarbonyls also react very efficiently with DNA/nucleotides 
resulting in the formation of labile imidazopurinone adducts. MG led to the 
formation of 3-(2'-deoxyribosyl)-6,7-dihydro-6, 7-dihydroxy-6-methylimidazo 
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Fig. 1.2- Mechanism of formation of nucleotide AGEs from carbohydrate-
derived metabolites. 
[2, 3 p] purine-9(8) one (MGdG) as detected by ^^P-post labeling technique 
in cellular DNA (Vaca et al., 1994). On extended incubation, the cyclic 
adduct degraded in favour of CEdGA,B (Papoulls et al., 1995; Frischmann et 
al., 2005). The reaction of glyoxal and guanosine also resulted in the 
formation of 3-(2'-deoxy-p-D-erythro-pentofuranosyl)-6,7-dihydro-6,7-
dihydroxy-imidazo[2,3-p] purin-9(8)one (GdG) glycation adduct, analogous 
to the MG adducts (Shapiro and Hachmann, 1966; Broude and Budowsky, 
1971). 
The pathways of formation of the various DNA adducts have also 
been studied. The reaction of the guanylate residues with MG led to the 
formation of the MdG adduct along with the N^-(l-carboxyethyl) guanine 
resides (Papoulis et al., 1995; Shapiro et al., 1969; Vaca et al., 1994), 
whereas N-acetyl guanine was produced by the degradation of the MGdG 
adduct in presence of H2O2 (Nukaya et al., 1990). Similarily, glyoxal reacts 
with the guanine base at N-1 and N-2 positions to fomri a tricyclic compound, 
GdG (Murata-Kamiya et al., 1997). 
The putative pathway for the fonnation of CEdGA,B has been shown 
by Frishmann et al. (2005), who suggested that the hydrated form of MG 
readily reacts with the amino group at the N-2 position of the 
deoxyguanosine molecule and further rearrangement and dehydration 
reaction culminates in CEdGA,B formation. The CEdGA.e formation involves 
two tautomerisation steps, similar to Amadori rearrangement of sugars and 
a-hydroxyaldehydes, involving MGdG adduct as an intermediate. 
1.2.3 Biological effects of glycation of DNA. 
While majority of studies on nucleic acid/ nucleotide glycation were 
carried out in vitro, some in vivo studies are also available. These include 
studies both on prokaryotic and eukaryotic model systems in order to study 
the mutagenic and genotoxic effects of DNA- and dNTPs-AGEs. Since 
nucleic acids are stable molecules they may accumulate dNTP-AGEs over a 
long time affecting their viability (Bucala et al., 1984; Thornalley, 2003b). 
Monosaccharide metabolites and associated nucleotide AGEs were 
found to induce a number of biological modifications in prokaryotic systems 
in vivo and in vitro including increased 76 transposition (Lee and Cerami, 
1991), plasmid DNA rearrangements (Bucala et al., 1985), plasmid DNA 
mutations (Thornalley, 2003b; Lee and Cerami, 1987; Bucala et al., 1985), 
inactivation and DNA repair of X bacteriophages (Khan and Hadi, 1994). 
Similarly, the consequences of DNA/ nucleotide glycation were also 
observed in eukaryotes, which included induction of diabetic complications 
(Cerami et a!., 1988), accumulation of chromatin-AGEs (Talasz et al., 2002), 
aging and age-related dysfunction (Bucala et al., 1984), transposition of Alu 
elements (Bucala et al., 1993), induction of single-strand breaks, DNA-
protein cross-linking and mutations (Roberts et a!., 2003; Murata-Kamiya et 
al., 2000; Migliore et al., 1990; Breyer et al., 2008; Murata-Kamiya et al., 
1997), as well as DNA damage and apoptosis (Kaneto et al., 1996). It was 
inferred that genotoxic effects of DNA-AGEs in prokar/otes and eukaryotes 
show some similarities, and result in high mutation and transposition 
frequencies, chromatin modifications and DNA strand breaks. Interestingly, 
the presence of the AGE, CEdGAB in a DNA molecule could block the 
Klenow fragment-mediated DNA synthesis in vitro (Cao et al., 2007). 
DNA glycation also generates some characteristic nucleotide adducts 
that were found to increase oxidative stress by causing the production of 
hydrogen peroxide, superoxide, and hydroxy) radicals, contributing to 
oxidative damage in nucleotides and DNA (Mistry et al., 2003; Thornalley, 
1996). 
Biological consequences of AGEs are also known to manifest in the 
form of various diseases of the human body. The accumulation of the AGEs 
in the tissues of the human body may play a pivotal role in the pathogenesis 
of diabetic nephropathy, chronic renal failure, atherosclerosis, cataract, 
Alzheimer's disease, and rheumatoid arthritis (Reddy et al., 2002; Busch et 
a!., 2004; Vlassara and Palace, 2003; Franke et al., 2003; Wells-Knecht et 
al., 1996; Kalousova et al., 2004; Forbes et al., 2003; Newkirk et al., 1998). 
Genomic damage in MNLs possibly induced by DNA glycation was 
enhanced in uraemic patients (Stopper et al., 1999; Stopper et al., 2001). 
However, it was not until 2006 when Li et al. (2006) using 
immunohistochemical detection showed the presence of DNA glycation 
products in human tissues from diabetics and uraemic patients. CEdGAB 
identified as a major marker of advanced glycation of DNA (Ochs and 
Severin, 1994; Schneider et al., 2004) was investigated for its role in the 
pathogenesis of diabetic nephropathy and uraemic vascular complications. 
1.2.4 Assay of AGEs. 
DNA adducts represent excellent biomarkers for assessing the extent 
of DNA damage to the genetic material. Thus, numerous analytical methods 
have been developed to detect, characterize and quantitate various DNA 
adducts. Generally, these experimental approaches are preceded by the 
isolation and digestion of the target DNA. The digestion procedure 
determines the chemical nature of the hydrolysate to be analyzed, and thus 
needs to be tailored to the selected analysis technique (Koc and Swenberg, 
2002). 
The background level of alkylated adducts in human DNA is thought 
to be at least 1 modification per 10^  nucleotides (Farmer et a!., 2005). Since 
modifications are present at low levels, detection of DNA adducts requires 
analytical techniques that are highly sensitive and specific. 
The techniques that are currently used for adduct determination 
include immunoassays, ^^P-postlabelling, HPLC/ECD or HPLC/fluorescence, 
conventional mass spectrometry and accelerator mass spectrometry 
(Farmer et al., 2005). Experimental approaches such as ^^P-postlabeling, 
immunoassays, and laser-induced fluorescence (LIF) are highly sensitive to 
detect DNA adducts at levels ranging from one adduct in 10^ to 10^ ° bases, 
but have several limitations. Analysis by ^^P-postlabelling is very sensitive, 
but entails use of radioactive materials, and can produce ambiguous results 
due to non-specific labeling. Similar complications may also occur when 
using LIF detection. This technique relies on tagging the desired products 
with a fluorophore prior to the analysis. Non-specifically labelled products 
can also be formed in this derivatization step, and lead to false positives. 
Highly specific detection can be accomplished using immunoassays which 
helps visualize the location of DNA adduct in situ, however, synthesis of 
epitopes and raising of specific antibodies is time consuming and expensive. 
The additional sample handling may also cause critical sample loss. Analysis 
by immunoassays was also susceptible to false positives due to cross-
reactivity with structurally similar adducts (Koc and Swenberg, 2002). 
Furthermore, all techniques do not permit de novo structural identification 
and have to rely on comparison with authentic standards (Table 1.1). 
The techniques used for the analysis of DNA adducts can be grouped 
into two on the basis of sensitivity and specificity. "^ ^P-postlabelling and 
accelerator mass spectrometry have high sensitivity but lack specificity. 
However, immunoassays, HPLC and stable isotopic dilution analysis mass 
spectrometry techniques are highly specific but may lack sensitivity. With the 
advent of tandem mass spectrometry, highest standards of sensitivity and 
specificity could be achieved and thus, making this technique the complete 
method for DNA adduct analysis (Koc and Swenberg, 2002). 
Over the past decade, mass spectrometry (MS) has gained popularity 
in the study of biomolecules. Ionization techniques such as matrix-assisted 
laser desorption ionization (MALDI) and electrospray ionization (ESI) have 
enabled routine analysis of non-volatile and fragile molecules by MS. The 
capabilities of MS detection have been further enhanced through the online 
coupling of MS to separation techniques such as HPLC, which can be used 
to remove the interferences from a sample that would impact upon sensitivity 
(Doerge et al., 2000). 
Excellent resolution of DNA adducts from unmodified constituents can 
be accomplished using reversed-phase HPLC due to differences in 
hydrophilicity. Various DNA glycation adducts have been purified by HPLC 
(Table 1.2). The use of LC-MS has not only revolutionized the analysis of 
DNA adducts, but also those of proteins, particularly resulting from glycation. 
Thornalley et al. (2003c) developed a quantitative screening technique for a 
comprehensive range of protein biomarkers of early glycation, advanced 
glycation, oxidation and nitrosation, protein localized and free, in cellular and 
extracellular proteins and body fluids using LC-MS/MS (liquid 
chromatography coupled with tandem mass spectrometry) detection with the 
help of internal standardization by stable isotope-substituted standards. 
Using this technique, free biomarkers were detemnined by analysis in the 
ultrafiltrate of physiological fluids, whereas protein biomarker residues were 
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Table 1.1-Techniques currently being used for the analysis of DNA adducts 
Sensitivity Amount of DNA 
(ca. adduct/nucleotides) required for analysis 
(ftg) 
1-100 
1-100 
10-100 
1-10 
1-2000 
Source: Farmer et a!., 2005. 
.C/ECD or fluorescence 
Immunoassay 
Mass spectrometry 
^^P-postlabeling 
Accelerator mass 
spectrometry 
1/10^ 
1/10^ 
1/10^ 
1/10 °^ 
1/10^^  
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Table 1.2- Various DNA-AGEs isolated by HPLC. 
Nucleobase 
derivative 
Guanosine 
Guanosine 
Guanosine 
2'-deoxyguanosine 
2'-deoxyguanosine 
9-Methylguanine 
2'-deoxyguanosine 
2'-deoxyguanosine 
2'-deoxyguanosine, 
DNA 
2'-deoxycytidine, 
DNA 
Product 
N^-(1-carboxy-3,4,5-
trihydroxypentyl)-
guanosine,(CTPGA,B) 
2-(p-D-glucopyranosyl 
amino)-guanosine 
N -^(1 -carboxymethyl)-
guanosine (CMG) 
2-(p-D-glucopyranosyl 
amino)-guanine 
N2-(1-carboxy-3,4,5-
trihydroxypentyl)-2'-
deoxyguanosine 
(CTPdGA,B) 
N^-(l-Carboxymethyl)-
9-methylguanine 
N^-(1-carboxyethyl)-2'-
deoxyguanosine 
(CEdGA,B) 
N -^[2-(N2-2'-deoxy 
guanosyl)-propionyl]-
lysine 
Cyclic adduct of 
glyoxal with 2'-
deoxyguanosine 
(GdG) 
2'-deoxyuridine,5-
hydroxy acetyl-2'-
deoxycytidine 
Reference 
Knerr and 
Severin, 1993. 
Knerr €5tal., 
1994 
Seidel and 
Pischetsrieder, 
1998b 
Knerr etal., 
1994 
Ochs and 
Severin, 1995 
Al-Abedetal., 
1998 
Ochs and 
Severin, 1994 
Peich etal., 
2005 
Kasaietal., 
1998 
Kasaietal., 
1998 
Comment 
Only at 
elevated 
temperatures 
In the 
presence of 
oxygen, also 
from glyoxal at 
elevated 
temperature 
Only at 
elevated 
temperatures 
In the 
presence of 
propylamine 
In the 
presence of 
lysine; 
potential 
DNA-protein 
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Table 1.2 - continued 
2'-cleoxyguanosine, GdG, N -
2'-deoxyadenosine, (hydroxyacetyl)-2'-
2'-deoxycytidine, deoxyadenosine, 5-
cytidine, thymidine hydroxyacetyl-2'-
deoxycytidine 
Olsen et al., 
2005 
2'-deoxyguanosine N^,7-Bis(1-hydroxy-2- Schneider et 
oxopropyl)-2'- a!., 1998 
deoxyguanosineA,B,c,D 
Also fomned 
fronn 1,3-di 
chloropropene 
epoxide 
2'-deoxyguanosine, CEdGA.s, N-(1-
2'-deoxyadenosine carboxyethyl)-2'-
deoxyadenosine 
(CEdAA,B) 
Guanosine Cyclic adduct of 
methylglyoxal 
with guanosine 
(MGGua) 
2'-deoxyguanosine Cyclic adduct of 
,DNA methylglyoxal 
with dG (MGdG) 
2'-deoxyguanosine, Cyclic adduct of 
DNA glyoxal with 2'-
deoxyguanosine 
(GdG) 
Frischmann et 
al.,2005 
Shapiro etal., 
1969 
Vacaetal., 
1994 
Awadaetal., 
2001 
Phosphoglyco 
aldehyde is an 
oxidation 
product of 2'-
deoxyribose in 
DNA 
Guanosine N^-(l-carboxyethyl)-
guanosine (CEGA.B), 
N^-(1-carboxy-3-
hydroxypropyl)-
guanosine (CHPGA.B) 
Larisch etal., 
1997 
2'-deoxyguanosine N^-(1-Oxo-2,4,5,6-
hydroxyhexyl)-2'-
deoxyguanosineAB 
Hayaseetal., Only at 
1998 elevated 
temperatures 
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determined following delipidification and enzymatic hydrolysis of protein 
samples (Thornalley et al., 2003c). 
LC-MS/MS has also been used in the characterization and 
quantitation of DNA-AGEs both in vitro and in vivo. The cyclic adduct formed 
by the reaction of glyoxal with 2'-dG (i.e. GdG) was quantified by LC-MS/MS 
(Dennehy and Loeppky, 2005; Olsen et al., 2005). Schneider et al. (1998) 
conducted the first study on the analysis of the various adducts of MG 
induced DNA glycation. Further, Frischmann et al. (2005) used the technique 
for the analysis of MG adducts of 2'-dG or DNA using a triple quadrupole MS 
after ESI. 
1.2.5 Role ofHistone modification. 
Monofunctional alkylating agents like N-methyl-N'-nitro-N-nitroso-
guanidine (MNNG) are potent inducers of DNA strand cleavage, which 
activate the nuclear enzymes poly (ADP-ribose) polymerase and poly (ADP-
ribose) glycohydrolase. The coordinated activities of these two enzymes 
cause the conversion of a large fraction of the millimolar range NAD pool 
within minutes to free ADP-ribose in close proximity of histones. Enzymic 
post-translational modifications of histones such as hisjtone carbonylation by 
free ADP-ribose may alter chromatin function (Strahl et al., 2000). It has 
been reported that the nucleosomal histones protects the DNA from iron-
mediated damage (Enright et al., 1992). Nuclear polyamines like spermine 
are effective antioxidants protecting DNA from attack by ROS. In an 
analogous manner preferential histone carbonylation could serve to protect 
the chemical integrity of DNA. On the other hand oxidative DNA damage has 
been demonstrated as a result of the decay of histone HI-bound 
hydroperoxides in vitro suggesting a deleterious effect of oxidized histones 
on genomic integrity (Wondrak et al., 2000). 
The modification of histones by glycation has important implications 
for the non-enzymatic modification of long-lived nuclear biomolecules 
involved in the maintenance of genomic integrity. Age associated changes in 
chromatin structure have been described previously by other researchers 
(Bucala et al., 1992; Bojanovic et al., 1970) and both individual histones 
(Liebich, et al., 1992) and histones in nucleosomes (Gugliucci, 1994) have 
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been reported to be glycated in vitro. Genomic integrity requires efficient 
repair of molecular damage to DNA and repair of DNA damage is 
accompanied by the synthesis of ADP-ribose polymers, which are rapidly 
degraded to ADP-ribose. The possibility that ADP-ribose might be the 
principal source of ribose moiety in vivo for protein glycoxidation has been 
suggested by Sell and Monnier (1989). Its subsequent studies also suggest 
that ADP-ribose is an efficient source for glycation and glycoxidation of 
histones in vitro (Laurean et al., 1996). 
1.3 Glycation and oxidative stress. 
An imbalance between pro- and anti-oxidant factors plays an 
important role in many disease processes, including diabetes mellitus. 
Reports show that DNA damage and mutations are caused by ROS, which 
also induce apoptosis in several cell types. This rise in ROS could be either 
due to inhibition of mechanisms for ROS destruction or rise in ROS 
formation via glycation reactions (Kaneto et al., 1996). 
Cu, Zn-superoxide dismutase (Cu, Zn-SOD) is an anti-oxidant 
enzyme in the human body and levels of its glycated forni increase during 
diabetes mellitus. The glycation reaction causes enzyme inactivation and is 
accompanied by enhanced ROS formation that causes damage and 
cleavage of DNA. Cu, Zn-SOD undergoes both site specific cleavage and 
random fragmentation by glycation. Cu^^ ions are released facilitating a 
Fenton type reaction to convert H2O2 into hydroxy free radical. The radicals 
then cause DNA cleavage and the fomnation of 8-hydroxydeoxyguanosine 
(8-OHdG) which is a marker for ROS mediated damage (Kaneto et al., 
1994). 
Reducing sugars may also trigger ROS formation. This occurs mainly 
through the glycation reaction, and is the outcome of rise in in vivo blood 
glucose levels wherein the glucose enters the cells via glucose transporter 
and transformed to glucose-6-phosphate, fructose-6-phosphate, fructose-
1,6-bisphosphate during glycolysis as well as to sorbitol and fructose via the 
polyol pathway. Most of these reducing sugars are stronger glycators than 
glucose and can readily glycate Cu, Zn-SOD (which is abundant in the 
mammalian cell cytoplasm). After the Cu^^  ions are released from the 
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glycated Cu, Zn-SOD, and the dismutation of superoxide anion produced 
from the glycated Cu, Zn-SOD results in production of H2O2. Some of the 
released Cu^ "^  (or Cu^) and H2O2 may enter the nucleus and damage nuclear 
DNA through the production of hydroxy radical in proximity to the 
nucleosomes. There are many kinds of metal-containing proteins in 
cytoplasm, and such proteins may also induce DNA breakage through the 
glycation related reaction (Kaneto et al., 1994). 
Wondrak et al. (2000) have reported increased levels of carbonyl 
compounds in histones of cells exposed to alkylating agents and oxidative 
stress. These stresses commonly cause single strand breaks in DNA and 
lead to increase in the synthesis and turnover of poly-ADP-ribose and in the 
intracellular pool of ADP-ribose monomer. ADP-ribose is a potent protein 
glycating agent and maybe the source of AGEs in DNA in response to 
chemical and physical stresses. Oxidative stress induced by glycation 
and/or AGEs/ALEs, may also catalyze the production of ROS, enhancing 
oxidative damage to DNA (Baynes, 2002). 
In addition, it would be expected that glycation contributes to "site-
specific" radical mediated DNA damage. The Amadori products and 2-
amino-2-deoxy aldose are knovi/n to have higher autoxidizing and DNA 
strand breakage activities than aldoses or ketoses (Kashimura et al., 1986 
and 1987). Glycated proteins are also found to autoxidize to yield oxygen 
radicals (Gillery et al., 1988; Sakurai et al., 1990) and induce DNA strand 
breakage (Kashimura et al., 1990). If the Amadori or Heyns products are 
formed on DNA or on proteins bound to DNA, they may autoxidize and 
produce highly reactive oxygen radicals and other free radicals in the 
neighbourhood of DNA molecules. This in turn may cause secondary critical 
damage to DNA (e.g., strand breakage and further degradation of DNA) as 
well as the development of fluorophores and chromophores. 
The level of oxidized DNA damage in cells has been used as a 
measure of oxidative stress. 8-oxodG is known to be the major and 
ubiquitous product of DNA oxidation. The route of its formation involves OH' 
radical attack on dG and hydration of the guanine radical cation to produce 
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the deoxyguanosyl radical which in turn oxidizes to 8-oxodG (Cadet et ai., 
2003). This adduct could be also be formed from ROS such as the 
superoxide radical (O2-), singlet oxygen (^ 02) or hydrogen peroxide (H2O2) 
(Singh et al., 2003). 8-oxodG levels can be measured either by quantifying 
the single lesion of the adduct (after DNA extraction and hydrolysis), or 
preserving the DNA and studying the formation of 8-oxodG in situ (Ravanat 
et al., 2002). 
Studies have shown that trace metals ions such as copper and iron, 
which are present in biological systems, may react with H2O2 to produce 
hydroxyl radicals and in turn induce DNA strand breakage (Imlay et al., 
1988; Sagripanti and Kraemer, 1989). It was shown by Kaneto et al. (1994) 
that glycation of proteins by glucose fonns s-amino fructosyl lysine residues. 
These autoxidize with the production of superoxide anion and H2O2. This 
autoxidation is due to tautomerism to the enediol form. The glycated protein 
releases Cu^* that gets reduced to Cu"^  by superoxide anion or the enediol. 
The reduction of H2O2 by Cu"" may generate hydroxyl radicals. Thus, 
glycation reactions are accompanied by H2O2 and ROS production 
(Mullarkey et al., 1990; Kang, 2003) which further promote formation of 8-
oxodG. 
1.4 Inhibitors of glycation. 
A number of inhibitors of glycation have been proposed and these 
could be divided into various groups on the basis of their action. While one 
class of AGE inhibitors compete with reducing sugars and modify free 
amino groups of biomolecules thereby preventing sugar attachment, the 
other comprises those that divert the sugars from the Maillard reaction, 
acting on more than one step of the complex cascade, Aldehyde pyridoxal-
5'-phosphate and aspirin (Reiser, 1998; Harding, 1985) belong to the fomner 
while Aminoguanidine (AG) belongs to the latter group of glycation inhibitors 
(Hirsch etal., 1995; Khatami eta!., 1998; Thornalley, 2()03a). 
Yet other group of AGE inhibitors like DETAPAC, phytate and 
pencillamine act by sequestering free metal ions in vivo (Wells-Knecht et al., 
1995). Antioxidants provide protection against the glycation derived free 
radicals. Vitamin E (800 mg per day) has been shown to reduce levels of 
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glycated hemoglobin and accumulation of AGEs in the arterial walls of 
diabetic patients (Ceriello et al., 1991). A number of plant derived flavonoids 
(quercetin, rutin and kaempferol) with antioxidant activity are reported to be 
effective inhibitors of glycation, at least during in vitro studies (Asgary et al., 
1999). 
AG is the most widely studied and was effective enough to reach 
stage-H clinical trials (which were later abandoned due to safety concerns 
and lack of efficacy). This molecule traps dicarbonyl intermediates to form 
substituted triazines (Thornalley, 2003a). Another popular class of inhibitors, 
the Amadorins like pyridoxamine (Vitamin B6 derivative) have the potential 
to scavenge post-amadori products, thus, inhibiting AGEs formation (Glomb 
and Monnier, 1995; Harding, 1985). 
1.5 Significance of studies on DNA glycation and objectives of the 
present study. 
Due to the ubiquitous presence of reducing sugars throughout the 
body, it is inevitable that the non-enzymatic glycation of biological 
macromolecules occurs in vivo (Lee and Cerami, 1992). The intracellular 
levels of reducing sugars rarely rise in vivo, yet the long lived nature of DNA 
and its propagation to daughter cells renders DNA glycation by reducing 
sugars potentially genotoxic. Such glycations may even explain the well 
recognized age-related increase in malignancies. 
Measurements of AGEs in proteins are useful for assessing the rate 
and magnitude of glycation damage, but it is the damage to the genome 
that has the greatest impact on the viability of the organism. Damage to 
DNA accumulates not only in the form of chemical modification, but as 
chemically "silent" errors in repair- insertions, dek;tions, substitutions, 
transpositions, and inversions in DNA sequences- that affect the expression 
and structure of proteins (Baynes, 2002). Such mutations are random, vary 
from cell to cell, and are passed fonward from one cell generation to 
another. Although these may not be detectable in DNA by conventional 
analytical techniques, purines and pyrimidines modified by Maillard reaction 
intermediates are detectable in urine, and studies on these compounds 
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should provide insight into role of Maillard reactions of DNA in aging and 
disease (Baynes, 2002). 
Photosensitized DNA damage in skin is thought to be an important 
mechanism of UV phototoxicity. Proteins modified by AGEs are 
photosensitizers of DNA damage with the implications for photoaging and 
photocarcinogenesis suggesting that multiple mechanisms are involved in 
AGE sensitization (Wondrak et al., 2002). 
Despite the evidence that DNA is an accessible target for the 
Maillard reaction, in vivo studies in this area are hampered by the fact that 
damage to DNA does not accumulate to a significant extent and maybe 
"silent". The modified bases are excised and replaced, hence may not 
accumulate to a very significant extent in vivo in DNA as in case of proteins. 
Further, since the rate of the Maillard reaction is slow, levels of modified 
bases in DNA at a given time are also low. The DNA repair processes work 
with high efficiency and fidelity yet are not error free. Thus, Maillard 
reactions, like other nucleophilic modifications of DNA, can lead to a gradual 
loss in the integrity of the genome, resulting from accumulated mutations, 
expressed in the form of altered sequence rather than altered composition 
of DNA (Baynes, 2002). 
As discussed above compared to researches available on protein 
glycation, those on DNA glycation are quite limited. Lack of highly sensitive 
techniques for the measurement of DNA glycation is among the important 
reasons for absence of infonnation on glycation of DNA especially in vivo. 
An attempt was therefore made to investigate the effects of various sugars 
including glucose, fructose and ribose on the behaviour of plasmid, calf 
thymus and herring sperm DNA. Further the formation of various DNA-AGEs 
during nucleotide-sugar incubations both in presence and absence of AG 
and DETAPAC was studied. Also a monoclonal antibody was utilized to 
detect the major DNA glycation adduct, CEdGA,B in DNA in vitro. 
An optimized procedure for the synthesis and characterization of the 
major adducts fomned from the reaction of MG with 2'-dG and an LC-MS/MS 
assay for the detection and quantitation of DNA glycation adducts as well as 
the DNA oxidation adduct, 8-oxodG by mass spectroscopy was developed. 
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A protocol for the effective extraction, isolation and digestion of total genomic 
DNA from cellular and tissue samples was optimized so as to prevent the 
degradation of the adducts within the sample, while minimizing any potential 
for the fonnation of additional adducts during sample work-up. 
Further, the optimized procedure for DNA isolation, hydrolysis and 
adduct analysis were used to quantitate the adducts in sugar incubated 
nucleotide samples as well as in DNA extracted from human MNLs and 
HL60 cells. Additional studies were carried out to measure the levels in 
biological fluids obtained from type-2 diabetics and patients of ESRD. 
Based on the hypothesis of Thornalley (2003b), that overexpression 
of Glo- I produced MDR in the tumour patients, investigations were carried 
out to determine if the use of cell permeable Glo-I inhibitor, S-p-
bromobenzylglutathione cyclopentyl diester (BBGC) could overcome MDR in 
different tumour cell lines, by promoting DNA glycation in these cells. 
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2. EXPERIMENTAL PROCEDURES 
2.1 MATERIALS 
The plasmid pBr 322 DNA was purchased from Bangalore Genei Ltd., 
India and herring sperm DNA (not highly polymerized) from ICN Biomedicals 
Inc., USA. D-ribose, D-glucose-6-phosphate, skimmed milk, sodium fonnate 
were obtained from Fluka, USA. Dihydroxyacetone (Merck, Gennany), [U-
^^ Cio,^ ^N5]-2'-dG (>98% isotopic purity) was purchased from Cambridge 
isotope laboratories (Andover, MA, USA). BSA, methylglyoxal (40% 
aqueous), Histopaque-1077, Sodium iodide (> 99% pure), 2'-
deoxyguanosine monohydrate, DETAPAC, Tween-20, RNase A (from 
Bovine pancreas), Phosphodiesterase II (type-1. Bovine spleen), DNase 11 
(Type-IV, from porcine spleen), Acid phosphatase Type IV (from potato), 
RNase Ti(from Aspergillius oryzae), desferoxamine mesylate (DFOM), 
magnesium sulphate, ammonium chloride, aminoguanidine hydrochloride, 
magnesium chloride(anhydrous), Triton X-100, 3,3',5,5'-tetramethylbenzidine 
dihydrochloride solution (TMB), anti-mouse IgG horseradish peroxidase 
conjugate, sodium phosphate monobasic, sucrose, D-glucose, D-fructose 
from Sigma Co. USA were used. Qiagen protease from Qiagen was used for 
DNA isolation. Ammonium acetate, sodium chloride, Tris base, methanol 
(HPLC grade), Acetonitrile (HPLC grade) and formic add (HPLC grade) 
were purchased from Fischer Scientific. RPMI-1640 wth L-glutamlne used 
for culturing HL-60 cells was obtained from Bio-Whittaker (UK), Disc filters 
(0.2 i^ m) from Millipore (USA) were used for filtration and Nanosep-10K 
microspin filters from Pall Life Sciences (Germany) were used for sample 
concentration and ultrafiltration. Standard clear Corning and Costar 96 Well 
Plate, Corning Inc, Life Sciences, Acton, MA, USA were used for cell culture 
experiments. 
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2.2 METHODS 
2.2.1 Continuous incubation of pBr 322 DNA with glucose and fructose. 
Plasmid DNA was incubated with 200 mlVIMOO mlVI glucose or fructose in 50 
mM Tris-HCI buffer, pH - 8.0 in a final volume of 30 ^L under dark and sterile 
conditions at 37°C. After various time inten/als, aliquots were withdrawn, and 
mixed with 4-5 i^L of sample buffer (0.05% Bromophenol blue dye, 40 mM 
EDTA, 50% glycerol in water) and loaded on a 1% agarose gel. The gels 
were run in Tris-acetate-EDTA (0.04 M Tris-acetate, 0.001 M EDTA, pH- 8.0) 
buffer at 100V, till the dye migrated out of the gel. The gels were stained with 
ethidium bromide and visualized on a UV- transilluminator. 
2.2.2 Interrupted incubation of pBr322 with ribose. The incubation 
reaction was setup in the manner described above. However, after 24 h of 
incubation at 37°C, the DNA sample was subjected precipitation (Sambrook 
et al.,1989) and washing with ethanol to remove excess ribose. The washed 
DNA was resuspended in 30 |il of 50 mM Tris-HCI buffer and further 
incubated at 37°C. At the indicated time intervals aliquots were withdrawn 
from the incubated samples and analyzed by agarose gel electrophoresis. 
2.2.3 Incubation of pBr322 DNA with BSA preincubated with the sugars. 
Two sets of BSA samples were incubated in the presence of 500 mM 
glucose, fructose or ribose in 50 mM phosphate buffer, pH-8.0 containing 
0.05% azide at 37°C under dark and sterile conditions. After 24 h incubation, 
one set was subjected to overnight cold dialysis with two changes of 50 mM 
phosphate buffer, pH-8.0 containing 0.05 % azide. The dialysis was 
performed using a cellulose dialysis tubing (MW cut off-12,000, Sigma-
Aldrich). 
pBr322 DNA was incubated in 50 mM Tris-HCI buffer, pH-8.0 with 
BSA subjected to preincubation in presence or absence of 500 mM glucose, 
fructose or ribose in a total volume of 30 \i\. The reaction was allowed to 
proceed at 37°C and aliquots were withdrawn at various time intervals and 
analyzed by agarose electrophoresis. 
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2.2.4 Restriction digestion of pBr322 subjected to continuous or 
interrupted incubation with the sugar. The DNA samples incubated with 
400 mM glucose or fructose were subjected to restriction digestion by the 
single site cleavage enzyme EcoRI (Bangalore Genei, India). Also the 
samples of DNA exposed to BSA preincubated with ribose were subjected to 
restriction digestion in the presence of single-site cleavage enzymes- EcoRI 
and Bam HI (Bangalore Genei, India) or multiple site cleavage enzyme- Hinf 
I (Bangalore Genei India). The digestion mixture contained 1^ g of glycated 
DNA and 3 units of the restriction enzyme, specific enzyme assay buffer and 
distilled water in a total reaction volume of 20 iiL. The assay buffer for Eco 
Rl contained 50 mM Tris-HCI (pH-8.0), 100 mM NaCI, 10 mM MgCb, 5.0 mM 
pME, whereas the assay buffer for Bam HI comprised of 10 mM Tris-HCI 
(pH-8.0), 100 mM NaCI, 10 mM MgCb, 1.0 mM DTT, 100 i^g.mL"^  nuclease 
free BSA. The composition of the assay buffer for Hinf I was 10 mM Tris-HCI 
(pH-7.8), 50 mM NaCI, 10 mM MgCb, 10 mM DTT. The incubations were 
carried out at 37°C in a water bath and the reaction was stopped after 2 h 
using the sample buffer (0.05% bromophenol blue dye, 40 mM EDTA, 50% 
glycerol in water). The digested DNA samples were analyzed by 
electrophoresis on agarose gels at 100 V and visualized by ethidium 
bromide staining. 
2.2.5 Effect of DETAPAC on the reaction of DNA with fructose and 
ribose. The effect of the metal ion chelator was studied by incubating DNA 
with the fructose in presence of 25 mM DETAPAC at 37°C in 50 mM Tris 
buffer, pH-8.0. In other experiments 10 mM DETAPAC was used. The 
effectiveness of this chelator in inhibiting sugar induced DNA damage during 
the incubation of DNA with BSA which had been preincubated with ribose 
was also assessed. All the above in vitro incubations were performed in 
triplicate for reproducibility. 
2.2.6 Competitive ELISA for the measurement of CEdGA,B formation in 
DNA samples. The ELISA was performed using the monoclonal anti-
CEdGA,B antibody (MAb M-5.1.6) which was raised in Balb/c mice using the 
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CEguanine-keyhole limpet hemocyanine conjugate (Schneider et al., 2004). 
The samples for ELISA measurements were prepared by incubating DNA 
with D-ribose in 50 mM Tris buffer, pH 8.0 in a shaking water bath at 37°C 
for 5,7,10 days accordingly. After completion of the incubation time, aliquots 
were withdrawn and frozen immediately until further analysis. The 
competitive ELISA procedure was carried out to monitor the CEdGA,B 
modifications in DNA. Ninety-six well microtitre plates were coated with 
lOO i^L per well of a carboxyethylguanine-BSA solution (0.2 |ig-mL"^  BSA 
conjugate in 0.2M sodium carbonate buffer, pH-9.7) at 4°C overnight. The 
plates were washed twice with washing buffer [1 mM KH2PO4, 7mM 
K2HPO4, 15 mM NaCI, 0.02 mM potassium sorbate, and 0.05% (v / v) 
Tween-20 (Sigma-Aldrich)] after each step. Non-specific binding was 
minimized by blocking the wells with 150|aL per well of skimmed milk powder 
(Fluka) in water (3%) for 1.5 h at room temperature. Aliquots of 50 |iL of the 
samples were added after a 1:50 dilution in phosphate buffered saline, pH-
7.4 along with 50 fiL per well of the MAb diluted 1:100 in diluting buffer 
(0.2% BSA (Sigma-Aldrich) and 0.05% Tween-20 in PBS) and incubated for 
1 h at room temperature. Labeling was performed with anti-mouse IgG-
horseradish peroxidase conjugate (Sigma-Aldrich) diluted 1:2500 in PBS 
containing 1mg-mL'^  BSA. The plates were incubated for 45 min at room 
temperature, washed three times with the wash buffer and antibody binding 
was determined using 100 jiL of 3,3',5,5'-tetramethylbenzidine 
dihydrochloride solution (TMB) (Sigma-Aldrich). The reaction was stopped 
after 12 min by adding 25 i^ l of 2N sulfuric acid and the absorbance 
measured at 450 nm. The concentrations of carboxyethyl-modified 
nucleobases were calculated from a calibration curve using CEdGA.e as the 
standard. In all the ELISA measurements carried out, each sample was 
coated in triplicate on the plate. The concentration of CEdGA.e obtained was 
the mean of the three measurements and standard deviation was calculated 
for the three values obtained for each independent incubated sample. 
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2.2.7 Interrupted and continuous incubation of herring sperm DNA with 
ribose. For the ELISA studies, the incubation of herring sperm DNA 
(1mg/ml) with 400 mM ribose in 50 mM Tris buffer, pH-8.0 was monitored 
upto 7 days. In this study, after an initial incubation of 24 h with 400 mM 
ribose at 37°C, the excess sugar was removed from one set of samples by 
either ethanol precipitation or dialysis. The incubations were carried out 
further and adducts formed were monitored at different time intervals in 
absence of the sugar. Another study was carried out in which the sugar 
concentrations of fructose and ribose were varied from 0.05 - 0.6 M and the 
incubation was carried out for a period of 10 days at 37°C. 
2.2.8 Characterisation and quantitation of nucleotide adducts using LC-
MS/MS. Samples were analysed by liquid chromatography with tandem 
mass spectrometric detection (LC-MS/MS). Analytes were quantified by 
stable isotopic dilution analysis. Analysis was performed using a Waters 
Acquity UPLC system with Waters Quattro Premier XE tandem mass 
spectrometer. Analytes were separated by reversed phase UPLC using a 
BEH Ci8 column (1.7^m, 2.1 X 100 mm). The mobile phase was 0.1% formic 
acid with a linear gradient of 0-10% acetonitrile from 2-10 min and isocratic 
10% acetonitrile from 10-15 min. After analysis, the column was washed with 
50% acetonitrile, 0.1% formic acid for 10 min and thereafter re-equilibrated 
with initial mobile phase for 10 min. The column temperature was varied 
from 4 - 30°C as required. The flow rate was maintained at 0.25 ml/min, 
however for the first 4 min of the run, the flow was directed to waste and in 
the interval 4-15 mins, flow from the column was directed to the MS/MS 
detector. After this time the flow was again diverted to waste. Automated 
switching valves were used to divert the interfering compounds to the waste 
instead of ionization source, to reduce the suppression effect. The mass 
data analysis was carried out in the multiple reaction monitoring (MRM) 
mode. Electrospray ionisation (ESI) was performed in the positive mode. The 
ionisation source temperature was 100°C and the desolvation temperature 
was 250°C. The cone gas flow was maintained at 250 Uhr and the 
desolvation gas flow was 905 Uhr. Isotopic internal standards used for the 
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calibration were as follows: 0.1 nmol [U-^ ^Cio.U-^ ^Ns] dG, 1 pmol each of [U-
'^ Cio,U-^ ^N5] 8-oxodG, [U-^ ^Cio.U-^ ^Ns] MGdG, lU-'^ Cio.U-^^Nsl GdG adduct 
respectively and 0.1 pmol [U-^ ^Cio.U-^ ^Ns] CEdG A,B-
In order to achieve maximum sensitivity and selectivity, it was 
necessary to optimize the MS/MS conditions and maximize the detection 
response. Two parameters that were critical to be optimized were the cone 
voltage and collision energy used to induce fragmentation. The instrument 
was optimised for the following parameters - best parent ion mass, best 
fragment ion mass, cone voltage and collision energy for each parent-
fragment ion pair of the various analytes. This was carried out by the infusion 
experiments where standard analyte (20 nmol/ml; IOOp.1) in mobile phase 
was infused (10 ^1/ min) into the solvent flow immediately prior to the 
electrospray source of the mass spectrometer. Detection conditions were 
then optimized automatically by the auto-optimization routine of the 
Masslynx software- including selection of the mass of at least two fragment 
ions for two related MRM transitions giving the strongest detection response. 
Collision energy was optimized to ± 1 eV and cone voltage to ± 1V (Table 
2.1). 
2.2.9 Quantification of 8-oxodG, MGdG, CEdGA.B and GdG. All analyses 
were carried out using tandem mass spectrometry with electrospray 
ionization using a Quattro premier XE mass spectrometer coupled to the 
Waters Acquity UPLC system. The calibration curve for 2'-dG was prepared 
in the range 0.5-10 nmol with 0.1 nmol of [U-^ ^Cio, U-''^ N5] isotopic 2'-dG per 
sample (Fig 2.1). The limit of detection for 2'-dG as determined by 
regression analysis was 0.87 nmol (~870 pmol). Similarly, the calibration 
curve for 8-oxodG was plotted in the range 0.05-1.0 pmol of the normal 8-
oxodG standard, with 1.0 pmol of IU-^ ^Cio, U-^ ^Ns] isotopic oxodG per 
sample. The limit of detection, also determined by regression analysis, was 
calculated to be 0.06 pmol (-60 fmol) (Fig. 2.2). The standard plots for 
MGdG, CEdGA,B and GdG were constructed in the range - 0.05-1.0 pmol of 
the normal and 1.0 pmol of the [U-^ ^Cio.U-^ ^Ns] isotopic adducts. The limit of 
detection determined by regression analysis, for the three analytes MGdG, 
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Table 2.1- Chromatographic retention times and mass-spectrometric MRM 
detection of mariners of nucleotide glycation. 
Analyte Rt Parent Fragment Cone CE Fragment Internal LOD 
(min) lon,[M+1]^ Ion, Fr^  voltage (eV) loss standard (pmol) 
(Da) (Da) (V) (Da) 
2'-dG 7.3 268.12 151.95 12 13 116.17 [U-'^Cio,U-^^N5]dG 0.87 
8-oxodG 8.4 283.80 168.00 12 12 115.80 [U-^^Cio,U-^^N5]oxodG 0.06 
MGdG 7.2-8.6 340.00 224.00 11 12 116.00 [U-^^Cio,U-^^N5]MGdG 0.08 
CEdGA,B 9.8,11.1 340.00 224.00 11 12 116.00 [U-"Cio,U-^^N5]CEdG 0.02 
GdG 6.7 325.70 209.90 12 12 115.80 [U-^^Cio,U-^^N5]GdG 0.03 
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Fig. 2.1- Calibration plot for 2'-deoxyguanosine (268.12>151.95 mass 
transition). 
Fig. 2.2 - Calibration plot for 8-oxodG (283.8> 168.0 MRM mass transition). 
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CEdGA,B and GdG were found to be 0.08 pmol (-80 fmol), 0.02 pmol (-20 
fmol) and 0.03 pmol (-30 fmol), respectively (Fig. 2.3-2.5). 
2.2.10 In vitro incubations of 2'-dG with tlie sugars. The nucleoside, 2'-
dG was incubated with 5 mM or 20 mM glucose, fructose or ribose in 50 mM 
sodium phosphate buffer, pH-7.4 at 37°C. Then the samples were aliquoted 
at 0, 1, 2, 7 and 14 days and then frozen until further analysis using LC-
MS/MS. 
2.2.11 In vitro incubations of 2'-dG witli the sugars in presence of the 
metal ion chelator (DETAPAC). The incubation was set up with 5 mM 2'-
dG and 20 mM concentration of the three sugars- glucose, fructose or 
ribose, in presence and absence of 100 nM DETAPAC. The aliquots were 
withdrawn from the samples at the end of 21 days of incubation and 
analyzed by LC-MS/MS. 
2.2.12 Effect of the AGE inhibitor AG during in vitro incubations of 2'-
dG with the sugars. The incubations of 5 mM 2'-dG with 20 mM of the 
sugars - glucose, fructose and ribose were carried out in presence and 
absence of 500 ^M AG in 50 mM sodium phosphate buffer, pH-7.4 at 37°C. 
Then the samples were aliquoted at 2, 7 and 14 days and frozen until 
analysis using LC-MS/MS. 
All in vitro incubations were carried out in quadruplicate and under 
sterile conditions. 
2.2.13 Interrupted and continuous incubation of calf-thymus DNA with 
the sugars. Calf thymus DNA was suspended in DNase free, sterile water 
(containing 0.2 mM DFOM) and was allowed to fully redissolve over a period 
of 24 h at 4°C. The concentration of DNA was detemnined by UV 
absorbance at 260 nm (50 i^g/ml DNA has an absorbance of 1 at 260 nm). 
For the experiment, 150 ng of calf thymus DNA was incubated with 
400 mM fructose or ribose in a final volume of 1 ml using 50 mM Tris buffer, 
pH-8.0 at 37°C. After 24 h, the incubation was interrupted by ethanol 
precipitation of the DNA in order to free it from excess sugar. The DNA was 
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Fig. 2.3- Calibration plot for MGdG (340.0>244.0 mass transition). 
Fig. 2.4- Calibration plot for CECIGA.B (340.0>244.0 m^ss transition). 
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Fig. 2.5- Calibration plot for GdG (325.7>209.9 mass transition). 
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resuspended in 1 ml of 50 mM Tris buffer, pH-8.0 and incubated further for 
10 days at 37°C in absence of tlie sugar. At the end of 10 days the DNA was 
subjected to enzymatic hydrolysis and the hydrolysate was analyzed using 
LC-MS/MS for the various adducts of nucleotide glycation. 
A parallel experiment was also set up to study the effect of interrupted 
incubation on DNA under physiological conditions in which 1 mg/ml of calf 
thymus DNA was incubated in the presence of 5 mM glucose, fructose or 
ribose in 50 mM phosphate buffer, pH-7.4 at 37°C. After an initial 24 h 
incubation, the reaction was interrupted to remove the excess sugar by 
repeated washes with fresh 50 mM phosphate buffer, pH-7.4, using 
concentrating filters (Nanosep-10K) and centrifuged at 5000 g, 4°C. Then 
the final volume of the solution was made upto 1.0 ml using fresh 50 mM 
phosphate buffer, pH-7.4. The samples were further incubated for 7 days at 
37°C then subjected to enzymatic hydrolysis and analyzed using LC-MS/MS. 
2.2.14 Synthesis and purification of MGdG. 
The synthesis was carried out as described by Fleming et al. (2008) 
using a mixture of 2'-dG (50 mg, 1.05 mmole, MW. 285.26) and MG (40% 
solution in water, 42.17 ^1, 1.67 mmole) in water (5.0 ml), and kept stirring 
for 4 days at room temperature. At the end of the incubation period, an 
aliquot (1|al + 49^1 solvent A) was analysed on the LC-MS/MS. 
The crude mixture of the cyclic adduct of MG was purified by reverse 
phase HPLC on a Dionex Ultimate 3000 series preparative HPLC system 
equipped with a binary pump, themiostatted column compartment, 
autosampler, in-line degasser, variable wavelength PDA detector. A Waters 
RCM (25mm x 10 cm) Ci8 column was used and the absorbance of the 
eluate was monitored at 254, 280 and 300 nm. The mobile phase used was 
50 mM ammonium acetate buffer, pH- 4.6. The elution was carried out under 
isocratic conditions of 50 mM ammonium acetate, pH- 4.6 for 20 min and 
then 100% acetonitrile was used for washing the column for 10 min. The 
sample for injection on the Prep-HPLC system was dissolved in the mobile 
phase, and its pH adjusted to pH- 4.6. The fractions of the desired peak 
were collected using an automated Gilson fraction collector. The purified 
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fractions were monitored by LC-MS/MS to precisely determine the fractions 
containing the desired purified adduct. Then the pooled fractions were freeze 
dried to a white powder. 
2.2.15 Synthesis and purification of CEdGA.B- The MGdG synthesis 
mixture was further incubated at 37°C beyond the 4 day incubation period, 
after adjusting the pH of the solution to 7.4 using 500 mM phosphate buffer. 
Aliquots of the mix were analysed on days - 5, 6 and 7, to monitor the 
degradation of the cyclic adduct and formation of the new product- CEdGA, B-
After 10 days of incubation, the reaction was stopped and the mixture freeze 
dried to a white powder. 
It was difficult to effectively separate the 2'-dG and CEdGA,B peaks 
using RP-HPLC, therefore anion exchange chromatography was carried out 
on a Protein PAK DEAE-cellulose matrix packed in a Waters-AP-2 (2X10 
cm) glass column. Eluent A used was 5 mM ammonium formate buffer, pH-
4.0 and eluent B- 100 mM ammonium fomriate buffer, pH- 4.0, the flow rate 
was maintained at 4 ml/min. The column matrix had to be in the formate form 
before loading to ensure effective binding of the carboxyethyl group. This 
was achieved by washing with atleast 10 column volumes of 100 mM 
ammonium formate pH- 4.0. The column was equilibrated with 5 mM 
ammonium formate buffer, pH- 4.0. Then a few milligrams of the crude 
sample dissolved in 5 mM ammonium formate buffer, pH- 4.0 were loaded 
onto the column. Gradient elution (time/%A): 0 min / 100, 10 min / 100, 40 
min / 0, 45 min /100 was carried out. Since the sample contained phosphate 
ions an additional wash with 100 mM ammonium formate for ~10 min was 
essential to ensure complete removal of phosphate from the column before 
the next run. Later the column was re-equilibrated for 10 min with the initial 
buffer, 5 mM ammonium fomnate. The fractions were collected for the 
desired peak and then freeze dried to a dry powder of the purified product, 
the purity for which was further analysed using NMR. 
2.2.16 H^ and ^^ C NMR. The NMR experiment was carried out on a Bruker 
Avance 400 MHz machine, temperature 25°C, solvent was D2O and the 
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spectra were calibrated with the solvent signal. HMQC-^ ^C, H^ and COSY 
spectra was obtained from the sample prepared in D2O. 
2.2.17 Extraction of DNA from cells in culture. The isolation protocol was 
adapted from the published work of Ravanat et al. (2002) with a few 
modifications. The cells were collected by centrifugation at 250 g for 5 min. 
Then the cellular pellet obtained was washed twice with phosphate buffered 
saline (PBS) at 250 g for 5 min each time. The washed pellet was 
resuspended in 2.0 ml of lysis buffer A, pH-7.5 (320 mM Sucrose, 10 mM 
Tris, 5 mM MgCb, 0.1 mM DFOM, 1% Triton X-100) and kept on ice for 20 
min to facilitate swelling. Then the cells were lysed by vigorous agitation, 
which involved three cycles of vortexing (5 min) followed by 5 min incubation 
on ice alternately. The nuclei were collected by centrifugation at 1500 g for 
10 min at 4°C and then washed with 2.0 ml of lysis buffer A at 1500 g for 
10minat4°C. 
The sedimented nuclei were suspended in 1.2 ml nuclear lysis buffer 
B, pH- 8.0 (10 mM Tris, 5 mM EDTA-Na2, 0.15 mM DFOM) and left on ice to 
swell for 20 min. The efficient lysis of the nuclear membrane was achieved 
by vigorous agitation involving three cycles of vortexing (5 min) followed by 5 
min on ice alternately. The removal of RNA was brought about by addition of 
40 \i\ RNase A (1.0 mg/ml in RNase buffer 10 mM Tris, 1.0 mM EDTA, 2.5 
mM DFOM, pH- 7.4) and 15 nl RNase T1 (lU/^il in RNase buffer 10 mM Tris, 
1.0 mM EDTA, 2.5 mM DFOM, pH- 7.4) and then incubation at 50°C for 15 
min. The proteins were degraded by adding 40 1^ of Qiagen protease (20 
mg/ml in water) and further incubation of the sample at 37°C for 2 h. 
The extracted DNA was precipitated by addition of 3.0 ml of sodium 
iodide solution, (7.6 M Nal, 40 mM Tris, 20 mM EDTA-Na2, 0.3 mM DFOM, 
pH- 8.0) along with 4.0 ml 100% 2-lso-propanol (chilled). Then after gentle 
inversion of the tube several times to allow proper mixing, the extracted DNA 
was spooled out using a spooler and transferred to a microcentrifuge tube. 
The DNA obtained was washed with 2.0 ml of 40% 2-iso-propanol (chilled) 
and then centrifuged at 4,495g, 15 min, 4°C. Further washing was carried 
out by addition of 2.0 ml of 70% ethanol. The sample was centrifuged at 
4,495g, 15 min, 4 °C and the purified DNA pellet was obtained. This was 
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dried by gentle flushing with argon and re-dissolved in argon-saturated water 
containing 200 |JM D F O M . To assist in dissolution of the DNA, the sample 
tube is rotary inverted for 24 h at 4°C in the dark. The concentration of the 
DNA in the sample was then determined by UV nanodrop spectrophotometry 
at 260 nm by diluting an aliquot (2 \i\) 50-fold in buffer (10 mM Tris/HCI, 1 
mM EDTA and 200 |JM DFOM, pH- 7.4). Genomic DNA was stored at 4°C 
overnight or -SOX for the longer periods (Fig. 2.6). 
2.2.18 Enzymatic hydrolysis of DNA. The enzymatic hydrolysis procedure 
was also adapted from the work of Ravanat et al. (2002) with few 
modifications. The extracted DNA sample was washed three times with 83 
mM NH4AC buffer containing 8.3 mM MgS04 + 20 mM NH4CI + 500 i^M AG 
(pH- 5.0), 0.1 mM DFOM at 4 °C, by three cycles of concentration to 100 pi 
and dilution to 500 in 10 kDa microspin filers (Nanosep, low binding 
polypropylene). After thorough washing to remove the TED buffer, the 
concentration of the DNA sample was determined using the nano-drop 
spectrophotometer. However, in order to achieve pH-7.4 for the DNA sample 
before accurately estimating DNA concentration, a 50-fold dilution was 
carried out using the TED buffer (Wilfinger et al., 1997). 
The amount of DNA required for the hydrolysis reaction was taken 
from the final concentrate and the enzymes DNAse II (2U/|ag DNA) and 
phosphodiesterase II (1.5 U/mg DNA) were added. After proper mixing, the 
samples were flushed with argon and incubated at 37°C for 20-30 min. Then 
acid phosphatase Type VII (35 U/ mg DNA) was added and after mixing, the 
samples were flushed with argon and incubated at 37°C for further 4 h. After 
the digestion was complete, the samples were allowed to cool before being 
filtered using Nanosep (low binding polypropylene), 10 kDa cut-off filters at 
14,000g, 10-15 min, 4°C to remove enzymes, prior to LC-MS/MS analysis. 
All the enzyme solutions were prepared in 83 mM ammonium acetate buffer, 
pH-5.0 (Fig. 2.7). 
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Fig. 2.6 - Schematic representation of the isolation of cellular DNA from 
cells in culture. 
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2.2.19 Assay of recovery of CECJGA.B. In order to assess the stability of the 
adduct during the hydrolysis and further LC-MS/MS analysis procedure, 
genomic DNA extracted from HL-60 cells in culture was spiked with 1.0 pmol 
of CEdGA.B standard then subjected to the enzymatic hydrolysis procedure 
as described earlier in the text. HL-60 DNA without any spiking by CEdGA.e 
was used as the control and also subjected to a similar enzymatic hydrolysis. 
Each reaction was carried out in triplicate for reproducibility and accuracy. 
The hydrolysate from control and spiked DNA was subjected to LC-MS/MS 
analysis. 1.0 pmol of CEdGA,B standard was also analysed by the LC-MS/MS 
along with these DNA hydrolysate samples. The peak area was calculated 
after integration of the data using MassLynx V4.1 data analysis software. 
Using the stable isotopic standards (synthesized in the laboratory of Prof. 
Paul J. Thornalley), % recovery of CEdGA.B adduct was accurately 
estimated. 
2.2.20 Study population and preparation of the biological samples for 
LC- MS/MS analysis. For the measurements of DNA-AGEs in humans in 
vivo, plasma and urine samples from normal healthy controls and patients 
with type 2 diabetes were analyzed. The study was carried out on normal 
healthy human subjects (part of the EU-funded Vitamin A, Vitamin E and 
Carotenoid Status and Metabolism during AGEing: Functional and Nutritional 
Consequences (VITAGE) project) and patients with type 2 diabetes with and 
without overt nephropathy (part of the EU-funded PREDICTIONS project) 
recruited at the Human Nutrition & Metabolism Research and Training 
Center, Graz, Austria. 
In addition to these, other normal healthy human subjects and 
patients with ESRD on haemodialysis where recruited at the University 
Hospital of Coventry and Warwickshire, Coventry, U.K. Venous blood 
samples (all subjects) were collected in the fasting state and plasma 
prepared. The urine from the VITAGE and PREDICTIONS studies were 
collected over a period of 24 h. The normal healthy controls (n= 28) from the 
VITAGE study had a male/female ratio of 28:0, and following clinical 
characteristics, BMI- 26.1± 1.8(kg/m )^, creatinine clearance value- 94 ± 33 
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(ml/min/1.73 m )^ and fasting plasma glucose levels were 5.6 ± 0.5 mM. 
While type-2 diabetics recruited in the PREDICTIONS study belonged to two 
groups, those with nephropathy (n=28) with 21 males and 7 females, and the 
other without nephropathy (n=28) with 20 males and 8 females (Table 2.2). 
The samples from ESRD patients belonged to (n=8) 6 males and 2 females. 
Normal healthy volunteers were also recruited as controls (n=5) with 4 males 
and 1 female. For the healthy controls, the average age of patients was 
61.7±6.4 years, BMI- 27.1 ±1.4 (kg/m^), fasting plasma glucose levels were 
4.7±0.5 mmol/L and HbAlc (%) was 5.9±0.7(%), while for patients with 
ESRD the values were, age- 47.7±10.4 years; BMI-25.1±2.2 kg/m^ fasting 
plasma glucose- 4.3±0.5 (mmol/L) and HbAlc (%)- 5.5±0.4 %. 
Before proceeding for LC-MS/MS analysis ultrafiltrates were prepared 
by microspin ultrafiltration (Nanosep-10 kDa cut-off) of all plasma and urine 
samples (100 |JI) at 14000 x g at 4°C and thus 50 i^ l ultrafiltrate was 
obtained. The final LC-MS/MS sample contained 40 ^1 ultrafiltrate spiked 
with 10 fil of isotopic standards containing 0.1 nmol [U-^^Cio.U-^^Ns] dG, 1.0 
pmol [U-^^Cio,U-^^N5] 8-oxodG, 1.0 pmol [U-^^Cio,U-^X] MGdG , 1.0 pmol 
[U-^^Cio.U-^^Ns] GdG and 0.1 pmol [U-^^CicU-^^Ns] CEdGA.B-
2.2.21 Statistical analysis. Statistical analysis was carried out using SPSS 
statistics software (version 17.0). The median, range (min-max.) values were 
estimated for the various adducts in plasma and urine from nonnal healthy 
controls and type-2 diabetes patients. To test the level of significance in 
difference in the mean plasma 2'-dG, 8-oxodG and GdG levels between 
control and diabetics the non-parametric Mann-Whitney U test was applied, 
whereas for MGdG and CEdGA.e levels Student's t-test for independent 
means was used. While for the urine samples, the non-parametric Mann-
Whitney U test was carried out. Similarly, for plasma 2'-dG, CEdGA,B and 
GdG measurements in ESRD patients, Mann-Whitney U non parametric test 
was conducted to decide if there was any significant difference in the mean 
values of control and ESRD samples. While Student's t-test for independent 
samples was employed to determine whether the levels of 8-oxodG and 
MGdG measured in ESRD patients were significantly different as compared 
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Table 2.2 - Details of human subjects employed in the study. 
Fasting Creatinine MKAI^ Urinary 
" ^ " f ^/M/pf ^ ^ \ . .T '^^ P,"'"'^ Clearance ^^^-^J" albumin 
N (M/F) (years) (kg/m) glucose (rnl/min/1.73m )^ ^^ "^  (mg/24h) 
Control 28 28/0 61±8 26.1±1.8 5.6±0.5 94.1+32.6 N.A. N.A. 
Type 2 
28 21/7 60±10 32.1±8.0 9.3±3.8 49.7±31.4 7.5±1.5 3283.7±2701.4 
with 
nephropathy 
Type 2 
28 20/8 63±6 28.5±5.0 9.4±3.0 86.1±23.7 7.6±1.2 13.1±10.2 
without 
nephropathy 
N.A. - not available 
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to the controls. All data are represented as mean ± S.D. p< 0.05 was 
considered significant. 
2.2.22 Cell lines and cell culture. The various cell lines used for the study 
were human myeloblastic leukemia cell type HL-60, Human Alveolar 
epithelial cell type A549, Human Osteosarcoma MG63 cell type, Human lung 
carcinoma NCI-H522 cell type and Human Pleural effusion adenocarcinoma 
NCI- H460 cell type. The cell lines A549, NCI-H522, NCI-H460 were 
supplied by the Developmental Therapeutics program, National Cancer 
Institute, Frederick, MD 21701 and MG63 cell type was provided by 
European Collection of Cell Cultures. Whereas HL60 cells were purchased 
from the European Collection of Animal Cell Cultures (ECACC), Porton 
Down, Wiltshire, U.K. 
The cell lines (NCI-H522, NCI-H460, A549) were seeded 12 h before 
the experiment and cultured in RPMl until 70-80% confluency was achieved, 
and cell growth was assessed (using the CyQUANT Cell Proliferation Assay 
Kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's 
instructions). The medium was replaced with fresh medium, for the control 
(i.e. RPMl-1640 containing 10% fetal calf serum, 1% Pencillin-Streptomycin-
gentamycin but without the Glo-I inhibitor BBGC). Whereas, MG63 cells 
were also seeded 12 h before the experiment and cultured in EMEM medium 
until 70-80% confluency (cell growth was assessed using the CyQUANT Cell 
Proliferation Assay Kit), then the medium was replaced with fresh medium 
but without the Glo-I inhibitor. After culturing for 24 h, at 37° C under an 
atmosphere of 5% CO2 in air, 100% humidity, the culture medium was 
extracted for analysis. The cells were washed with PBS and then trypsinised 
to ensure detachment of the cells. Further processing was can-ied out as per 
the protocol for DNA extraction described earlier to obtain the DNA from the 
control samples. 
For the inhibitor treatment, cells were seeded at a concentration of 
5,000 cells per well in 96-well plates (Standard clear Coming and Costar 96 
Well Plate, Corning Inc, Life Sciences, Acton, MA, USA), using their nomrial 
media. After 24 h, the medium was removed and replaced with that 
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containing the cell permeable Glo-I inhibitor, BBGC. There were six 
replicates of each of the following concentrations of BBGC: 0, 1,2, 2.5, 5, 
10, 15, 20 and 25 pM. After a further 24 h culture, cell growth was assessed 
using the CyQUANT Cell Proliferation Assay Kit. Dose response curves 
were then constructed and IC50 determined. IC50 represents the 
concentration of a drug that is required for 50% inhibition of cell 
accumulation in vitro. These cell lines were also cultured in larger number 
(20 X 10^ cells in 150 cm^ T-flasks) for 24 h with and without 20 i^M BBGC , 
and then DNA extraction and analysis of DNA adducts was carried out. The 
cell culture experiments were performed by Dr. Thomas Santarius, Cancer 
Genome Project, Welcome Trust Sanger Institute, University of Cambridge, 
Cambridge, U.K. BBGC was prepared and purified in the laboratory of 
Professor Paul J Thornalley at the University of Warwick, UK, by members of 
his research team. 
Human myeloblastic leukemia cell type (HL-60 cells) was another cell 
type used in our study. It was established in 1977 from a female patient with 
acute myeloblastic leukaemia (Collins et al., 1977). Initially and still often 
classified as a human promyelocytic leukaemia cell line, classification as a 
myeloblastic leukaemia with differentiation is considered to be a more 
accurate description of the cell lineage (Dalton et al., 1988). HL60 cells were 
purchased from the European Collection of Animal Cell Cultures (ECACC), 
Porton Down, Wiltshire, U.K. The cells were seeded at an initial cell density 
of 1 X 10^/ml and incubated at 37°C in RPMI 1640 media containing 10% 
fetal calf serum (FCS) under an atmosphere of 5% CO2 in air, 100% 
humidity. Cells were maintained in exponential growth by sub-culturing at 
intervals of 4 days. For the extraction of DNA, cultures were scaled up to 
produce 10x10^ cells on day 4 of the culture. 
2.2.23 Isolation of peripheral mononuclear lymphocytes. Venous blood 
(50 ml) was drawn into a tube containing EDTA (1 mg/ml of blood) and 
centrifuged at 2,000 g, 10 min. After removal of the plasma, the buffy coat on 
top of the RBC layer was carefully extracted taking care to have minimum 
RBC's contamination in the lymphocyte fraction. This cellular pool containing 
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RBC's, lymphocytes, monocytes was resuspended in 4.0 ml of RPMI 1640. 
The cell suspension was layered on top of 4.0 ml of sterile Ficoll-Hypaque 
1077 in a sterile 15 ml tube and centrifuged (400 g, 30 min). The interface 
layer (at the midpoint of the solution) was removed and washed twice with 
10 ml of RPMI 1640 (200g, 10 min). Thus, the pellet of mononuclear cells 
was obtained and resuspended in 2.0 ml RPMI 1640. An aliquot of 20 1^ was 
diluted with 80 |il of RPMI 1640. A 1:1 dilution using 0.4 % trypan blue in 
PBS was carried out in order to count the cells on the haemocytometer. A 
further dilution of the mononuclear cells in RPMI 1640 was done to obtain 2 
X 10^ cells/ ml. In order to remove the monocytes present in the solution, 
these cells were cultured in a 24 well plate at a density of 2 x 10^ cells per 
well, at 37°C in a CO2 incubator for 60 min. The supernatant containing 
MNLs was collected and centrifuged at 200 g, 10 min, 4°C. The pellet of 
cells obtained was resuspended in 2.0 ml RPMI and the cell number 
estimated using tryphan blue counting, as described earlier. After estimation 
of cell count, the cell number required for DNA extraction was taken and the 
DNA extracted using the protocol described earlier in the text (pig. 2.8). In 
our study the lymphocytic cells were extracted from blood received from 
three healthy volunteers. 
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Fig. 2.8- The procedure adopted for the isolation of DNA from mononuclear 
lymphocytes in the blood obtained from normal, healthy human 
subjects. The cells obtained were subjected to lysis to obtain DNA 
and the extracted DNA was subjected to enzymatic hydrolysis 
procedure as described earlier. 
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ml 40% isopropanol;2 x 2 ml 70% ethanol; 4 "C), and 
dried under argon Ml 
DNA 
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In vitro studies on the 
glycation of 
deoxyguanosine /DNA 
by various reducing sugars 
3.1 INTRODUCTION 
The free carbonyls of reducing sugars react with amino groups of 
biological macromolecules in a series of complex chemical processes 
termed as non-enzymatic glycosylation or glycation (Monnier, 1989). 
Glycation is initiated by the fomnation of an acid-labile Schiff base (Olff et al., 
1987; Harding, 1985) that undergoes rearrangements into more stable 
Amadori or Heyns products (Cerami et al., 1986; Yaylayan et al., 1994; 
Monnier, 1990; Fu et al., 1994). The early glycation products are gradually 
and irreversibly transformed to AGEs (Baynes, 1991; Bucala and Cerami, 
1992). 
Glycation reaction of long-lived macromolecules may account for 
several physiological complications. The outcome of the glycation reactions 
are determined by the reactivity of the sugars involved, and their nature viz. 
aldoses or ketoses, phosphorylated or non-phosphorylated (Levi and 
Werman, 2003). 
Logically, short-lived molecules, such as proteins in plasma and 
blood, are expected to be modified primarily by the early glycation products, 
while long-lasting molecules like collagen, lens crystalline, myelin and DNA 
tend to accumulate AGEs (Stadtman, 1990). 
Several in vitro studies revealed that the amino groups of the DNA 
bases are sites of nonenzymatic glycosylation. The first evidence that 
reactive carbonyl compounds can react with guanine and its derivatives, 
producing AGEs was provided by Staehelin (1959) and subsequently by 
Shapiro et al. (1966, 1969). Further researches showed that incubation of 
DNA with sugars at 37°C leads to the characteristic browning (Bucala et al., 
1984). In vitro incubations of single-stranded/ double-stranded DNA or 
nucleotides carried out with glucose and glucose-6-phosphate showed 
changes in absorbance and fluorescence similar to those seen in proteins 
upon modifications by reducing sugars (Bucala et al., 1984). Another study, 
using end-labeled DNA fragments of defined sequence as substrates was 
able to show that reducing sugars such as D-fructose and D-fructose-6-
phosphate induce the formation of alkali-labile sites in DNA, especially at the 
pyrimidine residues in pyrimidine-purine (5-3') sequences (Morita, 1985). 
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Further studies on DNA giycation and the consequent alterations were 
carried out, in which the mutagenicity of glucose-6-phosphate on the double-
stranded plasmid pBR322 DNA was tested under in vitro conditions. It was 
shown that products of DNA giycation cause various types of structural 
rearrangements in DNA (Bucala et al., 1985). An in vivo model was created 
to study the plasmid DNA mutations induced by the reducing sugars, and it 
was seen that observed increase in plasmid mutations, of the type such as 
insertions, deletions, and point mutations, correlated with in vivo rising 
concentrations of the reducing sugar in the medium (Lee and Cerami, 1987). 
The early studies established that the nonenzymatic glycosylation of 
nucleic acids by the reducing sugars, such as glucose or glucose-6-
phosphate alters both the physical and biological properties. Lee and Cerami 
(1991) worked on these findings and showed that a number of insertional 
plasmid mutations observed in the earlier work were the result of the 
movement of the transposable element y5 from the host genome into the 
plasmid. The frequency of yb transposition was also a function of the 
concentration of glucose-6-phosphate that accumulated in the bacterial cells 
and suggested a novel mechanism of induction of mutation by reducing 
sugars. 
In addition, it would be expected that glycated DNA contributes to 
"site-specific" radical DNA damage. The Amadori products and 2-amino-2-
deoxy aldose are known to have higher autoxidizing and DNA strand 
breakage activities than aldoses or ketoses (Kashimura et al., 1986 and 
1987). Glycated proteins are also found to autoxidize to yield oxygen 
radicals (Gillery et al., 1988; Sakurai et al., 1990) and induce DNA strand 
breakage (Kashimura et al., 1990). Amadori or Heyns products formed on 
DNA or on proteins bound to DNA, then they may autoxidize and produce 
highly reactive ROS and other free radicals in the neighbourhood of DNA 
molecules. This may readily cause secondary critical damage to DNA (e.g., 
strand breakage and further degradation of DNA) and contribute towards the 
fomriation of fluorophores and chromophores. 
Since D-glucose is the most abundant monosaccharide in the tissues 
and its concentration is elevated during diabetes, major research on 
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glycation has focused on glucose (Knerr and Severin, 1993). However, 
recent studies have shown that D-fructose (Suarez et al., 1988; Suarez et 
al., 1989; McPherson et al., 1988) and some pentoses are more potent 
glycators than D-glucose in vivo and may contribute significantly to 
complications related to diabetic and age-related processes (Monnier, 1989; 
Bunn and Higgins, 1981). Bucala et al. (1985) studied the glycation of DNA 
and nucleotides by aldoses whereas the work of Morita and Kashimura 
(1991) highlighted the action of ketoses on nucleotides or polymer DNA. The 
changes in absorption and fluorescence spectra of the nucleotide or DNA in 
presence of ketoses verified that ketoses such as D-fructose 6-phosphate 
react with primary amino group of DNA bases to form Schiff base that 
undergoes Heyns rearrangement (Morita and Kashimura, 1991). 
Ribose, a more reactive sugar than glucose was used to glycate 
proteins like Bovine Serum Albumin (BSA) and RNase (Khalifah et al., 
1996). The study showed that the removal of excess and reversibly bound 
ribose from the presumed Amadori intermediates led to the rapid formation 
of AGEs with a half life of exponential kinetics, only a few hours. This 
interrupted glycation method provides a new mechanism based strategy for 
understanding the pathway of reactions leading to AGE fomnation (Khalifah 
etal., 1996 and 1999). 
Apart from reducing sugars, their metabolic derivatives also cause 
glycation. Glyoxal is one such compound and is the major a-dicarbonyl 
formed from glucose autoxidation, wherein 250 mM glucose was found to 
yield 0.5 mM glyoxal in a time span of 21 days (Wells-Knecht et al., 1995). 
Manini et al. (2006) showed glyoxal formation from other sugars/ 
carbohydrates as well with yields being in the order, D-fructose, D-ribose=D-
arabinose and 1,3-dihydroxyacetone. It is also the major product generated 
from DNA and its related compounds by Fenton-type oxygen-free radical-
forming systems (Loeb et al., 1988). 
MG is another reactive a-ketoaldehyde generated in vivo mainly by 
the fragmentation of triose phosphates, dihydroxyacetone phosphate and 
glyceraldehyde-3-phosphate (Richard, 1993; Phillips and Thornalley, 1993). 
Degradation of glucose produces MG (Phillips and Thornalley, 1993) and 
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also fructose formed from glucose via the polyol pathway is another major 
source of MG (Wang et al., 2006). MG is present in 3 forms in aqueous 
solution, unhydrated (1%), monohydrate (71%) and dihydrate (28%) fomns, 
which are in rapid equilibrium (Creighton et al., 1988; Rae et al., 1990). MG 
has been shown to react with polynucleotides, poly-G, poly-A and poly-C in 
the reactivity ratio 100:7:3, and was unreactive with poly-U (Krymkiewicz, 
1973). MG modified guanylate residues to form MGdG and N^-(1-
carboxyethyl) guanine (CEG) (Papoulis et al., 1995; Shapiro et al., 1969; 
Vaca et al., 1994). N -^acetylguanine was fomied from the decomposition of 
MGdG in the presence of H2O2 (Nukaya et al., 1990) (Fig. 3.1, Thornalley et 
al., 1996). MG reacts with 2'-dG to fonn CEdGAB which has been considered 
as the major marker of nucleotide/DNA glycation. Seidel and Pischetsrieder 
(1998c) concluded that CEdG-adducts when present in the DNA led to 
depurination, single strand breaks (Pischetsrieder et al., 1999) and local 
distortion in the double helix (Cuniasse et al., 1990). In a recent study it was 
further shown that CEdGA.s modification introduced into a plasmid vector 
leads to a decrease in protein activity after transfection in prokaryotic and 
eukaryotic cells (Breyer et al., 2008). Under certain conditions, the DNA 
replication inactivated due to this lesion does continue beyond the damage 
site giving rise to mutagenesis, which has been observed in both bacterial 
(Schaaper and Loeb, 1981) as well as mammalian cells (Gentil et al., 1992). 
The work of Cao et al. (2007) was the first of its kind to predict the fate of 
diastereomers of CEdGA,B in vivo by stereospecific synthesis of 
oligodeoxyribonucleotides containing CEdGA,B. 
MG was found to induce apoptosis in HL-60 cells in vitro and this 
cytotoxicity was correlated with inhibition of DNA synthesis in the cells which 
was due to the formation of DNA adducts of MG (Kang et al., 1996). 
Fleming et al. (2008) developed an analytical procedure for the nucleotide 
AGEs produced by the reaction of MG and glyoxal with 2'-dG under 
physiological conditions, namely- MGdG and GdG respectively. 
Among the nucleobases, guanine and its derivatives react most 
readily with the sugars and dicarbonyl compounds (Papoulis et al., 1995). 
Thus, free guanosine, guanine, or 2'-dG were used in most model 
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incubations with sugars and sugar degradation products in search of 
possible DNA-adducts generated in vivo. At the elevated temperatures, 
giucosylamine was identified as the main product on incubation of 2'-dG and 
D-glucose (Knerr et al., 1994), whereas at physiological temperatures 
CTPdG was found to be the major AGE formed (Ochs and Severin, 1995; 
Knerr and Severin, 1993). In the in vivo environment glucose is mostly 
phosphorylated to glucose-6-phosphate, hence the latter seems to be a 
more relevant DNA-AGE precursor. Glucose-6-phosphate reacts with 2'-dG 
resulting in fonnation of a CTPdG derivative phosphorylated at position 5. 
The product was indirectly identified by enzymatic conversion into CTPdG 
(NissI et a!., 1996). The two diastereomers of 2-I9-(2-deoxy-p-D-
ribofuranosyl)-6, 9-dihydro-6-oxo-1H-purin-2-ylamino] propionate, also 
named CEdGA.e were first isolated as reaction products of glyceraldehyde 
and 2'-dG. Later on, it was shown that CEdGA.s or the analogous derivatives 
from guanosine, guanine or 9-methylguanine - CEG, CEguanine and 
CEmG- were also formed from many other sugars and sugar degradation 
products, such as glucose, ribose, glucose-6-phosphate, dihydroxyacetone, 
or ascorbic acid (Papoulis et al., 1995; NissI et al., 1996; Seidel and 
Pischetsrieder, 1998a; Larisch et al., 1997). In the presence of oxygen and 
glucose, lower concentrations of CMG were additionally detectable (Seidel 
and Pischetsrieder, 1998b; Al-Abed et al., 1998). 
As seen in case of proteins the reaction between a-dicarbonyls and 
guanosine results in rapid formation of the cyclic adduct, MGdG at room 
temperature (Schneider et al., 1998; Frischmann et al., 2005). However 
longer incubations seemed to result in the degradation of the cyclic adduct to 
CEdGA.B (Papoulis et a!., 1995; Frischmann et a!., 2005). Evidence suggests 
that the occurrence of DNA-AGEs does not only occur limited to reactions of 
isolated DNA in vitro, but also takes place under cell culture conditions and 
in vivo. Using the ^^P- labeling technique, the cyclic adducts of MG and 2'-
dG have been identified in human lymphocytes or human buccal epithelial 
cells, exposed to MG (Hou et al., 1995; Vaca et al., 1994; Vaca et al., 1998). 
A polyclonal antibody was raised which was specific to CEdG A,B and 
facilitated the analysis of DNA-AGE formation in vitro by ELISA (Seidel and 
57 
Pischetsrieder, 1998a). However, the assay was not sensitive enough to 
estimate formation of CECIGA.B in DNA of living cells. Schneider et al. (2004) 
gave the first evidence of the fomriation of CEdGA.e in vivo. Using a 
monoclonal antibody raised against CEdGA.e, the CEdGA.B concentrations in 
121 human urine samples were found to vary between 1.2 and 117 ng / mg 
creatinine (Schneider et al., 2004). Using immunoaffinity chromatography 
coupled to HPLC-DAD the presence of CEdGA,B was confirmed in human 
urine, as well as genomic DNA of human smooth muscle cells and bovine 
aorta endothelial cells (Schneider et al., 2006). CEdGA.s was also found to 
be present in kidneys and aorta using the monoclonal antibody in 
immunohistochemistry (Li et al., 2006). 
CEdGA,B is one DNA-AGE whose formation has been reported in 
vivo, however, its biological consequences are not known. In order to 
investigate factors that influence cellular DNA glycation, a reliable analytical 
LC-MS/MS method was employed to determine the rate of CEdGA,B 
formation in genomic DNA of cultured HSC-T6 hepatic stellate cells (Breyer 
et al., 2008). Insights into the functional consequences of DNA glycation 
were obtained by introducing CEdGA.e into a luciferase reporter gene vector 
and then transfecting into human embryonic kidney (HEK 293 T) cells. 
Chemiluminescence of luciferase showed that CEdGA,B adducts led to a 
dose dependent and highly significant decrease in the protein activity 
(Breyer etal., 2008). 
In the present work, in vitro incubations of plasmid pBr322 DNA with 
reducing sugars- glucose, fructose and ribose were carried out to show how 
glycation damage affects DNA topology and structure. 
Further, the work described in this thesis shows that the nucleoside-
sugar reaction results in the formation of same adducts as reported earlier 
(Fleming et al., 2008; Kang et al., 1996; Vaca et al., 1994) and measuring 
them could provide infonnation on the toxicity of the monosaccharides. LC-
MS/MS techniques were employed and formation of the various products of 
glycation damage in DNA - MGdG, GdG and CEdGA.B were quantified as a 
function of time and concentration. The effect of anti-AGE compounds like 
AG and DETAPAC on the formation of these DNA adducts was also studied. 
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The interrupted glycation strategy of Khalifah et al. (1996; 1999) was 
tested on the glycation reaction of plasnnid DNA as well as calf thymus DNA 
with the reducing sugars- glucose, fructose and ribose. The adduct formation 
in DNA samples subjected to continous and interrupted glycation reaction 
was studied by monitoring plasmid transfonnation using gel electrophoresis, 
as well as quantitative estimates were achieved by tandem mass 
spectrometry employing stable isotopic standards. 
Besides ELISA measurements using monoclonal anti-CEdGA,B 
antibody to assess the formation of CEdGA,B by reducing sugars were made 
during in vitro incubations with herring sperm DNA. In another study, ribose, 
a more reactive sugar than glucose which was used in earlier studies by 
Khalifah et al. (1996; 1999) to glycate proteins like BSA and RNase was 
used. Their strategy was tested on the glycation reaction of herring sperm 
DNA with ribose and the amount of CEdGA,B was estimated using a 
competitive ELISA using anti-CEdGA.e antibody. 
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3.2 RESULTS 
3.2.1 In vitro incubations of plasmid pBR322 with the sugars. 
The in vitro studies on DNA glycation were carried out using pBr322 
plasmid DNA, in which incubations were performed in the presence of 
glucose, fructose or ribose at 37°C. Initial experiments were carried out 
using 200 mM glucose and fructose. 
The results obtained in Fig. 3.2 show that 200 mM glucose or fructose 
did not induce significant modification in the plasmid DNA after 3 days of 
incubation as revealed by gel electrophoresis. Transformation of the plasmid 
was however observed when the incubation was extended to 5 days. The 
supercoiled form of the plasmid was converted to open circular form, as 
indicated by the appearance of an intense band of slow mobility. The degree 
of transformation was greater in the sample incubated with fructose as 
compared to those incubated with glucose. Extension of incubation to 10 or 
15 days caused only minor additional transformation to open circular form. 
There was no Indication of linearization of the plasmid. 
In order to speed up the reaction additional studies were carried out 
using 400 mM sugar concentration. It was observed that both fructose and 
glucose induced significant transformation of supercoiled form of plasmid to 
open circular form in a period of 3 days (Fig. 3.3 (a)). Further incubation upto 
7 days revealed (Fig. 3.3 (b)) that fructose was a stronger glycator than 
glucose and caused greater plasmid transformation. This transformation to 
the open circular form by fructose was nearly complete at the end of 14 days 
of incubation (Fig. 3.3 (c)). When these glycated DNA samples were 
subjected to EcoRI digestion it was seen that plasmid DNA modified by 
fructose (Fig. 3.3 (a, b, c), lane-7), was unaffected at the end of 3 days, but 
resistance to digestion by EcoRI was seen, as an extra upper band in the 
gels of open circular form at the end of 7 days. Further incubations upto 14 
days showed that the samples incubated with glucose also showed 
significant resistance to digestion by EcoRI (as was seen in samples 
incubated with fructose for 7 days) indicated by an intense band of the open 
circular form of the plasmid (Fig. 3.3 (c), lane-6). 
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Fig. 3.2 - Agarose gel electrophoresis of plasmid DNA after incubation with 
glucose or fructose. pBr322 DNA was subjected to incubation at 
37°C, for 3, 5, 10 and 15 days with 200 mM glucose or fructose as 
detailed in the methods. The treatment given to each DNA sample 
is indicated in the key above every lane (SC- supercoiled and OC-
open circular). 
Fig. 3.3- Restriction digestion by EcoRI of plasmid DNA incubated with 
glucose or fructose. pBr322 DNA incubated with 400 mM glucose 
or fructose for (a) 3 days, (b) 7 days and (c) 14 days was digested 
by EcoRI. The treatment given to each DNA sample is indicated in 
the key above every lane. (SC- supercoiled, OC- open circular and 
L- linear). 
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When DNA-sugar incubations were carried out in the presence of 
EDTA, the degree of plasmid transformation was reduced (Fig. 3.4 (a, b, c,) 
lane-3). The metal ion chelator, DETAPAC, was more effective and 
prevented the sugar induced DNA damage (Fig. 3.4 (a, b, c), lane-6). 
Ribose and its derivatives like ADP-ribose are highly reactive in 
protein glycation leading to AGE formation and may be an important source 
of glycation in various cellular organelles (Laurean et al., 1993). An 
interesting inhibition of protein glycation by ribose was observed at high 
concentration of the sugar, but removal of excess sugar after the initial 
reaction dramatically increased the formation of specific AGEs (Khalifah et 
al., 1996). 
In the present study, we therefore studied the effect of 400 mM ribose 
on plasmid DNA under continuous and interrupted incubation conditions. 
Also the effect of BSA subjected to continuous and interrupted incubation 
with glucose, fructose, ribose on plasmid DNA at 37°C was examined. 
As evident from Fig. 3.5, transformation of the super coiled form of 
the pBr322 DNA to the nicked open circular form was detectable after three 
days of incubation with ribose. The damage was more marked in the sample 
in which DNA was precipitated after 24 h incubation in order to remove 
excess ribose and further incubated in the absence of the sugar. 
Furthermore, a faint band representing linear form of the plasmid also 
appeared in the sample in which the reaction was interrupted. The 
transformation of the plasmid to open circular form was more marked after 
five days of incubation and the super coiled form completely disappeared 
when the incubation was extended to seven days. The band representing 
the linear form also increased in intensity when the incubation was continued 
for seven days. In contrast, when the plasmid was incubated without 
interruption and removal of ribose up to seven days, transformation of the 
plasmid to the open circular form was slow and the sample contained only 
traces of the linear form. Considerable amount of the super coiled form 
remained in the sample even after seven days of incubation. 
Fig. 3.6 shows that the plasmid DNA incubated with the ribose-
exposed BSA was more rapidly transformed from the supercoiled to open 
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Fig. 3.4 - Effect of EDTA and DETAPAC on plasmid DNA subjected to 
incubation with fructose. pBr322 DNA was incubated with 400 mM 
fructose for (a) 5 days, (b) 7 days and (c) 14 days, in presence of 
EDTA or DETAPAC as detailed in the methods. The lane-1 of (a), 
(b) and (c) show the unincubated plasmid control (SC- supercoiled 
and OC- open circular). 
Fig. 3.5 - Agarose gel electrophoresis of plasmid DNA after incubation with 
ribose. pBr322 DNA was subjected to continuous or interrupted 
incubation for 3, 5 and 7 days with 400 mM ribose as detailed in 
the methods. The treatment given to each DNA sample is 
indicated in the key above every lane (For details refer to legend 
of Fig. 3.4). 
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Fig. 3.6 - Agarose gel electrophoresis of plasmid DNA incubated with BSA 
subjected to preincubation with ribose. pBr322 DNA was exposed 
for (a) 1& 3 days, (b) 5 &7 days to BSA which had been subjected 
to interrupted or continuous incubation with 500 mM ribose as 
detailed in the methods. The treatment given to each DNA sample 
is indicated in the key above every lane (For details refer to 
legend of Fig. 3.4). 
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circular and linear forms, in absence of the sugar as compared to the DNA 
sample incubated with the ribose-exposed BSA in presence of sugar. The 
difference in the extent of DNA damage was evident as early as after 24 h of 
incubation (Fig. 3.6 (a)). The plasmid incubated with the ribose-exposed 
BSA in absence of sugar showed more rapid loss of the supercoiled form 
and linearization. Samples incubated for 5 and 7 days in absence of ribose 
also showed some non-specific cleavage indicated by the smearing in the 
lanes 4 and 7 (Fig. 3.6 (b)). 
Fig. 3.7 shows that at the end of 10 days (Fig. 3.7 (a)), plasmid DNA 
incubated with sugar-exposed BSA in absence of sugar showed more rapid 
transformation from supercoiled to open circular and even linear form (lane-
6), as compared to the DNA sample incubated with sugar-exposed BSA in 
presence of the sugar. This plasmid transformation was even more rapid 
than that of DNA incubated with fructose for a period of 10 days (lane-3). 
When the plasmid was incubated with glucose - exposed BSA in absence 
and presence of the sugar (lanes-4 and 5) (which is a slower glycator as 
compared to fructose or ribose) no linearization of plasmid was visible even 
at the end of 10 days. 
However, at the end of 14 days plasmid DNA incubated with glucose-
exposed BSA also showed a band for the linear form of the plasmid (Fig. 3.7 
(b), lane-4). Although the transformation of the plasmid to the open circular 
and linear form was slower for the plasmid DNA incubated with glucose-
exposed BSA as compared to the plasmid incubated with fructose-exposed 
BSA (lanes- 5 and 7). 
On longer incubations (upto 21 days), it was observed that DNA 
incubated with glucose/fructose exposed BSA incubated in both absence 
and presence of the respective sugar showed the appearance of a band of 
intermediate mobility, corresponding to the linear form of plasmid. The 
degree of linearization was greater in plasmid DNA incubated with sugar-
exposed BSA subjected to incubation in absence of fructose or glucose (Fig. 
3.7(c), lanes-4 & 6). 
To further examine the modification of plasmid DNA resulting from the 
brief exposure to ribose or ribose-exposed BSA, susceptibility of the plasmid 
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Fig. 3.7 - Agarose gel electrophoresis of plasmid DNA incubated with BSA 
subjected to preincubation with glucose or fructose. pBr322 DNA 
was exposed for (a) 10 days, (b) 14 days, (c) 21 days to BSA 
which had been subjected to interrupted or continuous incubation 
with 500 mM sugar as detailed in the methods. The treatment 
given to each DNA sample is indicated in the key above every 
lane. The lane-1 of (a), (b) and (c) show the unincubated plasmid 
control (For details refer to legend of Fig. 3.4). 
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to hydrolysis by restriction enzymes was investigated. pBR 322 DNA 
incubated with ribose-exposed BSA for seven days showed clear increase in 
resistance to dijgestion by Bam HI (Fig. 3.8). As also seen in the figure, some 
undigested DNA as well as non-specifically cleaved DNA was visible in the 
lanes. The digestion of these samples by multiple-site cleaving enzyme, Hinf 
I (Fig. 3.9) showed that the pattern generated by the restriction enzymes was 
slightly altered for the DNA sample incubated in the presence of dialyzed 
BSA sample as indicated by Ihe appearance of an extra band (Lane-5). 
pBR 322 DNA incubated with BSA subjected to preincubation in 
absence of ribose for seven days showed clear increase in resistance to 
digestion by EcoRI (Fig. 3.10, lane-5). Some resistance was also seen in the 
DNA sample incubated with 500 mM ribose for 7 days. 
The effect of DETAPAC on alterations induced by ribose and ribose-
exposed BSA on the plasmid DNA was also investigated. Fig. 3.11 indicates 
that DETAPAC was remarkably effective in inhibiting the alterations in 
plasmid DNA, which were evident after 5 and 7 days of incubation. The 
transfomiation of plasmid DNA induced by incubation with BSA which had 
been preincubated with ribose was also decreased remarkably in presence 
ofDETAPAC (Fig. 3.12). 
3.2.2 /nV/tro incubations of 2'-dG with the sugars. 
Sugar nucleotide adduct formation was investigated using 2'-dG as 
the model nucleoside. For this purpose 2'-dG was incubated separately with 
5 mM or 20 mM glucose, fructose or ribose. The incubations as described in 
the methods were carried out at 37°C for upto 14 days. Analysis indicated 
that GdG was formed in highest concentration irrespective of the sugar used 
as compared to other adducts investigated. The order of formation of other 
adducts was 8-oxodG > CEdGA,B > MGdG. More adducts were formed when 
incubation mixtures contained 20 mM sugars as compared to those formed 
while using sugars at 5 mM concentration. 
Fig. 3.13 shows the kinetics of formation of GdG. As evident, 5mM 
glucose and fructose caused little GdG fomriation. While significant amounts 
of the adduct was formed when 2'-dG was incubated with 5 mM ribose. 
Marked increase in the GdG formation was evident especially in the samples 
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Fig. 3.8 - Restriction digestion by Bam H1 of plasmid DNA preincubated 
witli BSA, which had been incubated with ribose under interrupted 
or continuous conditions. pBr322 DNA preincubated with BSA, 
which had been subjected to incubation under interrupted or 
continuous conditions, for 3 and 7 days was digested by Bann H1. 
The treatment given to each DNA sample is indicated in the key 
above every lane (For details refer to legend of Fig. 3.4). 
Fig. 3.9- Restriction digestion by Hinf I of plasmid DNA preincubated with 
BSA, which had been incubated with ribose under interrupted or 
continuous conditions. pBr322 DMA preincubated with BSA, which 
had been subjected to incubation under interrupted or continuous 
conditions for 7 days, was digested by Hinf I. The treatment given 
to each DNA sample is indicated in the key above every lane (For 
details refer to legend of Fig. 3.4). The arrow highlights the extra 
band in lane-5, depicts the altered restriction pattern for the DNA 
incubated in the presence of BSA subjected to interrupted 
incubation. 
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Fig. 3.10- Restriction digestion by EcoRI of plasmid DNA preincubated with 
BSA, which had been incubated with ribose under interrupted or 
continuous conditions. pBr322 DNA preincubated with BSA, 
which had been subjected to incubation under interrupted or 
continuous conditions for 7 days, was digested by EcoRI. The 
treatment given to each DNA sample is indicated in the key 
above every lane (For details refer to legend of Fig. 3.4). 
Fig. 3.11- Effect of DETAPAC on plasmid DNA subjected to interrupted or 
continuous incubation with ribose. pBr322 DNA was incubated 
with 400 mM ribose for 5 and 7 days in (a) absence and (b) 
presence of 10 mM DETAPAC under interrupted or continuous 
conditions as detailed in the methods. The treatment given to 
each DNA sample is indicated in the key above every lane (For 
details refer to legend of Fig. 3. 4). 
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Fig. 3.12- Effect of DETAPAC on DNA incubated with BSA which had been 
preincubated with ribose under interrupted or continuous 
conditions. pBr322 DNA was incubated for 5 and 7 days with 
10 mM DETAPAC, in the presence of BSA which had been 
subjected to interrupted or continuous pre-incubation with 500 
mM ribose as detailed in the methods. The treatment given to 
each DNA sample is indicated in the key above every lane (For 
details refer to legend of Fig. 3.4). 
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Fig. 3.13 - Time dependent fonnation of GdG from 2'-dG. Five mM 2'-dG 
was incubated with the sugars in sodium phosphate buffer, pH-
7.4 at 37°C. Aliquots were withdrawn at the indicated intervals 
for LC-MS/MS analysis as described in the text. ( A ) - 5 mM 
glucose, ( A ) - 20 mM glucose, ( D ) - 5 mM fructose, ( • ) -
20 mM fructose, (O) - 5 mM ribose, ( • ) - 20 mM ribose. 
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containing ribose when the sugar concentration was increased to 20 mM. 
The increase in GdG formation was linear upto 7 days but sloped to some 
extent between 7 and 14 days. Production of GdG in presence of ribose also 
showed greater dependency on sugar concentration, since a 4-fold increase 
in ribose concentration resulted in a nearly proportionate rise in GdG levels. 
Ribose was similarly far more reactive than glucose and fructose in forming 
8-oxodG, CEdGA.B and MGdG especially at 20 mM concentration (Fig. 3.14-
3.16). 
Glucose appeared least reactive and caused the formation of very 
small amounts of the adducts studied. At 5 mM concentration fructose also 
caused the formation of only small quantities of GdG and CEdGA,B (Fig- 3.13 
and 3.15). 
Fructose however induced the fomnation of significant 8-oxodG (Fig. 
3.14) and MGdG (Fig. 3.16) even at 5 mM. In fact, the extent of formation of 
8-oxodG in samples incubated with 20 mM fructose was comparable with 
those incubated at the same concentration of ribose for the duration. 
3.2.3 Effect of AG on in vitro incubation of 2'-dG with the sugars. 
In order to study the mechanism of formation of the AGEs, the sugar-
nucleoside incubations under in vitro conditions were carried out for a period 
of 14 days in the presence and absence of the AGE inhibitor- AG. The 
formation of adducts under the different conditions was monitored at various 
time intervals. 
AG inhibited the fomnation of GdG by glucose and fructose upto 14 
days but only 2 days in case of ribose. After 14 days of incubation the 
inhibition was below 20% in the samples containing fructose. Among the 
ribose treated samples, those incubated with AG showed a small increase in 
the GdG formation starting at 7 days as compared to samples incubated in 
absence of inhibitor (Fig. 3.17). AG (500 nM) was however able to effectively 
restrict the generation of the oxidation adduct (8-oxodG) during reactions of 
2'-dG with the three sugars- glucose, fructose and ribose upto 14 days (Fig. 
3.18). 
As in the case of GdG, CEdGA.B formation from 2'-dG was inhibited 
by AG incubated with glucose upto 14 days, by fructose upto 7 days and 
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Fig. 3.14 - Time dependent fonnation of 8-oxodG from 2'-dG. Please refer 
to the legend of Fig. 3.13 for details. 
Fig. 3.15 - Time dependent formation of CEdGA,B from 2'-dG. Please refer to 
the legend of Fig. 3.13 for details. 
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Fig. 3.16- Time dependent fomiation of MGdG from 2'-dG. Please refer to 
the legend of Fig. 3.13 for details. 
Fig. 3.17- Effect of AG on the time dependent formation of GdG in the 
presence of 20 mM sugar at 37°C. ( • ) - glucose, ( D ) -
fructose, (S) - ribose. 
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Fig. 3.18- Effect of AG on the time dependent formation of 8-oxodG in the 
presence of 20 mM sugars at 37°C ( • ) -glucose, ( D ) -
fructose, ( S ) - ribose. 
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ribose upto 2 days only (Fig. 3.19). In fact analysis of CECIGA.B and MGdG 
concentrations in samples incubated with fructose and more markedly with 
ribose showed that after 2 weeks of incubation more adduct was formed in 
the samples that contained AG than those to which no AG was added (Fig. 
3.19 and 3.20). 
The inhibitory effect of AG on glucose induced formation of MGdG 
was evident upto 14 days, while in case of fructose and ribose the inhibitory 
effect was not detectable beyond 7 and 2 days of incubation respectively 
(Fig. 3.20). 
3.2.4 Effect of the metal ion chelator- DETAPAC on in vitro incubations 
of 2'-dG with the reducing sugars. 
The role of oxidative stress and ROS is increasingly being realised as 
a contributor to the damage caused by non-enzymatic glycosylations, 
therefore a study was carried out to investigate the effect of DETAPAC on 
the glycation reaction of glucose, fructose and ribose each, with 2'-dG 
incubated at 37°C for a period of 21 days. Adducts of 2'-dG were measured 
by analysing the various selected ion monitoring chromatograms (SIM) 
obtained in LC-MS/MS analysis of the incubated samples. The amount of the 
glycation and oxidation adducts generated by 5 mM and 20 mM sugars were 
quantified using stable isotopic standards. DETAPAC was highly effective in 
inhibiting the formation of 8-oxodG (~ 98%- glucose, 99%-fructose and 96%-
ribose) as well as GdG (~99%- glucose, 99.8%- fructose and 99.8%-ribose) 
(Fig. 3.21 -3.23). Fomnation of other AGEs was inhibited to a lower extent. 
3.2.5 Effect of in vitro reaction of calf thymus DNA with glucose, 
fructose and ribose. 
A remarkable inhibitory effect of ribose (at concentrations higher than 
150 mM) on the advanced stages of the glycation reaction has been 
reported (Khalifah et al., 1996 and 1999). Attempts were therefore made to 
investigate if ribose and other sugars also exerted similar inhibitory effect 
during DNA glycation. For this purpose, calf thymus DNA was incubated with 
the sugars and the excess sugar in the incubation mixture was removed 
after an initial incubation. The DNA was incubated with 400 mM sugar in Tris 
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Fig. 3.19- Effect of AG on the time dependent formation of CEdGA,B in the 
presence of 20 mM sugars at 37°C ( • )- glucose, ( Q )-
fructose, ( S )- ribose. 
Fig. 3.20- Effect of AG on the time dependent formation of MGdG in the 
presence of 20 mM sugars at 37°C ( • ) -glucose, ( D ) -
fructose, ( S ) - ribose. 
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Fig. 3.21- Effect of DETAPAC on the formation of the DNA adducts by D-
glucose after incubation for 21 days at 37°C ( • ) - 8-oxodG, 
( H ) - IVIGdG, ( • ) - CEdGA,B and ( n ) GdG. 
Fig. 3.22- Effect of DETAPAC on the formation of the DNA adducts by D-
fructose after incubation for 21 days at 37°C. Refer to legend of 
Fig. 3.21 for details. 
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Fig. 3.23- Effect of DETAPAC on the formation of the DNA adducts by D-
ribose after incubation for 21 days at 37°C. Refer to legend of 
Fig. 3.21 for details. 
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buffer and the excess, unreacted sugar was removed after 24 h of initial 
incubation at 37°C, using Nal method for DNA precipitation. Then after 
further incubation for 10 days in absence of free sugar, the DNA samples 
were enzymatically hydrolyzed and the hydrolysate was tested on the LC-
MS/MS for the various adducts of oxidation and glycation. The results 
obtained in the study are detailed in Fig. 3.24. 
The studies carried out in Tris buffer, pH- 8.0 with ribose and fructose 
that are potent glycators, showed that number of adducts produced per 
million nucleotides were higher in case of the samples where the sugar was 
present during the entire duration of incubation as compared to samples in 
which the sugar was removed after 24 h. Further, it was observed that the 
levels of adducts produced were higher in case of ribose as compared to 
fructose. 
The study showed that more oxidation adducts were produced in the 
samples incubated continuously with the sugar. The quantities of MGdG 
adducts generated in the DNA samples incubated with sugar were higher as 
compared to those formed on incubation without the sugar. Similarly, the 
quantity of CEdGA.B adducts produced by the incubation of DNA in presence 
of the sugars were higher as compared to the samples where excess sugar 
had been removed by precipitation of DNA. Although, ribose produced 
greater amounts of CEdGAB and GdG as compared to fructose, the levels of 
GdG adducts produced in samples where incubation was continued in 
absence of the sugar were fewer as compared to samples subjected to 
continuous incubation in presence of the sugars. 
In another study, the experimental conditions were setup to be almost 
identical to the physiological environment. Thus, phosphate buffer was used 
instead of Tris buffer, sugar concentrations used were also physiologically 
relevant, besides precipitation of DNA was avoided to prevent artifactual 
adduct formation. The DNA was incubated with 5 mM glucose, fructose and 
ribose in phosphate buffer and the excess, unreacted sugar was removed 
after 24 h of initial incubation at 37°C, by filtration and repeated washes with 
fresh phosphate buffer. Then after further incubation for 7 days in absence 
of free sugar, the DNA samples were enzymatically hydrolyzed and the 
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Fig. 3.24 - Levels of adducts per million nucleotides, generated in calf 
thymus DNA subjected to interrupted and continuous 
incubation with 400 mM fructose and ribose in 50 mM Tris 
buffer, pH-8.0 for 11 days. The plots show the adducts formed 
as a result of DNA oxidation (a) 8-oxodG ( • ) and glycation (b) 
MGdG(j),CEdGA,B( | ) and GdG ( g ). 
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hydrolysate was tested on the LC-MS/MS for the various adducts of 
oxidation and glycation. 
The studies carried out showed that MGdG levels were highest 
followed by 8-oxodG> GdG > CEdGA.s- The number of adducts produced 
per million nucleotides were higher in case of 5mM ribose and fructose as 
compared to glucose, since these two sugars are more potent glycators. On 
the other hand, the samples subjected to interrupted incubation showed 
lower adduct formation as compared to samples which were subjected to 
continuous incubation (Fig. 3.25). 
3.2.6 ELISA measurements to quantify CEdGA,B formation during in 
vitro incubation of DNA with 400 mM ribose. 
The amount of CEdGA.B formed during the in vitro reaction of herring 
sperm DNA (1mg/ml) with 400 mM ribose in 50 mM Tris buffer, pH-8.0 was 
also monitored upto 7 days. In this study, after an initial incubation of 24 h 
with 400 mM ribose at 37°C, the excess sugar was removed from one set of 
samples by ethanol precipitation or dialysis. The incubations were carried 
out further and adducts formed were monitored at different time intervals in 
absence of the sugar. 
The results of the competitive ELISA procedure showed that further 
incubation at 37°C after removal of the sugar, did not enhance the 
generation of adducts whereas continuous incubation of DNA with ribose 
showed a steady rise in CEdGA.B levels (Fig. 3.26 (a) and (b)). 
3.2.7 The effect of concentration of the reducing sugar on the 
generation of CEdGA,B • 
The effect of sugar concentration on the rate of glycation of DNA was 
studied by estimating the formation of the DNA glycation product, CEdGA,B. 
Concentration of sugar was varied between 0.05 to 0.6 M. The samples 
were prepared by incubating herring sperm DNA (1mg/ml) with varying 
concentrations of ribose and fructose for a period of 10 days at 37°C in 50 
mM Tris buffer, pH-8.0. A sugar concentration dependent increase in the 
glycation of DNA was observed and highest levels of CEdGA.e were formed 
at 0.6 M sugar concentration. At 0.4 M ribose/ fructose, the concentration 
used for most of the other studies, appreciable amounts of CEdGA.e were 
generated (Fig. 3.27). 
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Fig. 3.25 - Levels of adducts per million nucleotides generated in calf 
thymus DNA subjected to intei"rupted and continuous incubation 
with 5 mM glucose, fructose and ribose in 50 mM phosphate 
buffer, pH-7.4 for 8 days. Refer to legend of Fig. 3.21 for details. 
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Fig. 3.26- Formation of CECJGA.B during continuous and interrupted 
incubation with ribose. Herring sperm DNA (1mg/ml) was 
incubated as described in the methods, with 400 mM ribose for 
24 h at 37°C at pH-8.0. One sample fraction was subjected to 
either dialysis (a) or ethanol precipitation (b) to remove excess 
ribose. The incubation of remaining fraction was continued 
without interruption ( ^ ) - DNA+ Tris buffer, ( ^ ) - DNA+ 400 
mM ribose (dialysis/precipitation) and ( • ) - DNA+ 400 mM 
ribose. 
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Fig. 3.27- Studying the formation of CEdG A.B (nmol/^g DNA) as a function 
of sugar concentration. The formation of CEdGA,B was estimated 
during incubation of herring spemn DNA (1mg/ml) with varying 
concentrations of ribose and fructose in 50 mM Tris buffer, pH-
8.0 at 37°C for a period of 10 days ( D ) - DNA+ ribose, ( • ) -
DNA+ fructose. 
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3.3. DISCUSSION 
In spite of the striking differences between the structures of proteins 
and nucleic acids, considerable similarities exist between their reactions with 
sugars. For example, incubation of nucleotides or DNA with sugars results in 
spectral changes comparable with those obtained during non-enzymatic 
reaction of sugars with proteins (Seidel and Pischetsrieder, 1998b; Morita 
and Kashimura, 1991). Mironova et al. (2005) have also shown that E.coli 
DNA subjected to in vivo glycation reveals the formation of fluorescent 
adducts resembling those associated with glycated proteins. Glycated DNA 
also showed immunoreactivity to a monoclonal antibody against N*-
(carboxymethyl) lysine (Mironova et al., 2005). Using UV and fluorescence 
spectroscopy, HPLC and capillary electrophoresis it was observed that 
physical factors that influence protein glycation also play an important role in 
DNA glycation (Dutta et al., 2005). Because of the potential of the three 
sugars- glucose, fructose and ribose to glycate DNA in vivo, their possible 
effects on the plasmid pBR 322 DNA were investigated. There are multiple 
routes to the production of glucose and fructose in vivo, and the sugars are 
also obtained in significant quantities in the diet. As mentioned earlier, ADP-
ribose generated from NAD by multiple metabolic pathways is usually the 
principal in vivo source of the pentose (Sell and Monnier, 1989). During 
oxidative stress and DNA damage/ degradation the synthesis of nuclear 
polymers of ADP-ribose is stimulated, which in turn can release monomeric 
ADP-ribose (Laurean et al., 1996). Such a situation may lead to rise of 
ribose concentrations in the vicinity of DNA and cause DNA glycation. 
Higher concentrations of sugar were used in the initial experiments of 
the present study in order to enhance the reaction rate, and induce 
measurable DNA damage in a short duration. It was observed that when 
concentrations below 400 mM of sugars were used for the study the DNA 
damage on the gels was visible only after a prolonged period of incubation 
(Fig. 3.2). While such concentrations as 400 mM may not arise in vivo, 
increase in local concentration of the sugar in the vicinity of the biomolecules 
is not unlikely and rates of glycation maybe enhanced in membrane 
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surrounded systems like cell organelles such as the nucleus (Derham and 
Harding, 2002). 
The results suggested that the reactivity of the sugars studied could 
be arranged in the order- ribose>fructose>glucose. This difference in 
reactivity (Figures 3.2, 3.3, 3.7, 3.13-3.16) was explained earlier by Bunn 
and Higgins (1981) on the basis of existence of fraction of sugars in cyclic 
form in solution. The open chain free aldehyde form represents 0.05% of the 
total ribose, but only 0.002% of the total glucose (Bunn and Higgins, 1981). 
Because of this 25-fold difference in the concentration of the free aldehyde 
form, ribose can more readily form Schiff base with free amino groups. In 
addition, the initial step in sugar autoxidation involves enolization of 
a-hydroxyaldehydes; therefore, this process should also proceed at a higher 
rate with ribose than with glucose (Carubelli et a!., 1995). The slow reactivity 
of glucose during the Maillard reactions was attributed to the stable ring 
structure of the monosaccharide (Bunn and Higgins 1981). 
It was also observed that small reducing sugars showed greater 
reactivity with the nucleosides than the higher molecular weight 
carbohydrates. This was attributed to the diminished steric hindrance of the 
carbonyl groups in small size sugars relative to those of high molecular 
weight sugars when interacting with the free amino groups of nucleosides 
(Dutta et al., 2005). This may also explain the higher reactivity of ribose, a 
pentose sugar as compared to the hexoses- glucose and fructose. 
The interrupted incubation of plasmid DNA with ribose promotes the 
formation of strand breaks (Fig. 3.5). Analogously, it has been shown in 
earlier studies that interrupted glycation of proteins with ribose promotes 
AGE formation (e.g. pentosidine) and protein damage (Khalifah et a(., 1996). 
Two hypotheses could explain the reaction occurring during 
incubation of plasmid DNA with ribose. In similarity to the studies with 
proteins, early DNA-adducts are formed which can further react to form 
DNA-AGEs. The reactions may include metal catalyzed redox reactions and 
accompanied by the formation of ROS (Wonderak et a!., 2002; Chetyrkin et 
al., 2008). Crosslinking of DNA was however not detected in the gels 
indicating absence of significant intemnolecular reactions. 
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Alternatively, the Initial reaction of ribose with DNA may generate 
adducts, which then induce the strand breaks. Again this process could 
involve redox reaction catalyzed by the metal ions and high concentration of 
the sugar (especially ribose) may have an antioxidative effect. Such a 
mechanism would be different from that suggested in case of proteins 
(Chetyrkinetal.,2008). 
Induction of comparable changes in pBR 322 DNA by BSA subjected 
to continuous or more prominently to interrupted incubation with glucose, 
fructose or ribose suggests that the initial protein adducts may react further 
and continue to generate ROS for several days. The adducts or the 
generated ROS or both may further modify/damage DNA (Fig. 3.6 and 3.7). 
This assumption is also supported by the observed moderate increase in 
resistance of pBR 322 plasmid to the action of Eco Rl, Bam HI and Hinf I 
when subjected to incubation with the sugar exposed BSA. BSA subjected to 
interrupted incubation was more effective in imparting resistance of the 
plasmid DNA to digestion by restriction enzymes (Fig. 3.8, 3.9 and 3.10). 
This resistance to digestion by the restriction enzymes could be caused by 
the steric hindrance of DNA adducts or by the loss of the symmetry of the 
recognition site. 
The damage to DNA was prevented by DETAPAC, a known chelator 
of metal ions (Hunt et al., 1988; Wolff et al., 1984) suggesting the role of 
metal ions in the process (Fig. 3.4 and 3.11). DETAPAC is known to chelate 
metal ions involved in autooxidation of sugars and formation of 
oxoaldehydes (Thornalley, 1985). Three possible steps were suggested for 
the formation of free radicals during glycation: a) reducing sugars cause 
transition metal-catalyzed autoxidation via enediol anion intermediates, 
generating oxygen-derived free-radicals and dicarbonyl compounds, b) 
Amadori or Heyns products can enolize and thereby reduce molecular 
oxygen, yielding oxygen radicals and dicarbonyl compounds, c) autoxidation 
of dicarbonyl compounds generated from Amadori or Heyns products. More 
likely, DNA and BSA incubated with the sugar may produce ROS, which in 
turn could lead to oxidative DNA strand breaks catalyzed by metal ions. The 
presence of excess sugars during subsequent incubations may lower the 
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DNA damage by neutralising some of the ROS. Thus, the transfomiation of 
plasmid DNA induced by incubation with BSA which had been preincubated 
with ribose was decreased remarkably in presence of DETAPAC (Fig. 3.12). 
The amadori product formed as a result of reaction between sugars and 
DNA/protein can undergo enolization and thereby reduce molecular oxygen 
yielding superoxide radical (Morita and Kashimura, 1991; Wonderak et al., 
2002; Wei et al., 2009). Levi and Wemian (2001) have shown that H2O2 can 
cause damage to pBR 322 DNA comparable with that by sugars. Since H2O2 
was equally efficient in causing DNA damage during these processes it was 
suggested that besides direct glycation, oxidation reactions maybe involved 
in the modification of DNA by sugars. 
Several studies have highlighted the role of monosaccharides in the 
non-enzymatic glycosylation reaction with nucleic acids leading to the 
formation of various DNA-AGEs (Barea and Bonatto, 2008). Among the 
various known DNA-AGEs, CEdGA,B was the most well characterized and 
treated as the major marker for DNA glycation. However, our study is the 
first in showing the formation of other products in addition to CEdGA,B during 
the reaction of glucose, fructose or ribose with 2'-dG and DNA, namely, GdG 
and MGdG using LC-MS/MS techniques. 
In all the in vitro experiments carried out, ribose produced highest 
levels of all adducts, followed by fructose and glucose. This result further 
substantiates that the reactivity of the sugars follows the order-
ribose>fructose>glucose (Fig. 3.13-3.16). As stated eariier this difference in 
reactivity was explained by Bunn and Higgins (1981). 
Studies on degradation of reducing sugars in solution have shown 
that the sugar molecules undergo fragmentation under alkaline conditions 
and to some extent also in weakly acidic solutions. This fragmentation was 
enhanced in the presence of amines (Novotny et al., 2007). NissI et al. 
(1996) have suggested that the interaction between nucleotide and sugar 
was also accompanied by cleavage of the sugar carbon chain. The study 
also suggested that such reactions involve Schiff bases of the sugar derived 
dicarbonyls as intermediates. 
107 
Therefore, under the conditions used in this study the three reducing 
sugars used, glucose, fructose and ribose could be expected to degrade to 
a-dicarbonyls, nnainly MG and glyoxal which are far more reactive than the 
parent monosaccharides themselves and rapidly react with the nucleoside 
leading to the formation of the Schiff base molecules- GdG, MGdG, and the 
AGE molecule -CEdGA.e (Figures 3.13, 3.15 - 3.16). Also similar to proteins, 
DNA and nucleoside AGE formation was found to be affected by several 
factors, with the most important ones being the chemical structure and 
concentration of reactants, the ionic strength, temperature, and time of 
incubation (Dutta et al., 2005). This explains the higher levels of nucleoside 
AGE formation during the incubations with 20 mM sugars. 
In the in vitro experiments carried out, formation of adducts by the 
various sugars followed the following trend, GdG> 8-oxodG > CEdGA,B > 
MGdG. The reaction of glyoxal with DNA and deoxynucleotides leads to the 
formation of GdG (Fig. 3.28), the major cyclic adduct fomried during reactions 
between glyoxal and DNA (Kasai et al., 1998). These findings led us to study 
the formation of the glyoxal-dG cyclic adduct by incubating 
deoxyribonucleoside with different sugars. 
As stated earlier, glucose autooxidation results in the formation of 
glyoxal. Wolff and Dean (1987) showed that only small amounts of the 
dicarbonyls compounds (<10^M) were fonned under antioxidative 
conditions, confirming the need for oxygen and traces of metal ions to form 
dicarbonyl sugars from glucose (Wolff and Dean, 1987) and fructose 
(McPherson et al., 1988; Suarez et al., 1989). The kinetics of degradation of 
glyoxal (0.5 mM) were similar under oxidative and antioxidative conditions 
(ti/2 = 17.3 and 18.7 days, respectively), suggesting a nonoxidative route for 
disappearance of glyoxal at pH 7.4 (Wells-Knecht et al., 1995). The study by 
Manini et al. (2006) concluded that removal of oxygen decreased the levels 
of glyoxal fomriation. Thornalley et al. (1999) showed the multiple routes of 
glyoxal formation from glucose, which explains the maximum formation of 
glyoxal (as a result maximum generation of GdG) as compared to other 
dicarbonyl compounds (Fig. 3.13). Besides, the generation of the GdG 
adduct during in vitro incubations carried out could be promoted by the 
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Fig. 3.28 - The reaction of glyoxal with deoxyguanosine. 
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oxidative conditions during which the incubations were conducted. The 
finding of Murata-Kamiya et al. (1997) showed that the formation of glyoxal 
during Fenton catalyzed oxidation of deoxynucleosides was 13-fold higher 
than the oxidation adduct 8-OHdG itself, and glyoxal generated from DNA 
and DNA precursors, immediately reacts with the DNA and the precursors to 
cause base modifications resulting in even higher GdG than the oxidation 
adduct (Fig. 3.13 and 3.14). Kasai et al. (1998) showed that the purified GdG 
monomer gradually decomposed to 2'-dG in phosphate buffer, pH-7.4, 37°C, 
having a ti/2 of 14.8 h while that formed in ss- and ds-DNA was 19 and 40 
times more stable than the monomeric GdG (ti/2 285 and 595 h respectively) 
(Kasai et al., 1998). This could further support the observed maximum levels 
of GdG adducts on incubations upto 14 days. 
Glyoxal was also found to markedly increase cellular H2O2 levels and 
H2O2 - induced hepatocyte ROS formation. Thus, it increased cytotoxicity, 
due to ROS formation and oxidative DNA damage due to oxidative stress 
(H2O2). Detoxification of H2O2 caused hepatocyte GSH and NADPH 
depletion which in turn inhibited glyoxal metabolism (Shangari et al., 2006). 
Therefore, it is likely that glyoxal generated from the sugars promotes 
oxidative damage. This synergism between the GdG and 8-oxodG formation 
provides an easy explanation to strong inhibitory effect of the metal ion 
chelator DETAPAC on the fomnation of GdG and 8-oxodG by glucose, 
fructose or ribose as compared to the inhibition of MGdG and CEdGA,B 
adduct formation (Figures 3.21 - 3.23). DETAPAC was less effective in 
inhibiting the formation of CEdGA.e, a rearrangement product of MGdG (Fig. 
4.6 and 4.11). The study of Morita et al. (1991) on DNA glycation reaction in 
the presence of the radical scavengers and metal ion chelator- DETAPAC 
showed that a transition metal ion-catalyzed autoxidation reaction is partially 
involved in the glycation of DNA bases and subsequent formation of 
chromophores and fluorophores. 
The level of oxidized DNA damage in cells has been used as a 
measure of oxidative stress. In our study we focused on 8-oxodG because it 
is the major and ubiquitous product of DNA oxidation. 8-oxodG levels could 
be measured, either by quantifying the single lesion of the adduct (after DNA 
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extraction and hydrolysis), or preserving the DNA and studying its formation 
in situ (Ravanat et a!., 2002). We adopted the direct approach and measured 
8-oxodG levels both in incubated nucleosides and hydrolysed DNA samples 
using stable isotopic dilution technique in LC-MS/MS analysis. 
Two possible routes were suggested for the formation of 8-oxodG 
from 2'-dG (Fig. 3.29) and one involved the attack by the hydroxyl radical 
formed as a result of oxidative stress. The hydroxyl radical (OH") radical may 
attack the C-8 carbon of 2'-dG forming the reducing deoxyguanosyl radical 
which oxidizes to produce 8-oxodG. The altenative route involves hydration 
of the guanine radical cation to produce the deoxyguanosyl radical and in 
turn by oxidation to 8-oxodG (Cadet et al., 2003). 8-oxodG can thus be 
formed from ROS such as the superoxide radical (O2-), singlet oxygen (^ 02), 
H2O2 and OH" (Singh et al., 2003). Earlier studies have shown that trace 
metals such as copper and iron, which are present in biological systems, 
may react with H2O2 to produce OH' and in turn induce DNA strand 
breakage (Imlay et al., 1988; Sagripanti and Kraemer, 1989). Further works 
have also shown that the glycation reaction are accompanied by H2O2 and 
ROS production (Mullarkey et al., 1990; Kang, 2003), which further 
contribute towards the production of 8-oxodG. Formation of 8-oxodG was 
observed in all the in vitro incubations of 2'-dG with the different sugars 
under aerobic conditions in absence of metal ion chelator (Fig. 3.14) and 
inhibition of 8-oxodG formation in the presence of 100 iiM DETAPAC 
supports the above theory (Figures 3.21 - 3.23). 
Autooxidation of monosaccharides is an important phenomenon 
occurring under physiological pH and temperature, resulting in depletion of 
oxygen by the enediol tautomer of simple monosaccharides to generate 
hydrogen peroxide and a-oxoaldehydes. Studies showed that D-fructose 
was much more sensitive to oxidative degradation than D-glucose in the 
presence of phosphate or arsenate. Ribose exhibited four times higher rates 
of autooxidation as compared to glucose in phosphate buffer, pH - 7.4 and at 
37 degrees (Thornalley, 1985). This may provide an explanation to the 
steady state levels of 8-oxodG achieved at the end of 14 days of incubation 
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Fig. 3.29 - The formation of the 8-oxodG from radical mediated oxidation of 
deoxyguanosine. 
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with ribose (Fig. 3.14) presumably resulting from anaerobic conditions due to 
its rapid autooxidation. Besides greater autooxidation of the monosaccharide 
results in higher levels of oxoaldehyde formation, which explains greater MG 
and glyoxal adducts, MGdG, CEdGA.B and GdG being formed from ribose 
followed by fructose and glucose (Figures 3.13, 3.15 - 3.16). 
MG (2-oxopropanal), like glyoxal, is a reactive a-oxoaldehyde and 
physiological metabolite (Thornalley, 1993). Several adducts of free 
nucleotides have already been described namely, the cyclic adduct 1, hf-
(1,2-dihydroxy-2-methyl)ethano-2'-deoxyguanosine (cMG-dGuo) (Shapiro et 
al., 1969), detected in lymphocytes (Vaca et al., 1994) and a bis adduct of 2'-
dG and MG, A/^ -7-bis(1-hydroxy-2-oxopropyl)-2'-dG (Schneider et al., 1998). 
CEdGA,B is known to be the major adduct formed during the reaction 
between 2'-dG and MG under physiological conditions and Frischmann et al. 
(2005) suggested a scheme for the formation of the MGdG and CEdGA.B 
adducts during the reaction of 2'-dG with MG (Fig. 3.30). 
MGdG may thus be produced as an intermediate (or early glycation 
product) during the glycation reaction of nucleotides with MG and CEdGA.s 
was formed at a later stage. Thus, it may not be incorrect to suggest that 
MGdG accumulation by the three sugars was minimum (Fig. 3.16) whereas 
higher levels of CEdGAs (Fig. 3.15) were observed during the 2'-dG-sugar 
incubations under physiological conditions. It is likely that MGdG levels 
decrease due to its rapid conversion to CEdGA.s (Frischmann et al., 2005). 
This is supported by the findings of Shapiro et al. (1966, 1969) on the basis 
of which Frischmann et al. (2005) concluded that the lower stability of the 
cyclic adducts was observed at neutral or slightly alkaline pH, particularly in 
the absence of the dicarbonyl compound. Therefore, the levels of 
dicarbonyls may become limited after longer incubations, especially in 
presence of lower sugar concentration (5 mM) (Fig. 3.16) causing additional 
conversion of MGdG to CEdGA,B-
AG (Pimagedine) is a prototype a,p-dicarbonyl scavenging agent that 
prevents the formation of AGEs from a,p-dicarbonyl precursors (Thornalley 
et al., 2003a). AG, a nucleophilic agent has two key reaction centers: the 
nucleophilic hydrazine group and the dicarbonyl-directed guanldino group 
115 
-HP 
O O 
% H 
H3C 
+NH2-R 
H 
dGuo 
NHR^ I /'JOH OH O^ 
H3C H 
-H2O 
R - N OH 
H3C H 
H ' 
R - N OH H 
H3C OH 
Q .0 
H3C H 
MG +dGuo 
N 
O OH 
dRib 
H 
cMG-dGuo 
OH 
N ^ ^ 3 
O * 
-H2O 
i N CH, 
I ^ H 
dRib 
O 
N . 
OH. 
I "^  H 
dRib 
CEdG 
117 
(Thomalley et al., 2003a). 
AG under physiological conditions may react either with the highly 
reactive unhydrated a-oxoaldehydes including MG and glyoxal or with the 
less reactive, monohydrate or cyclic hemiaceta.l forms of the a-oxoaldehydes 
(Fig. 3.31) (Hirsch et al., 1992). Many 3- to 6-carbon dicarbonyl compounds 
like glyoxal, MG, hydroxypyruvaldehyde, erythrosone, 3-deoxyerythrosone, 
ribosone, 3-deoxyribosone, glucosone and 3-deoxyglucasone, found in 
physiological systems are scavenged by AG through such a mechanism 
(Thornalley, 2003a). 
The kinetics of the reaction of a-oxoaldehydes with AG is influenced 
strongly by the interaction with unhydrated, monohydrated and hemiacetal 
forms. Glyoxal exists in solution as ca.0.005% unhydrated form, ca. 0.5% 
monohydrate, ca. 1-2% as dimers and the remainder dihydrate and MG 
exsists in unhydrated form, MG-H2O and MG-(H20)2 in the approximate ratio 
of 1:71:28. It is expected therefore, that AG would react and scavenge the 
a,(3-dicarbonyl groups of glycated molecules and a-oxoaldehydes at similar 
rates in vivo (Thornalley et al., 2000). 
The reaction of AG with glucose is slow and results in a (i-D-
glucopyranosyj AG adduct, described by Feather and co-workers (Hirsch et 
al., 1995). This reaction does not compete effectively with glycolytic 
metabolism for glucose but at high concentrations of AG, it may compete 
with the sugar in protein glycation reactions (Thornalley, 2003a). Similarly, in 
the in vitro experiments carried out in this study, AG may compete with the 
nucleoside for the sugar in the glycation reaction. The effective inhibition by 
AG is possible when greater interaction occurs between the inhibitor and the 
sugar as compared to that between AG and nucleoside. 
The observed differences in effects of AG on nucleoside glycation in 
presence of various sugars may result from the different reaction sequences 
adopted by each of the sugars depending upon the abundancy of their open-
chain or cyclic fornis (as explained earlier). Ribose has greater fraction of 
open chain form as compared to that of glucose, making it more reactive in 
the glycation reactions (Bunn and Higgins, 1981) (Figures 3.17 - 3.20). 
Booth et al. (1997) tested the efficacy of AG on the glycation reaction 
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Fig. 3.31 -Mechanistic interpretation of the kinetics of reaction of AG with 
a-oxoaldehydes. 
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of proteins and observed that the extent of inhibition was considerably less 
at late stages of the glycation reaction especially at low concentrations of the 
inhibitor. This led them to conclude that AG shows little post-Amadori 
inhibition. Also the inhibition unexpectedly diminished at later stages of the 
reaction. Due to the slowness of the glycation with glucose, this surprising 
observation was difficult to be established. Furthermore, the basis for this 
diminished inhibition is open to question considering the long temi instability 
of AG and its potential to produce H2O2 (Ou and Wolff, 1993). It has also 
been reported that glucose and ribose produce similar protein AGEs 
including pentosidine (Grandhee and Monnier, 1991; Dyer et al. 1991). It is 
therefore likely that the kinetic differences observed between the two sugars 
were related to relative differences in the rate constants of post-Amadori 
steps leading to AGE formation. 
While information on the post-amadori reaction rates are not available 
in case of DNA-AGEs, the post-amadori conversion rates of ribose to 
protein-AGEs were found to be remarkably higher (with U12 = <10 h) as 
compared to glucose (Khalifah et al., 1996). The results obtained in the 
present study using AG (Figures 3.17 - 3.20) show that the inhibitory effect 
of AG on glucose induced formation of CEdGA,B and MGdG was evident upto 
14 days, while in case of fructose and ribose the inhibitory effect was not 
detectable beyond 7 and 2 days of incubation respectively (Fig. 3.19 and 
3.20). Whereas the inhibitory effect of AG on fructose and glucose induced 
GdG fonnation was visible upto 14 days and only upto 2 days in case of 
ribose (Fig. 3.17). 
The observed difference may arise from different rates of nucleoside 
glycation by the sugars as well as their reactivity with AG. It is likely glucose, 
reacts slowly with AG and hence the inhibitor persists in the reaction mixture 
till the end of 14 days and continues to inhibit the formation of the AGEs. On 
the other hand the inhibitor may last in the mixture only upto 7 days in 
samples containing fructose and for 2 days in that with ribose. This explains 
the observed lack of inhibition by AG in the samples containing fructose and 
ribose after 2 and 7 days respectively. 
121 
The observation that AG slows down the rate of antigenic protein 
AGE formation in BSA and RNAse in the presence of sugar but has little 
effect on the final amount of AGE formed (Booth et al., 1997) supported this 
contention. Figures 3.17, 3.19 and 3.20 suggest that in case of ribose the 
formation of GdG, CEdGAB and MGdG was markedly higher in samples 
exposed for 7 and 14 days to AG as compared to controls lacking the 
inhibitor. Similarily, a small increase in the formation of MGdG and CEdGA,B 
was also seen in the samples incubated with fructose after 14 days of 
incubation. This paradoxical increase in the formation of DNA-adducts is 
difficult to explain but maybe related to long term instability of AG and its 
potential to produce H2O2 (Ou and Wolff, 1993). We speculate that AG 
adducts of ribose and to small extent fructose may cause enhanced 
formation of H2O2 and promote free-radical mediated fomnation of the DNA 
adduct (Wonderak et al., 2002, Miyata et al., 1997). In case of fructose and 
ribose, higher rates of autooxidation could complement this radical mediated 
phenomenon. We however have no explanation for the observed more 
marked inhibition of GdG and 8-oxodG (Fig. 3.17 and 3.18) as compared to 
CEdGA,B and MGdG (Fig. 3.19 and 3.20). The observation that CEdGA.B 
adduct formation involves the intermolecular rearrangement of the 6-
methylimidazopurinone isomer of MGdG (as proposed later in the study), 
explains the low inhibitory effect of AG on CEdGA,B formation (Fig. 3.19). 
Khalifah et al. (1996) observed that after initial exposure of RNase to 
ribose, continued presence of the sugar in the reaction mixture strongly 
inhibits AGE formation. It was also shown that removal of ribose subsequent 
to initial reaction with the sugar remarkably stimulates the formation of 
pentosidine and AGEs detectable by an antibody recognizing carboxymethyl 
lysine. It was therefore the aim of the in vitro incubation experiment with calf 
thymus DNA to examine if changes in the concentrations of sugar in the 
vicinity may invoke similar modifications in DNA. For this purpose the effect 
of continued incubation in presence/ absence of the sugar- glucose, fructose 
or ribose after initial exposure to the sugar, on DNA damage was 
investigated. 
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The higher reactivity of ribose as compared to fructose apparently 
resulted in increased formation of the adducts, GdG and 8-oxodG (Fig. 
3.24). Ribose showed four times higher rates of autooxidation as compared 
to glucose in phosphate buffer, pH 7.4 and at 37°C (Thornalley, 1985) 
leading to rapid formation of glyoxal. On the other hand, fructose was a 
superior source of MG and therefore higher levels of MGdG are expected to 
be formed in case of incubations of calf thymus DNA with fructose (Fig. 
3.25). However, the findings by Khalifah et al. (1996,1999) in case of 
proteins, that higher ribose concentrations maybe inhibitory to the formation 
of AGEs after exposure of protein to the sugar and removal of excess sugar 
after an initial incubation could speed up the fomation of AGEs, could not be 
reproduced in this study on calf-thymus DNA. It needs to be emphasized 
here that pentosidine and CML were the major protein AGEs studied by 
Khalifah et al. (1996), while the major DNA-AGEs - MGdG, CEdGA,B and 
GdG were investigated in this study. It is likely that the stimulation observed 
during interrupted glycation of protein with ribose maybe specific for the 
protein glycation reaction. 
In conclusion it maybe said that indeed glycation of nucleosides and 
DNA by reducing sugars leads to generation of MGdG, GdG and CEdGA.e 
along with the generation of 8-oxodG, indicating coupling of oxidation and 
glycation reactions in causing DNA damage. The fonnation of these adducts 
was inhibited by AG and DETAPAC although the magnitude and pattern of 
inhibition with the sugars studied was different. 
The competitive ELISA measurements allowed an accurate measure 
of the degree of glycation during DNA - sugar incubations in temris of the 
amount of CEdGA,B generated. The two diastereomers of CEdGA.e were 
chosen as important DNA glycation products, because they are fomned from 
a large variety of glycating agents and represent stable adducts that can 
accumulate during a lifetime (Frischmann et al., 2005). Furthermore, 
formation of CEdGA.B was demonstrated in vivo, where the extent of its 
formation was related to diseases, such as diabetic nephropathy (Schneider 
et al., 2004; Li et al., 2006; Nakamura et al., 2007). High concentrations of 
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sugar were used in the present study in order to speed up the reaction, and 
induce DNA damage in a short duration. 
ELISA using monoclonal antibody against CEdGA,B allows rapid and 
accurate determination of the AGEs generated in DNA during glycation. This 
monoclonal antibody shows a more than 600,000 fold higher binding affinity 
to CEdGA.B than to parent compound 2'-dG so that it is suitable for the 
quantification of nucleotide-AGEs fornied in vitro as well as in vivo 
(Schneider et al., 2004). In this study, a signal of the unmodified DNA could 
be ruled out as appropriate controls prepared by incubating the DNA in 
absence of the sugar were included. Most importantly the affinity of antibody 
to related structures such as 8-OHdG or other modified bases was not 
detected and nor did it cross react with AGE-proteins mainly CEL-modified 
proteins which are present in most biological samples and tissues 
(Schleicher et al., 1997; Yanagisawa et al.,1998). Some cross-reactivity was 
however detected for another nucleotide bound AGE, N^-
carboxymethylguanosine (CMG). Significant difference in its affinity to both 
diastereomers of CEdGA.e was observed. Therefore, the results are 
expressed in CEdGA,Bequivalents (Schneider et al., 2004). 
Herring sperm DNA incubated in presence of ribose showed a time 
dependent increase in CEdGA,B formation. However, when ribose was 
removed after the initial 24 h of reaction, further increase in the CEdGA,B 
concentrations was not detected during further incubation (Fig. 3.26 (a) and 
(b)). It is likely as stated earlier that the stimulation observed (Khalifah et al., 
1996) during interrupted glycation with ribose maybe specific for the protein 
glycation reaction only. 
A sugar concentration dependent increase in the glycation of DNA 
was observed and highest levels of CEdGA.B were fonned at 0.6 M sugar 
concentration (Fig. 3.27) indicating that fomnation of DNA-AGEs is 
dependent on the concentration of the glycating agent used. 
DNA is known to be glycated in vivo and that this process may be 
important in aging and also in diseases that are related to increased 
carbonyl stress, such as diabetes and uraemia (Baynes, 2002; Cerami, 
1986). However, fast, reliable and sensitive methods are required to 
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evaluate the role of DNA- AGEs in the human organism under physiological 
and pathological conditions. This study suggests the potential of the newly 
developed ELISA in the measurement of one of the important DNA-AGEs. 
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Synthesis and purification of 
various markers of nucleotide 
glycation 
4.1 INTRODUCTION 
Sugars can react via their carbony! group with the nucleophilic amino 
group of nucleotides and lead to DNA glycation. Further, elimination and 
cleavage reactions result in the formation of sugar degradation products, 
such as MG and glyoxal. Due to their smaller dimensions and the a-
dicarbonyl groups, these compounds are more reactive than the sugars 
themselves. Therefore, much research has focussed on these reactive 
molecules. 
A study involving incubation of DNA with radiolabelled MG provided 
first evidence that reactive dicarbonyl compounds could bind to DNA in vitro 
leading to fomnation of so called DNA-AGEs (Krymkiewicz, 1973). Among 
the nucleobases, guanine and its derivatives react most readily with the 
sugars and dicarbonyl compounds (Papoulis et al., 1995). Thus, free 
guanine, guanosine and 2'-dG were used in model incubations with sugars 
and sugar degradation products to identify the structure of possible DNA 
adducts (Fig. 4.1). There is much debate within the literature with regard to 
which among these adducts; open- or closed-ring are formed predominantly. 
This is due to inconsistencies of the protocols used for the synthesis of 
adducts, incomplete and/or poor structural characterization, as well as 
inappropriate sample processing (i.e. high temperature and alkaline pH) for 
analysis in vivo, particularly in regard to MG. 
At elevated temperatures, the glucosylamine of 2'-dG and D-glucose 
was the main product of the reaction of 2'-dG and D-glucose (Knerr et al., 
1994), whereas at physiological temperatures, CTPdG predominated (Ochs 
and Severin, 1995; Knerr and Severin, 1993). The reaction of glucose-6-
phosphate with 2'-dG resulted in the formation of a CTPdG derivative 
phosphorylated in position 5 identified indirectly by enzymatic conversion 
into CTPdG (NissI et al., 1996). The two diastereomers of CEdGA.s, were 
first isolated as reaction products of glyceraldehydes and 2'-dG (Ochs and 
Severin, 1994). Later on, it was shown that CEdGA.e or the analogous 
derivatives from guanosine, guanine or 9- methylguanine - CEG, CEguanine 
and CEmG- were also formed from a great variety of other sugars and sugar 
degradation products, such as glucose, ribose, glucose-6-phosphate. 
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Fig. 4.1- The structures of various DNA-AGEs derived from guanosine and 
2'-deoxyguanosine (Bidmon et al., 2007). g{d)G- 3-(2'-deoxy-p-
D-erythro-pento furanosyl)-6, 7-dihydro-6, 7-dihydroxy -imidazo 
[2, 3-p] purin-9(8) one and m(d)G- 3-(2'-deoxy-p-D-erythro-
pentofuranosyl)-6,7-dihydro-6,7-diiiydroxy-6-methyl-imidazo [2, 3-
p] purin-9(8) one. 
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dihydroxyacetone, or ascorbic acid (Papoulis et al., 1995; NissI et al., 1996; 
Seldel et al., 1998a; Larisch et al., 1997). In the presence of oxygen and 
glucose, lower concentrations of CMG were additionally detectable (Seidel 
and Pischetsrieder, 1998b; Al-Abed et al., 1998). 
As with protein glycation, a-dicarbonyl compounds react very 
efficiently with nucleobases: guanosine, for example, was converted 
completely into the cyclic adduct, MGdG by a 10-fold excess of MG in 5 min 
at room temperature (Shapiro et al., 1969; Schneider et al., 1998). However, 
during extended incubation of 2'-dG with MG for several days, the amount of 
the cyclic adduct seemed to degrade in favor of CEdGA.B (Papoulis et al., 
1995; Frischmann et al., 2005). 
Adducts of MG or glyoxal and 2'-deoxyadenosine or 2'-deoxycytidine 
were also formed in low concentrations (Frischmann et al., 2005; Olsen et 
a!., 2005). Comparative analyses of the various known protocols of MG 
adduct synthesis and purification are shown in Table- 4.1. It was concluded 
that CEdGA.B is the major AGE formed from the reaction between 2'-dG and 
MG, when physiological conditions of temperature (i.e. 37°C) and pH (i.e. 
pH-7.4) were maintained during incubation periods. When shorter 
incubations were carried out with excess MG however MGdG was the only 
adduct formed. 
Cyclic adducts, analogous to MGdG, are also fomied from glyoxal 
and guanine derivatives (GdG or glyoxal-guanosine) (Shapiro and 
Hachmann, 1966; Broude and Budowsky, 1971). The reactions of glyoxal 
with DNA and nucleotides occur preferentially with guanine to form a five-
membered ring fused between N-1 and N-2 and bearing a pair of vicinal 
hydroxy! groups (Staehelin, 1959; Shapiro and Hachmann, 1966). Kasai and 
co-workers (1998) reported the formation of bis-nucleosides by the action of 
glyoxal on various nucleosides and DNA. 
Broude and Budowsky (1971) showed that the kinetics of formation of 
GdG was slow as compared to those of adenosine or cytidine, however, the 
GdG adduct was more stable. The rate of reaction of guanosine with glyoxal 
increases with increasing pH and the optimum value was pH- 7.8. 
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Table 4.1- Synthetic protocols for MG-2'-clG adduct(s) from the literature. 
dG/ 
Methylgiyoxal 
ratio ^ 
Buffer Product Reference 
1:32 Na2HP04 (pH7.4) MGGua 
1:12 Na2HP04 (pH7.4) MGdG 
Shapiro (1969)§ 
1:2 Na2HP04 + EDTA (pH7.4) 
CEG-63% 
PapoulisCIQgS)" 
1:2 Na2HP04 + EDTA (pH7.4) 
CEG-3f% 
(CEG-22%) 
1:17 Na2HP04 (pH7.2) MGdG Vaca(1994) 
1:20 Na2HP04(pH7.4) MGjdG Schneider (1998) 
1:32 Na2HP04 {pH7.0) MGdG Frischmann (2005)^^ 
§ Original protocol used guanine and guanosine, ^ 40% solution in water (40g = 
84.49ml); IVIW 72.06, ** Original protocol used 9-methylguanine, ^ Adapted from 
Shapiro (1969). 
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Kasai et al. (1998) prepared the GdG adduct by reacting 2'-dG with 
an excess of glyoxal in phosphate buffer (pH- 7.4) at 37°C for 1 h and 
concluded that efficient fonnation of adduct nnay occur under physiological 
conditions. Further, Olsen et al. (2005) showed that synthesis of the known 
GdG adduct could be accomplished by adding glyoxal trimer dihydrate 
dissolved in 0.5 M phosphate buffer (pH- 4.5 or pH- 7.4) to a solution of 
deoxynucleoside or the nucleoside in 0.5 M phosphate buffer (pH-4.5 or pH-
7.4) in order to obtain a 40 times excess of glyoxal. The reaction was stirred 
at 37°C or 50°C and monitored by LC-ESI tandem quadrupole MS 
measurements for 7 days. The reaction of glyoxal with calf thymus DNA 
resulted in 2'-deoxyguanosine-glyoxal and 2'-deoxyadenosine-glyoxal 
adducts, the former being the major adduct (Olsen et al., 2005). 
Improved sensitivity and perfomnance, have made LC-MS the 
technique of choice to study DNA adducts in vitro and in vivo (Koc and 
Swenberg, 2002; Singh and Famier, 2006). The technique has an 
advantage over GC-MS in that the latter required an initial derivatisation 
step, which could damage the desired product. Therefore, LC-MS proves to 
be a rapid method for analysis, in which artefactual adduct formation could 
be avoided. 
Numerous LC-MS methods, have been developed for the analysis of 
nucleobase modifications, for example, for adducts derived from oxidation 
(8-OHdG), methylation, heterocyclic aromatic amines, or polycyclic aromatic 
hydrocarbons (Koc and Swenberg, 2002; Singh and Fanner, 2006; Turesky 
and Vouros, 2004; Yang et al., 2002; Beland et a!., 2005; Peoples and 
Karnes, 2005). 
The initial step in DNA adduct analysis by LC-MS involves release of 
the adducts from the DNA backbone, achieved either by acid (Rodriguez et 
al., 2000), thermal (Neagu et al., 1995) or enzymatic hydrolysis (Kasai et al., 
1998). The excess unmodified nucleobases as well as salts originating from 
sample workup and other contaminants can largely decrease sensitivity in 
mass analysis. This problem could be overcome by solid phase extraction 
and/or immunoaffinity chromatography (Schneider et al., 2006; Chaudhary et 
al., 1995; Singh et al., 2003) prior to LC-MS analysis. Besides, the clean-up 
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process was further improved by on-line coupling, using two-dimensional 
chromatography with automatic column switching (Koc and Swenberg, 2002; 
Churchwell et al., 2002). Direct analysis of the nucleoside adducts from the 
digested DNA without further purification has also been described (Frelon 
etal.,2000). 
The chromatographic separation of the modified nucleosides and 
nucleobases was best achieved on reversed phase columns with RP-18 or 
RP-8 stationary phases (Frischmann et al., 2005; Olsen et al., 2005; 
Chaudhary et al., 1995; Paehler et al., 2002). The adducts were eluted using 
aqueous phase—acetonitrile gradients (Frischmann et al., 2005; Olsen et al., 
2005; Paehler et a!., 2002; Tretyakova et al., 1998). In some cases, 
methanol was used instead of acetonitrile (Singh et al., 2003) but the 
formation of artifact adducts from methanol was observed, thus it was 
avoided in further studies (Dennehy and Loeppky, 2005). After liquid 
chromatography, DNA adducts are often ionized by electrospray ionization 
(ESI) (Cadet etal., 2002). 
MG adducts of nucleosides were first analyzed with LC-MS/MS by 
Schneider et al. (1998) on a triple quadrupole mass spectrometer after 
HPLC separation on a RP-18 column with a gradient of 0.1% trifluoroacetric 
acid and acetonitrile followed by ESI in positive and negative ion mode. The 
method was used to detect the MG bis-adduct, A/^ , 7-bis (1-hydroxy-2-
oxopropyl)-2'-deoxyguanosine (MGadG) derived from the incubation of 2'-dG 
with MG or 1,3-dichlorpropene epoxide. Frichmann et al. (2005) developed 
an LC-MS/MS method for CEdGA,B measurements in vitro and in vivo. 
Enzymatically hydrolyzed DNA, incubated in the presence of 100 mM MG, 
showed four major peaks, corresponding to the mono- and bis-adducts from 
MG and 2'-dG, respectively. The mono-adducts were identified to be 
CEdGA,B and A/^ -(1-carboxyethyl)-2'-deoxyadenosine (CEEdAAs), respectively 
and the bis-adducts involved a second molecule of MG reversibly bound to 
N-7 of CEdGA,B or CEdAA,B- The products were separated on a RP-8 column 
with an ammonium formate buffer—acetonitrile gradient as eluents and the 
peaks were identified in the MRM using the three most intensive and 
characteristic mass transitions as qualifiers. This method allowed the 
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detection of all four adducts in DNA, which had been incubated with 10 mM 
MG, whereas only CEdGA,B were identified, when DNA had been reacted 
with physiological concentrations of MG (10|aM) (Frischmann et al., 2005). 
Dennehy and Loeppky (2005) developed a LC-MS/MS method for 
quantification of GdG, the cyclic adduct of glyoxal with 2'-dG. The analytes 
were detected in the positive ion mode by a triple quadrupole mass 
spectrometer after electrospray ionization. The mass transition 326^210 
miz, which accounts for the loss of deoxyribose, was used in the SIM 
reaction for peak identification. 
This study involved optimization of the isotopic dilution analysis LC-
MS/MS procedure adopted by Fleming et al. (2008) for the synthesis and 
purification of the imidazopurinone adducts produced by the reaction of 2'-
dG with MG and glyoxal, as well as the oxidation marker, 8-oxodG. The 
method was also optimized for column temperature and its effect was 
monitored on elution profile of the MGdG and GdG peaks. The MGdG 
adduct was prepared as per the protocol by Fleming et al. (2008), however 
the incubation reaction was prolonged to identify products fomried at 
advanced stages of the reaction. Furtherstill, the problem of initial sample 
clean-up was overcome by involving automated switching in the instrument. 
As a result the undesired salts and impurities were diverted to the waste 
instead of contaminating the MS source (Fig. 4.2). The standardized 
procedure using stable isotopic standard was used in this isotopic dilution 
assay for the measurement of glycation adducts formed in enzymatically 
hydrolysed DNA obtained from human MNLs as well as HL-60 cells in 
culture. 
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Fig. 4.2- The LC-MS/MS instrumental setup used for the analysis of the 
various samples. An automated switching valve which could 
change the direction of flow as desired was used. 
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4.2 RESULTS 
Nucleic acid glycation produces a number of AGEs and the adducts 
formed by MG and glyoxal, have been studied in detail (Frischmann et al., 
2005; Kasai et a!., 1998; Olsen et al., 2005). These studies (Table- 4.1) 
indicated that the ratio of deoxyguanosine to MG was crucial in determining 
the nature and amount of adduct formed. In this study the reaction of 2'-dG 
and MG was carried out with a 2'-dG/MG ratio of 1:1.6 (Fleming et al., 2008) 
as also described earlier in the methods. The initial reaction results in the 
formation of an imidazopurinone adduct. Glyoxal fomris GdG and MG forms 
MGdG adducts. 
The dicarbonyls react at the exocyclic amino group of the guanyl 
base, to form imidazopurinone or the closed ring derivative, besides there is 
formation of the open ring derivative or the reversible glycosamine- A/^-(1-
Carboxymethyl)-2'-deoxyguanosine from glyoxal (Seidel et al., 1998b) and 
r/-(1-Garboxyethyl)-2'-deoxyguanosine from MG (Ochs et al., 1994). A third 
adduct is also possible in which the dicarbonyl can react simultaneously at 
N-7 position of the imidazole ring and the exocyclic amino group 
(Frischmann et al., 2005). This MG adduct has only been characterized. The 
MG2dG may only be a minor adduct fonned in DNA due to the steric 
hindrances, but may be fonned more readily with the free bases, 
nucleosides or nucleotides (Frischmann et al., 2005). 
A study was also conducted to monitor the effect of column 
temperature on the elution profile of the adducts formed from MG and 
glyoxal. The sample used for the study was a cocktail containing 10 pmol of 
MGdG, CEdGA.B and GdG standards each. The column temperature was 
varied between 10-30°C at an interval of 5°C. The analysis at each 
temperature was repeated in triplicate to obtain confirmatory results and rule 
out any artefacts during the analysis. 
An interesting observation was that at higher temperatures (25-30°C) 
the MGdG adduct peak was broad, and incompletely resolved. However at 
lower column temperatures the single broad peak was split into three minor 
peaks (Fig. 4.3). At 10°C (which was the minimum default temperature in the 
instrument setup) the MGdG peak showed clear separation into three minor 
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Fig. 4.3- Effect of column temperature on the elution profile of the MGdG 
adduct. The column was operated at (a) 30°C, (b) 25°C, (c) 20°C, 
(d)15°Cor(e)10°C. 
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peaks (Fig. 4.3 (e)), indicative of different isomeric forms of the MGdG 
adduct. The two additional closely spaced peaks seen along with the MGdG 
peak were later found to be those of CEdGA,B. 
The improvement in peak shape was also observed in the 
chromatogram for the GdG adduct. The peak for the analyte was broad at 
higher temperatures. As the temperature was decreased, the resolution of 
the peak improved and the broad peak transformed into a sharp peak. Thus, 
optimal column temperature for the analysis of nucleoside markers was 
found to be 10°C and all further analyses was carried out at this 
temperature. The studies also showed that decrease in column temperature 
facilitated greater binding of the analyte to the column, as indicated by the 
increased retention time. When temperature of the cx)lumn decreased from 
30°C to 10°C an increase in retention time of 1 min for the MGdG peak (Fig. 
4.4) and simllarily an increase of 1.2 min in the retention time for the peak of 
the GdG adduct was observed (Fig. 4.5). 
The fonnation of the glycation adducts resulting from the reaction of 
2'-dG and MG was also monitored over a time span of 10 days (Fleming et 
al., 2008). At the end of the 4 days of incubation, an aliquot was withdrawn 
for purification of the adduct by reverse phase preparative HPLC with UV 
absorbance monitored at 254, 280 and 300 nm. The purity of the product 
was tested by LC-MS/MS analysis and a major peak for the m/z - 340>224 
transition was observed confirming the formation of a pure MGdG adduct 
(Fig. 4.6(a)). 
At the end of 5 days of incubations at 37°C (after adjusting the pH of 
the mixture to 7.4) the chromatogram with the m/z value of 340 showed the 
emergence of two new peaks at 9.7 and 11.1 min alongwith the major broad 
peak of the MGdG adduct which in turn was a combination of 3 minor peaks 
at 7.3, 7.7 and 7.9 min (Fig. 4.6(b)). The chromatogram at the end of 6 days, 
showed a decrease in the peak intensity of the principal MGdG adduct 
whereas the intensity for the new pair of peaks was enhanced (Fig. 4.6(c)). 
At the end of 7 days, the peak intensity of the MGdG adduct was minimal 
with a corresponding rise in the intensity of the new peak pair (Fig. 4.6(d)). 
At the end of 10 days, the chromatogram showed near 
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Fig. 4.4- Effect of column temperature on the chromatographic behaviour of 
the MGdG adduct. 
Fig. 4.5- Effect of column temperature on the chromatographic behaviour of 
the GdG adduct. 
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Fig. 4.6 (a) - The mass chromatogram for MGdG (mass transition: 340>224) 
adduct obtained at the end of the 4 days incubation analysed 
by LC-MS/MS in the positive ion mode, (A) [U-^ ^Cio, U-^ N^g] 
isotopic standard, (B) sample analyzed. 
Fig. 4.6 (b) - The mass chromatogram for MGdG (mass transition: 340>224) 
adducts obtained at the end of 5 days of incubation, analyzed 
by LC-MS/MS in the positive ion mode. For details refer to 
legend of Fig. 4.6(a). 
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Fig. 4.6 (c) - The mass chromatogram for MGdG (mass transition: 340>224) 
adducts obtained at the end of 6 days of incubation, analyzed 
by LC-MS/MS in the positive ion mode. For details refer to 
legend of Fig. 4.6(a). 
Fig. 4.6 (d) -The mass chromatogram for MGdG (mass transition: 340>224) 
adducts obtained at the end of 7 days of incubation, analyzed 
by LC-MS/MS in the positive ion mode. For details refer to 
legend of Fig. 4.6(a). 
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disappearance of the MGdG peak, however prominent peaks of the new 
adduct formed were visible (Fig. 4.6(e)). This gradual decrease in MGdG 
alongwith the corresponding enhancement in the formation of the new 
adducts was clearly highlighted in Fig. 4.6(f). It was seen that in a span of 
three days, at the end of the 7 days, a 42-fold decrease in MGdG levels was 
observed. While the formation of CEdGA.B was enhanced 300-fold. 
Attempts were made to purify and characterize the molecule 
corresponding to the new pair of peaks. Firstly, anion exchange 
chromatography was carried out on a Protein PAK DE/^ E-cellulose matrix, 
and the purity analysed using LC-MS/MS (Fig. 4.7). 2'-dG contamination 
within the purified product was estimated to be ~ 0.038 nM. Further ^^ C, ^ H 
and COSY 2D-NMR studies were carried out on the purified product, and the 
analytical characteristics of NMR of the new adduct were similar to those 
reported by Cao et al. (2007). The results confirmed the formation of an 
equimolar mixture of R and S epimers of CEdGA, B-
Spike and recovery studies were performed to assess method validity 
for DNA analysis, adduct stability, and overall procedure efficiency. The 
study was carried out to judge the stability of the CEdGA.s adduct during the 
enzymatic hydrolysis procedure and subsequent sample recovery and clean 
up from the Ci8 column during LC-MS/MS procedure. Percent recovery = 
(Amount of CEdGA,B in DNA spiked with CEdGA,B standard - Amount of 
CEdGA.B in DNA without any spiking with CEdGA.s standard)/Amount of 
CEdGA.B stock added) X 100. The recovery of CEdGA.B in DNA extracted 
from HL-60 cells was estimated to be 70.34 %. 
It was observed that the various markers of nuclcjotide glycation and 
oxidation, namely, MGdG, CEdGA.s, GdG and 8-oxodG, respectively were 
eluted from the C^ ^ reverse-phase matrix at specific time intervals depending 
upon their structural characteristics, whereas their fragmentation pattern 
during ESI inside the mass spectrometer was an accurate depiction of the 
charge to mass ratio of the parent as well as fragment ion. As depicted in 
Fig. 4.8(a), MGdG which can exist in many isomeric forms produces a 
chromatographic profile which was a combination of multiple peaks (Rt = 
7.2-8.6 min), whereas the parent-fragment ion (i.e. parent ion[M+1f> 
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Fig. 4.6 (e) -The mass chromatogram for MGdG (mass transition: 340>224) 
adducts obtained at the end of 10 days of incubation, analyzed 
by LC-MS/MS in the positive ion mode. For details refer to 
legend of Fig. 4.6(a). 
Fig. 4.6(f)- A plot showing decrease in MGdG formation and a 
corresponding rise in CEdGA.B formation as a function of 
incubation time when 2'-dG and MG are incubated at 37°C. 
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Fig. 4.7- The LC-MS/MS chromatogram of the purified product-CEdGA.B-
The concentration of the analyte was 0.1 nM in 0.1% formic acid in 
water. For details refer to legend of Fig. 4.6 (a). 
Fig. 4.8(a)- The chromatogram for MGdG showing the site of 
fragmentation during MS scan (inset). 
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fragment ion [Fr+]) had m/z values of 340.0>224, due to the loss of 
deoxyribose moiety during ionisation in the MS. Similarly, Fig. 4.8(b) shows 
the chromatogram for 8-oxodG (Rt= 8.4 min) along with the fragmentation 
pattern of this oxidation adduct with m/z values as 283.8>168.0. CEdGA,B 
which exists as an equimolar mixture of R and S epimers produced a 
chromatogram with two closely spaced peaks (Rt = 9.8 , 11.2 min) and the 
m/z values- 340.0>224 (Fig. 4.8(c)). On the other hand, the glyoxal adduct, 
GdG gave a single peak (Rt = 6.7 min), m/z values- 325.7> 209.9 (Fig. 
4.8(d)). 
Since this LC-MS/MS analysis procedure using stable isotopic 
standards allowed accurate characterization and quantitation of various 
markers of DNA giycation and oxidation, a study was carried out to assess 
the formation of the various DNA adducts in HL-60 c«lls in cultures and 
human MNLs extracted from the blood of normal, healthy subjects. It was 
found that DNA from both these sources showed maximum levels of MGdG 
adducts followed by 8-oxodG, GdG and minimum CEdGA.s adduct fomnation. 
HL-60 cells showed greater levels of MGdG and 8-oxodG as compared to 
MNLs obtained from normal healthy subjects, wherein the CEdGA.B and GdG 
levels were found to be higher (Fig. 4.9). The adduct levels (adducts per 10^ 
nucleotides; n = 3) in HL-60 cells were GdG 2.04 ± 0.07, MGdG 21.1 ± 5.33, 
CEdGA,B 0.56 ± 0.05 and 8-oxodG 10.31 ± 0.57 and mononuclear 
lymphocyte DNA contained GdG 2.11 + 0.74, MGdG 8.73 ± 2.41, CEdGA.e 
1.03 ± 0.38 and 8-oxodG 2.79 ± 0.64 adducts per 10^ nucleotides. 
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Fig. 4.8 (b)- The chromatogram for 8-oxodG showing the site of 
fragmentation during MS scan (inset). The asterisk {*) 
indicates fomnation of 8-oxodG from dO in the sample, when 
present in the electrospray ionisation prolDe of the mass 
spectrometer. 
Fig. 4.8 (c) - The chromatogram for CEdGA.e showing the site of 
fragmentation during MS scan (inset). 
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Fig, 4.8 (d) - The chromatogram for GdG showing the site of fragmentation 
during MS scan (inset). The asterisk (*) indicates formation of 
GdG from dG in the sample, when present in the electrospray 
ionisation probe of the mass spectrometer. 
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Fig. 4.9- Estimation of nucleotide adducts formed per 10^ nucleotides in 
the DNA extracted from • - MNLs and D - HL-60 cells. The 
values plotted here are the mean values of three different 
observations. For the lymphocytes the results are mean values of 
the levels obtained from the blood of three healthy human 
subjects (n=3). 
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4.3 DISCUSSrON 
The DNA molecule is quite prone to alteration by electrophilic 
reagents due to the presence of nucleophilic sites on its purine and 
pyrimidine bases. The most active of these nucleophilic sites are nitrogen 
atoms at position 7 of guanine and position 3 of adenine (La and Swenberg, 
1996; Singer and Grunberger, 1983). 
Electrophilic compounds can react with the DNA bases, acting as 
nucleophiles, resulting in the covalent modification of the DNA base. This 
covalently modified DNA base Is referred to as a DNA adduct. DNA adducts 
represent excellent biomarkers for determining the extent of damage to the 
genetic material, which has long been of Interest in understanding the 
mechanism of disease and in the assessment of risk posed by various 
glycation agents. Various methods have been develope<i for quantitation of 
DNA adducts. Of these, the most commonly used ones are ^^P-postlabeling 
(PPL), high-perfomriance liquid chromatography (HPLC) with electrochemical 
detection, and various chromatographic techniqu(5s utilizing mass 
spectrometric detection. HPLC with fluorescence detection. Immunoassays, 
and accelerator mass spectrometry (AMS) are also used for quantitatbn of 
the DNA adducts (Fanner et al., 2005). 
The present work was an attempt to synthesize adducts of DNA 
glycation and study them as potential markers for assessment of in vitro and 
in vivo DNA glycation. It was found advantageous to use LC-MS/MS for the 
characterisation and quantitation of these DNA adducts, because the 
procedure dkJ not require the hazardous radioactive compounds and hard to 
obtain antibodies. In addition, the technique provides specific qualitative 
information in the form of molecular weights and characteristic 
fragmentation. Measuring DNA adducts themselves Is a more precise and 
reliable way to determine the risks of the damage to DNA. An accurate 
measurement was possible by using Isotopic dilution mass spectrometry 
where isotopic analogs of the analytes studied were added as Internal 
standards (Fanner et al., 2005). In order to achieve maximum sensitivity In 
the MS/MS mode for each adduct and its Isotopic analog, while the Identity 
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of each adduct was retained, the transition from its molecular ion to the most 
abundant characteristic daughter tons was measured using multiple reaction-
selected ion monitoring. The quantitation of DNA adducts was done at a 
physiologically significant value of 1 adduct per 10^ nucleotides which 
provided a clear picture to assess their potential to cause damage in vivo 
(Farmer etal., 2005). 
The purity of the various analytes synthesized was assessed by 
isotopic dilution mass spectrometry, a technique with the unique ability to 
differentiate compounds on the basis of their m/z value. The ability to 
measure m/z values is advantageous because even very high molecular 
weight compounds can easily be quantitated and thus, allowing analysis 
across a wide range of mass. The isotopic molecule which is identical 
chemically to the analyte was added as an internal standard, to allow 
accuracy of the results obtained. Use of the isotopic standard allows to 
correct for losses during the sample preparation and variations in the mass 
spectrometric response, since the analyte and its corresponding stable 
isotopic internal standard behave identically during the processes to which 
the sample is subjected to. Thus, the analysis of the ftnal purified product by 
LC-MS/MS can be considered highly accurate (Fig. 4.7). 
The stable isotopic dilution analysis- tandem mass spectrometry 
method employed in the present work for quantitation of DNA-AGEs has 
several advantages. It shows linear response to analyte concentration, high 
sensitivity and recovery as indicated by the calibaration plots for the various 
analytes, in the methods section (Fig. 2.1-2.5). The procedure provided a 
robust assessment of DNA damage by glycation with concurrent assessment 
of oxidative damage. Besides, the procedure developed allowed for the first 
time simultaneous synthesis of both MGdG and CEdGA,B under physiological 
conditions and provides evidence to show that MGdG is an intermediatory 
molecule in the pathway leading to CEdGAB productiof> under physiological 
environment as suggested earlier by Frischmann et al.(2005). 
The formation of an initial cyclic adduct from 2'-dG (Fig. 4.6 (a)) was 
supported by earlier findings of Shapiro et al. (1969) who were the first to 
investigate the reaction of guanosine with more than t2-fold excess of MG. 
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Their results showed that after 5 min of incubation, guanosine was 
completely converted into the cyclic adduct, MGdG. Later using ^^P-
postlabeling Vaca et al. (1994,1998) detected the formation of MGdG, when 
calf-thymus DNA was incubated with 40 mM MG for 25 h or in the DNA from 
human lymphocytes, which were treated with 3 mM MG overnight or with 30 
mM MG for 1 h. Frischmann et al. (2005) in their study on the identification of 
various adducts of MG were not able to isolate MGdG adducts and instead 
CEdGA.B formation was observed during prolonged incubation of DNA with 
physiological concentrations of MG. Whereas the incubations of 2'-dG with 
excess MG, concluded that MGdG was detected only during the initial 
incubations upto 24 h, and longer incubations led to loss of MGdG and 
formation of CEdGA.B. They however synthesized MGdG in a separate study 
using the procedure described by Shapiro et al. (1969). 
Quantitation of modified nucleotides in DNA in vivo has proven 
difficult because of inadequate sensitivity and specificity of detection 
responses and poor adduct stability and recovery during pre-analytic 
processing. It is noteworthy that none of the previous studies on the 
synthesis of MG-derived adducts were able to show the exsistence of the 
labile MGdG molecule upto 4 days of incubation (which was the time period 
adopted in our study) and thus, did not allow its isolation and purification to 
be used as a standard. Therefore, the previous works (Schneider et al., 
2004; Li et al., 2006) led to the conclusion that CEdGA.B was the major 
adduct formed during DNA glycatlon. The present work developed a robust 
procedure which allowed lsolatk)n of both MGdG and CEdGA.B adducts (Fig. 
4.6), which could be used as standards to estimate the degree of DNA 
glycation in vitro an6 in vivo. 
Frischmann et al. (2005) stated that the diastereomers of the cyclic 
adduct appeared in the KPLC-MS/MS as a novel peak pair with nr/z - 338 
(negative Ionization), and differed In retentran time from CEdGA,B- This was 
quite similar to our results where the MGdG cyclic adduct gave a broad peak 
at around 7.8 min whereas the peak for the CEdGA,B Isomeric pair appeared 
at 9.8 and 11.2 min respectively (Fig. 4.8 (a) & (c)). However since ionization 
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was conducted in the positive ion mode, the cyclic adduct had a m/z value of 
340.0. 
The peak splitting observed for the MGdG peak could be attributed to 
the various structural and stereoisomers of MGdG when in solution (Vaca et 
al., 1994). As observed from the structure, 8 epimers could possibly be 
formed. If in some structural orientation the two hydroxyl groups of the 
imidazopurinone are facing the column matrix, stronger binding would occur, 
whereas in the case where these groups are away from the column matrix, 
the resulting weak interaction may cause early elution of the analyte from the 
column during RP-HPLC. As a result, depending on the fraction of each type 
of epimer formed and degree of its interaction with the column, the single 
broad peak for MGdG could be split into multiple minor peaks (Fig. 4.6(a)). 
The chromatogram for the MGdG adduct shows three peaks, from 
which the first two peaks have equal intensity, indicative of an isomeric pair 
whereas the third minor peak may correspond to a different isomeric 
molecule. This was supported by the work of Vaca et al. (1994) on 
identification of the adducts formed from the reaction between 2'-
deoxyguanosine-3'-monophosphate and MG using ^^P-postlabeling 
technique. They concluded the formation of four chemical stereoisomers 
because of the stereocentres at position 6 and 7. The four adducts were 
present as two pairs of enantiomers. Tentative assignments for the multiple 
peaks obtained in MGdG, could be 7-methyl stereoisomers for the initial 2 
peaks and 6-methyl stereoisomers for the last peak. 7-methyl stereoisomers 
are expected to be dominant as their formation involves an initial reaction 
encounter of the nrK)st electrorvrrch N -^nitrogen of 2'-dG with the most 
electron-deficient aldehyde-carbon of MG. Similar reactivity of the exocyclic 
N -^amino group of 2'-dG with non-functional aldehydes such as 4-
hydroxynonenal (4HNE) has been reported (Chung et al., 2000). Since 
CEdGA,B exists as an epimeric pair, the chromatogram for CEdGA.B shov^^  a 
pair of closely spaced peaks (Fig. 4.7). It is important to highligfit that the 
relative detection response peak areas for component peaks for MGdG and 
CEdGA,B were constant for all the test and standards samples studied. This 
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suggests that isomer distribution is constant both in standard and test 
samples and hence the assay is highly accurate. 
Glyoxal is another widely used chemical with industrial applications. 
Therefore, occupational exposure may occur in the industries. Glyoxal is 
endogenously produced during normal cellular metabolism by a multitude of 
enzyme independent pathways (Olsen et al., 2005). Our positive ion LC-
MS/MS analysis results for GdG adduct show a similar fragmentation pattern 
as obtained by Olsen et aL (2005). They have shown that GdG adduct when 
subjected to positive ESJ resulted in a protonated molecular ion of m/z -326 
and a fragment ion at m/z- 210, which results due to loss of a deoxyribosyl 
moiety from the protonated ion. Our results substantiate these earlier reports 
and it was seen that GdG adduct analysed by positive ion mass 
spectrometry showed similar fragmentation patterns (Fig. 4.8 (d)). However, 
as observed by Bidmon et al. (2007) the isomers of the GdG adduct could 
not be separated with a water-acetonitrile gradient containing 0.1% formic 
acid, employed in this study. Therefore, it explains the occurrence of a single 
peak for GdG (Fig. 4.8 (d)). 
The mass spectra for the various DNA-AGEs showed similarities in 
the fragmentation pattern indicating the loss of the deoxyribose sugar from 
the 2'-dG molecule and production of an M-H"^  ion (Fig. 4.8). This was in 
accordance with earlier reports that most alkylated 2'-deoxynucleosides 
studied during positive ESI followed a similar fragmentation pattern wherein 
the bond between the sugar and the base was broken and a proton 
transferred from the sugar to the base, resulting in the formation of a 
protonated adducted base ion (Fig. 4.10). This protonated ion could easily 
be detected by positive-ion ESI-MS (Farmer et al., 2005). Therefore, all the 
LC-MS/MS studies were carried out in the positive ionization mode. 
The time dependent analysis enabled us to show that the reaction 
between 2'-dG and MG begins with the fomriation of the very labile cyclic 
adduct, MGdG. Under neutral or alkaline conditions, this cyclic adduct gets 
rapidly degraded leading to fonnation of the second more stable AGE, 
CEdGA,B (Frischmann et al., 2005) (Fig. 4.6 (a-e)). The study helped us 
understand the complete reaction for the generation of these AGEs, wherein, 
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Fig. 4.10-The electrospray MS/MS fragmentation scheme for ail<yl-2' 
deoxyguanosine (Farmer et al., 2005). 
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the reaction between amino group of the nucleoside and hydrated sugar 
produces an initial imidazopurinone. When further incubation was carried out 
after increasing the alkalinity of the solution, the intermediate undergoes 
ketonisation and results in the formation of the stable carboxyethyl derivative 
of2'-dG (Fig. 4.11). 
After developing an accurate and reproducible LC-MS/MS method for 
the quantitation of various adducts of DNA, the levels of these adducts were 
quantified in DNA extracted from HL-60 cells in culture and also MNLs 
obtained from blood of healthy human subjects. The concentration of MGdG 
in MNLs was found to be higher in our study than that obtained by the ^ ^P-
labelling studies of DNA digests (ca. 0.1 adducts per 10^ nucleotides) (Hou 
et al., 1995) presumably because the digestion protocol followed by the 
authors involved processing for 2 h at pH-9.0 wherein >95% of MGdG 
adducts get degraded. Since the half-life of MGdG was found to be <0.2 h at 
pH-9 (personal communication by Prof. P.J.Thomalley). It is noteworthy that 
MNLs are long-lived (Craddock et al., 1977) and thus, potentially vulnerable 
to cumulative changes (Lorenzi et al., 1987). 
Besides, our results of the nucleotide adduct measurements in MNLs 
showed a trend similar to that reported earlier by Thomalley (2008) in human 
MNLs. The levels of adducts reported in their study were (adducts per 10^  
nucleotide; n = 3): MGdG 15.7± 0.38, 8-oxodG 3.33 ±0.13 and GdG 1.59 ± 
0.08. It was clearly seen that the MGdG adduct was formed in maximum 
concentration. Although, till late CEdGA.B has been (X)nsidered the major 
marker for DNA glycation (Schneider et al., 2004; Li et al., 2006), the 
increased MGdG fomiation in the cells maybe attribut(Kj to various reasons. 
Till date, the isolation and characterization of the labile MGdG adduct has 
been a challenge for most researchers. Therefore, under incubation 
conditions employing excess MG it maybe noted that none of the earlier 
researches showed exsistence of MGdG adduct on longer incubation 
periods of days (i.e. 4 days). This led them to assume CEdGA,B (that 
presumably formed from MGdG) as the major nucleotide glycation adduct. 
The observed very low concentration of CEdGA,B in the present study, in 
apparent contradiction to the earlier work (Schneider et al., 2004; Li et al.. 
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2006; Schneider et al., 2006) may therefore represent the true value of the 
adduct formed in vivo. Besides, at low MG levels, MGdG formation maybe 
rapid and since physiological levels of the oxoaldehyde are in the micromolar 
range, MGdG adduct formation maybe greatly favored under these 
conditions. 
On the other hand, the HL-60 cells were cultured for a period of 4 days 
in a culture medium containing 11 mM D-glucose, before DNA was extracted 
for the measurement of various DNA adducts. This could explain the higher 
levels of the various adducts in HL-60 cells (especially MGdG) as compared 
to MNLs (Fig. 4.9). In contrast, MNLs were exposed to physiological 
concentrations of the sugars without any additional supplementation. 
This work emphasizes the need for developing an efficient and 
reliable method for the qualitative and quantitative analysis of various 
products of DNA glycation. With the recent advances in chromatography, 
LC-MS coupling, ionization and mass analysis, LC-MS/MS has become a 
very sensitive and reliable method for the analysis of DNA adducts. LC-
MS/MS has been successfully applied for the analysis of DNA-AGEs and 
nucleobase-AGEs which are formed in vitro. It can be expected that such 
LC-MS/MS studies will also be a valuable tool to detect and quantify DNA-
AGEs in vivo. Such studies promote our knowledge on the contribution of 
DNA glycation in aging and disease. 
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Studies on nucleotide 
oxidation and glycation 
adducts in Type-2 Diabetes, 
ESRD and carbonyl induced 
glycation damage in some 
tumour cells 
5.1 INTRODUCTION 
The role of AGEs in the pathophysiological complications of diabetes 
is now well recognized (Sampathkumar et al., 2005). The AGEs are 
chemically heterogeneous and induce several cellular responses through 
interaction with AGE specific cell-surface receptors (Vlassara et al., 1988 
and 1994; Esposito et a!., 1989; Kirstein et al., 1990; Kirstein et a!., 1992; 
Bucala et a!., 1991). Direct evidence on the in vivo pathogenic effects of 
AGEs, independent of hyperglycemia was provided by the experiments in 
which intravenous administration of exogenous AGEs to healthy animals 
induced multiple vascular defects including vascular permeability, 
subendothelial and perivascular mononuclear cell infiltration, and defective 
nitric oxide-dependent vasodilatory responses (Makita et al., 1995). 
Accumulation of AGEs has a catastrophic outcome in diabetes, affecting 
major tissues of the human body and resulting in various micro- and 
macrovascular complications associated with diabetes, including retinopathy 
(Stitt, 2003; Chibber et al., 1997; Tanaka et al., 2000), cataract (Perry et al., 
1987), atherosclerosis (Bucala, 1997), nephropathy (S>ugiyama et al., 1996; 
Forbes et al., 2003) and neuropathy (Vlassara et al., 1985). Diabetic 
embryopathy, another serious complication of diabetes has been attributed 
to glycation of DNA and histones by reactive sugars, resulting in errors in 
replication and transcription, thereby promoting mutations (Ahmad, 2005) 
Protein glycation end products such as N8-(carboxymethyl) lysine 
(CML), pentosidine and imidazolone accumulate in the kidneys and aortas of 
diabetic and nondiabetic uraemic patients (Aronson, 2002; Tanji et al., 2000; 
Wagner et al., 2001; Mao et al., 2003; Kitauchi et al., 2004; Sakata et al., 
1999; Niwa et al., 1997a; 1995; 1997b) 
Brownlee (2001) carried out research on diabetic complications and 
proposed four main hypotheses to explain the relationship between 
hyperglycemia and diabetic complications. These are increased polyol 
pathway flux; increased AGE formation; activation of protein kinase C (PKC) 
isofomris; and Increased hexosamine pathway flux. It was the first report to 
show that overproduction of superoxide by the mitochondrial electron 
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transport chain was a common outcome of all these mechanisms, resulting 
in oxidative stress. Further, the concept of 'hyperglycemic memory' was 
coined, which referred to the persistence and progression of hyperglycemia 
induced microvascular alterations during subsequent periods of normal 
glucose levels. The increased fonnation of superoxides during 
hyperglycemia could induce mutations in mitochondrial DNA. The defective 
subunits of the electron transport chain encoded by the mutated 
mitochondrial DNA could lead to increased production of superoxide also at 
physiological concentrations of glucose, with resulting activation of the four 
pathways. The study also points towards the need to do gene profiling for 
the hereditary occurrence of diabetic micro- and macrovascular 
complications, due to reports of familial clustering in nephropathy and 
retinopathy (Quinn et al., 1996). 
The study by Snieder et al. (2001) showed that HbMc levels (i.e. a 
predictor of the risk of microvascular complications) are largely genetically 
detennined and independent of the genes influencing fasting glucose. 
The work by Li et al. (2006) was the first to establish the role of 
CEdGA,B (the major known marker for DNA glycation) in the pathogenesis of 
diabetic nephropathy as well as uraemic vascular complications by 
immunohistochemistry of kidneys and aorta using an anti-CEdGA,B 
monoclonal antibody. In the kidneys CEdGA,B was detected primarily in the 
nuclei of epithelial, mesangial and endothelial cells of the glomeruli, parietal 
epithelial as well as tubular cells. More CEdG-positive cells were present in 
the glomeruli of patients with diabetic nephropathy compared to the controls. 
In the aortic walls, CEdGA,B was mainly localized in the nuclei of 
macrophages and myofibroblasts, with greater number of CEdG-positive 
cells detectable in the aorta of hemodialysis (HD) patients and more 
markedly in diabetic HD patients as compared with control. 
Synold et al. (2008) measured the CEdGA.B levels in the urine of 
normal and Streptozoticin induced diabetic Sprague - Dawley rats, 
employing LC-MS/MS with ESI and using isotopic CEdGA,B standard for 
quantitation. The study showed that 77pg/ml CEdG was excreted by the 
normal controls, whereas the induction of diabetes increased the urinary 
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levels ~ 4 fold. They also measured the CEdGA.e levels in human breast 
tumour and normal tissue and observed that both stereoisomers were 
present at ~ 3-fold higher levels in normal relative to tumor tissue. Within 
normal tissue, the levels of CEdG- A and -B were not significantly different, 
while in tumor there was a small bias favoring CEdG-A formation. 
Kocic et al. (2008) carried out a study on juvenile and adult insulin-
dependent diabetes as well as adults with type 2 diabetes. A fall in plasma 
RNase and nuclease activity was observed in juvenile diabetics, 
accompanied by increase in circulating nucleic acids and different-sized 
oligonucleotides that may contribute towards increase of nucleic acid 
"danger motifs" and to the immune stimulation. 
Diverse and multiple mtDNA deletions were detected in the skeletal 
muscles of ESRD patients. This was attributed to aiccumulation of uraemic 
toxins and imoaired free radical scavenging systems, and in turn to 
increased oxidative stress. Such stress mav resuft in oxidative damage and 
aainn-associated mutation of the mitochondrial genome (Lim et al.. 2000). 
AGEs are also imolicated in the oathoaenesis of the uraemic 
syndrome, for examole, diah/sis-related amyloidosis, dyslioidemia and 
vascular dysfunction (Schwenqer et al.. 2001). Genomic damaqe In 
DeriDheral blood hrniohocvtes ^PBLs). oossiblv induced by DMA olycation 
was found to be accelerated in uraemic oattents fStODoer et a l . 1999: 2001), 
The 4977 bp deletion of mtDNA in hair follicles was recoanized as a 
marker for DNA damaqe in ESRD iLiu et al . 2001). The enhanced Genomic 
damaae observed in mitochondria durina ESRD was due to the absence of 
orotective histones on mtDNA and low efficacy of DNA repair Since the 
DNA repair is impaired in ESRD patients higher incidence of cancer was 
observed during HD treatment. 
Uraemia is characterized by oxidative (due to iron overload) and 
carbonyl stress which promotes production of reactive carbonyl compounds, 
that form AGEs and in turn induce DNA damage. Several other theories 
were put fonward to explain this damage, including that of hypomethylatlon 
(Perna et al., 2006). Kidneys play a key role in excretion of AGEs and 
decreased renal function leading to rise in plasma AGEs and their 
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accumulation in the tissues. Patients subjected to standard HD displayed a 
2-fold higher frequency of micronuclei in PBLs than the healthy controls 
(Sebekova et al., 2007). In contrast, patients on daily HD show lower 
frequencies of micronuclei, comparable to the controls. Both groups of HD 
patients display markedly higher plasma AGE levels than the healthy 
controls, with higher values in the standard HD than daily HD patients. A 
direct relationship between the frequency of occurrence of micronuclei and 
the plasma concentrations of CML or imidazolone A (3-DG derived 
imidazolinone) was evident in PBLs. (Fragedaki et a!., 2005). Besides, the 
genomic damage in PBLs was lower in patients on daily HD than in those on 
standard HD and this was attributed to lower plasma concentrations of 
uraemic toxins, including circulating AGEs. 
The AGE-RAGE interaction initiates a downstream signaling cascade 
involving NF-KB, with induction of ROS formation and inflammatory 
responses to promote development of atherosclerosis. The role of NF-KB 
was established using the inhibitor dimethylfumarate, which was able to 
prevent the DNA damage (Schupp et al., 2005). Benfotiamine, a prodrug of 
thiamine known to reduce AGE levels and microangiopathy was also 
effective in decreasing the genomic damage in PBLs from patients on HD 
(Schupp et al., 2008). 
Studies on ESRD suggest the following (i) AGEs accumulate and 
cause enhanced DNA damage, (ii) Precursors of AGEs also induce DNA 
damage, (iii) a direct correlation exist between plasma AGE levels and DNA 
damage markers in ESRD, (iv) AGE and RAGE are expressed in tumor cells 
and the AGE-RAGE interaction participates in tumor invasive and metastatic 
activity, (v) Higher incidence of cancer is observed in ESRD patients and (vi) 
ESRD patients with cancer show increased DNA damage and associated 
DNA mutations (Nagy et al., 2003; Vamvakas et al.,1996). 
As stated earlier glycation of proteins may result in denaturation, 
cellular damage and enzyme inactivation, whereas the nucleotide glycation 
can cause mutagenesis and apoptosis. AGEs are involved in the 
physiological complications of various diseases like diabetes and renal 
failure. Thomalley (2003d) gave the novel concept of the enzymatic defense 
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against glycation, and related cellular damage, involving enzymes like Glo-1, 
by oxoaldehydes, reactive carbonyl species and some aldehyde reductase 
and dehydrogenase isozymes. The enzymatic defense is however not 
perfect, and glycation adducts of proteins, nucleotides and lipids are still 
formed under physiological conditions, albeit at low levels. But under certain 
diseased conditions, particularly diabetes, uraemia, this defense is overcome 
and AGEs levels rise mainly due to overproduction of MG. Therefore, Glo-I 
appears to be a major factor associated with risk of developing the vascular 
complications of diabetes and uraemia (Thornalley, 2003e). 
The glyoxalase system is known to be the major detoxifying pathway 
and comprises of two enzymes, Glo-I and glyoxalase 11 (Glo-ll), that convert 
MG to D-lactate, through the intermediate S-D-lactoylglutathione (Mearini et 
al., 2002) (Fig. 5.1). The Glo-I is present in all human tissues and protects 
them against glycation damage. The specific activity in fetal tissues is 
however nearly three times higher as compared to adult tissues. Human Glo-
I is a dimer and GSH dependent, with its activity proportional to the cellular 
GSH concentration (Thornalley, 2003e). 
Several studies suggest Glo-I expression is enhanced in malignant 
cells and tissues, most likely to effectively detoxify MG, the level of which 
rises due to high glycolytic activity (Ranganathan et al., 1995; Thornalley, 
1995; Davidson et al., 1999). Increased expression and activity of Glo-I has 
been reported in various human cancers including those of breast (Rulli et 
al., 2001), colon (Ranganathan et al., 1993), lung (Hio et al., 1987), bladder 
and kidneys (Ilio et al., 1995), prostrate (Samadi et al., 2001) and invasive 
ovarian carcinomas (Jones et al., 2002) (Fig. 5.2). 
MDR limits the efficacy of chemotherapies in various tumours. The 
resistance of HL-60 cells to anti-tumour agent induced apoptosis was 
studied by Sakamoto et al. (2000). The cDNA subtractive hybridization with 
mRNA from tumor cell line U937 and its drug resistant variant UK711 
showed that the latter showed overexpression of Glo-I and resistance to anti 
tumour drugs, etoposide- and adriamycin- caspase activation and apoptosis. 
Use of a Glo-I inhibitor enhanced the etoposide induced apoptosis in the 
resistant cells but not in the parental U937 cells. Further, studies on various 
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Fig. 5.1-The schematic representation of the Glyoxalase enzymatic system. 
Fig. 5.2- Glo-1 enzyme activity in human solid tumour cell lines and normal 
tissue samples (Tsuruo, 2003). 
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MDR cell lines showed overexpression of Glo-I mRNA and increased Glo-I 
activity, suggesting the role of overexpression in MDR. Thus, co-treatment of 
the cell types with anticancer drug as well as the Glo-I inhibitor, BBGC 
resulted in reversal of MDR and increased sensitivity of the resistant cell 
type to the drug. It was seen that human lung carcinomas, which showed 
maximum expression of Glo-I also exhibited highest sensitivity to BBGC and 
underwent apoptosis when treated with BBGC. The cells with lower Glo-I 
activity were far less sensitive to the drug (Sakamoto et al., 2001). 
The difference in resistance observed in various cell types is in 
agreement with a study by Castro et al. (1990) on various human tumour cell 
lines that suggested that every cell line showed different levels of expression 
of the glutathione-linked enzymes like Glo-I. A unique pattern of the 
glutathione-linked enzymes was observed suggesting that the resistance 
phenotypes of the cells differed accordingly. 
Glycation by glyoxal, MG and effect of Glo-1 are now believed to play 
a critical role in aging (Morcos et al., 2005), vascular complications 
associated with diabetes (Ahmad et al., 2005; Mclellan et al., 1994), renal 
failure (Agalou et al., 2005; Rabbani et al., 2007), Alzheimer's disease (Chen 
et a!., 2004; Ahmad et a!., 2004), tumorlgenesis and MDR in cancer 
chemotherapy (Sakamoto et al., 2001). 
The cell lines used in the present study were NCI-H522, NCI-H460, 
A549, and MG63. These were selected on the basis of their high Glo-I 
expression with link to MDR characteristics (Sakamoto et al., 2001). The cell 
lines belonging to the NCI series represent a unique collection of permanent 
human tumor cell lines established by single laboratory over a period of 
nearly 16 years. More than 300 cell lines were established and mainly from 
human lung cancers which were grouped into small cell and non-small cell 
types (Adietal., 1996). 
NCI-H522 cell type was obtained from a 60 years old Caucasian 
male. The tumour was a squamous adenocarcinoma with a doubling time of 
38.2 h at an inoculation density of 2,00,00. As per information on the 
homepage of Cancer Genome Project (http://www.sanger.ac.uk/cgi-
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bin/genetics/CGP/CGHviewer.cgi), it had a homozygous mutation in the 
TF^ 53 gene. The other cell line from NCI series, NCI-H460 cell type was also 
obtained from adenocarcinoma cells from a male (age unknown) (Takahashi 
et al., 1989). It was a non-small cell lung carcinoma cell line with 
neuroendocrine properties and a doubling time of 17.8 h and the optimum 
inoculation density for these cells was 7,500. This cell type was found to 
have homozygous mutations in the following genes- CDKN2A, KRAS and 
STK11 as well as a heterozygous mutation in the PIK3CA gene. This cell 
type was part of the NCI-60 cell line set. A mutation analysis study carried 
out by Ikediobr et al. (2006) determined the complete sequence of 24 known 
cancer genes of this cell line. One hundred thirty-seven oncogenic mutations 
were identified in 14 {ARC, BRAF, CDKN2, CTNNB1, HRAS, KRAS, NRAS, 
SMAD4, PIK3CA, PTEN. RB1, STK11, TP53, and VHL) of the 24 genes. 
This study was helpful in deciding anti-tumor agents against this cell type 
(Ikediobi et al., 2006). 
As per information available on the homepage of Cancer Genome 
project, MG63 used in the study was an osteosarcoma cell line obtained 
from a 14 years old male patient, containing the homozygous mutation in the 
CDKN2A gene. Zhang et al. (2006) induced MDR in this human 
osteosarcoma MG63 cell line by exposing the cells to high and gradually 
increasing doses of cisplatin. Compared to the parental tumor cells, the 
MG63 resistant cells showed increased expression of MDR markers, P-pg 
and bcl-2, with p53 expression confirming the occurrence of MDR. In another 
study, Oda et al. (2000) isolated MDR clones of MG-63 by stepwise 
selection on exposure to increasing doses of doxorubicin. The final clones 
selected showed 121-fold higher resistance to the drug than their parental 
cell lines. 
The fourth tumor cell line used for the study was A549, an 
adenocarcinoma cell line. It was initiated in 1972 by D.J. Giard through 
explant culture of lung carcinomatous tissue from a 58 years old 
Caucasian male (Giard et al., 1973). This cell type forms confluent 
monolayers with Type II pulmonary alveolar morphology and had a 
doubling time of 22.9 h (at the inoculation density of 7,500). Further 
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studies by Lieber et al. (1976) revealed that A549 cells could synthesize 
lecithin with a high percentage of desaturated fatty acids utilizing the 
cytidine diphosphocholine pathway. The cells were also positive for keratin 
by immunoperoxidase staining. The cell line showed homozygous 
mutations in the genes- CDKN2A, KRAS and STK11. Catlonized ferritin, a 
nonspecific absorptive marker, was found to be taken up by the cells in a 
concentration-, time-, and temperature-dependent fashion. Transferrin, a 
representative receptor-mediated endocytic marker, was found to be taken 
up by the cells in a concentration-dependent and competitive fashion. 
A549 monolayers were polarized, with a greater amount of intracellular 
transferrin being transported out of the basolateral side of the cells (Foster 
et al., 1998). Pan et al. (2009) developed a multidrug resistant A549 cell 
line by exposing the cells to intermittent high doses of cisplatin. 
The HL60 cell line used in this study originated from a 35 year old 
female patient whose leukaemia was first diagnosed as acute 
progranulocytic (FAB class M3) but on further investigation the diagnosis 
was altered to acute myeloblastic leukaemia with maturation (FAB class M2) 
(Dalton et al., 1988). The HL60 cell line continuously proliferates in vitro with 
a doubling time of 20-48 h (Bimie et al., 1988; Collins et al., 1987). 
The overexpression of Glo-I In MDR tumors may have a link to the 
increased generation of MG in response to DNA repair. Because anticancer 
drugs provoke the activation of DNA repair as a result poly-(ADP-ribose) 
polymerase activation, the cells are depleted of NAD*. The resulting 
diminished glyceraldehydes-3-phosphate dehydrogenase activity causes the 
rise in levels of glyceraldehydes-3-phosphate and other triosephosphates. 
Triose phosphates are the major precursors for MG. The levels of MG 
therefore rise in tumor cells, and induce the glycation of DNA and proteins 
involved with apoptosis. This could be the cause of the cytotoxicity of MG. 
However, this toxicity of MG maybe overcome by overexpression of Glo-I 
that restricts MG levels and ensures that the tumour cells become resistant 
to the drug (Thornalley, 2008). 
178 
Pharmacological intervention to inhibit Glo-I was expected to lead to 
an increase in the cellular concentration of MG in cell systems, and the 
development of MG toxicity-particularly in proliferating cells and organisms 
(Vince et al.,1969). Several inhibitors of Glo-I have been designed from 
analogues of the hemithioacetal substrate based on glutathione derivatives 
(Thornalley, 1991). 
This part of the thesis describes measurements of DNA-AGEs levels 
in plasma and urine from control and type-2 diabetics, as well as in plasma 
samples from ESRD patients, carried out using isotopic dilution technique 
with stable isotopic standards, and by LC-MS/MS tandem mass 
spectrometry. The Glo-I inhibitor, BBGC gave promising results against MDR 
(Sakamoto et al., 2001), therefore the present work is an attempt to monitor 
its effect on the levels of DNA-AGEs in various tumour cell lines 
overexpressing Glo-I. Another objective of the present study was to examine 
if inhibiting Glo-I could promote dicarbonyl induced glycation of DNA in 
tumour cells and test the hypothesis put forward by earlier researches 
(Sakamoto et al., 2001; Ramasamy et al., 2006). 
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5.2 RESULTS 
A study to examine the possible rise in DNA damage and consequent 
increase in DNA-AGEs in diabetics and patients of ESRD was undertaken. 
Blood plasma and urinary levels of 2'-dG, 8-oxodG, MGdG, CEdGA.B and 
GdG were quantified in groups of healthy controls and patients with 
established diabetes and ESRD. 
The method employed for the measurement was optimized in order to 
restrict artifactual formation of adducts, especially by oxidation on exposure 
to high pH and elevated temperatures during pre-analytic processing. Care 
was also taken to ensure prevention of loss of analyte during working, 
storage (autosampler at 4°C) or over the 24 h period of urine collection at 
room temperature. 
The concentration of the various adducts in plasma and urine 
samples analyzed using the optimized protocol gave interesting frequency 
trends. Fig. 5.3 shows the plasma levels of 2'-dG, the important precursor of 
several DNA-AGEs and 8-oxodG alongwith levels of DNA-AGEs- MGdG, 
CEdGAB, GdG in blood plasma of healthy controls and type-2 diabetic 
human subjects. Ninety six percent controls showed plasma 2'-dG median 
levels at 1.1 nM whereas 30% of the diabetics had the plasma 2'-dG levels 
of 4.2 nM (Fig. 5.3 (a)). The difference in 2'-dG levels of diabetics as 
compared to controls was significant. The median levels of 8-oxodG were 
0.15 nM for controls and 0.21 nM for diabetics (Fig. 5.3 (b)) but the 
difference was not statistically significant. MGdG level in type-2 diabetics 
showed more wide variation and was in the range 0.1-6.9 nM, wherein 48% 
subjects had plasma levels of the adduct at 1.1 nM and 18% between 2-2.5 
nM as compared to 0.8 nM in case of 71% controls (Fig. 5.3 (c)). CEdGAB 
levels in plasma from control and diabetic subjects were quite comparable 
and more than 90% population of normal and diabetics had CEdGA.e 
concentration at 0.2 nM (Fig. 5.3 (d)). Fig. 5.3 (e) shows that plasma GdG 
levels in the controls and diabetics were 0.07 nM and 0.31 nM respectively. 
The difference in GdG concentration between control and diabetics was 
found to be highly statistically significant (p<0.001). 
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Fig. 5.3- The frequency distribution plots for the various adducts of 
nucleoside oxidation and glycation measured in plasma from 
healthy controls and type-2 diabetics. The plasma samples from 
control and type-2 diabetic patients were analyzed by LC-MS/MS 
and the concentration of (a) deoxyguanosine, oxidation adduct 
(b) 8-oxodG, and glycation adducts (c) MGdG, (d) CEdGA.e , (e) 
GdG was estimated and plotted against frequency of occurrence 
of those concentrations in the control and diabetic subjects. 
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[Plasma 2'-dG](nM| 
Subjects n Median Range p 
Control 28 1.1 0.8-5.2 — 
Diabetic 56 4.2 0.8-13.7 <0.001 (Mann-Whitney) 
Diabetic 
Control 
2 4 6 
Plasma dG (nM) 
[Plasma 8-oxodG] (nM) 
Subjects n Median Range p 
Control 23 0.15 0.04-0.39 — 
Diabetic 52 0.21 0.01-0.46 0.08(t-te! 
DIabetJc 
Control 
(a) 
0.1 0.2 0.3 
Plasma OxodG(nM) 
(b) 
[Plasma GdG](nM) 
Sut)iects n Median Range p 
Control 28 0.07 0.04-0.20 — 
Diabetic 56 0.31 0.14^.61 <0.001(Mann-wtiitney) 
Diabetic 
Control 
0.2 0.4 
Plasma GdG (nM) 
Diabetic 54 1.1 0.1-6.9 0.343 (Mann-Whitney) 
(e) [Plasma CEdG^g] (nM) 
Sut)jects n Median Range p 
Control 24 0.18 0.05-7.10 — 
Diabetic 48 0.20 0.02-14.4 0.104 (Mann-Whitney 
Diabetic 
Control 
3.0 4.S 
Plasma MGdG(nM) 
(c) 
[Jabetlc 
Control 
Plasma CEdG(nM) 
(d) 
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Urine samples were also analyzed for the DNA-AGEs. The results in 
Fig. 5.4 (a) show that 70% of control but only 58% of diabetics had 2'-dG 
levels below 2 nM. Fig. 5.4 (b) shows 35% diabetics had nnedian 8-oxodG at 
9.6 nM while the controls showed levels of 11.6 nM and the difference 
between control and diabetic levels was statistically significant (p < 0.05). 
MGdG levels in urine from type-2 diabetics were 3.0 nM in 57 % of the 
patients whereas 78 % controls had MGdG levels at 2.7 nM (Fig. 5.4 (c)). 
Majority of diabetics had CEdGA,B levels at 0.4-0.8 nM while the levels in 
controls were 0.54 nM (Fig. 5.4 (d)). The difference was not satistically 
significant. Ninety-six percent of the controls had median urine GdG 
concentration of 0.13 nM whereas 23% of diabetic patients showed the GdG 
concentration at 0.8 nM (Fig. 5.4 (e)). Difference between the urinary levels 
of GdG in controls and type-2 diabetics (p< 0.001) was highly significant. 
The median values of the various adducts in plasma and urine of control and 
diabetics are summarized in Table 5.1. The data shows that among the 
DNA-AGEs, MGdG occurs in highest concentration but the levels of the 
adduct were unaffected neither in plasma nor urine in the diabetics. On the 
other hand diabetics contained high level of GdG in the plasma and excreted 
over 6 - fold higher concentration of the adduct in urine. 
Clinically creatinine clearance rate is used to measure glomerular 
filtration rate (GFR) and in turn the overall kidney function. It was therefore 
considered of interest to investigate whether a relationship exsist between 
creatinine clearance rate in patients of type-2 diabetes and the clearance of 
the DNA-AGEs from circulation. The creatinine clearance rate of healthy 
controls was 94.1 ±32.6 ml/min/1.73m^ which was markedly higher as 
compared to 86.1±23.7 ml/min/1.73m^ observed in case of diabetics without 
nephropathy and 49.7±31.4 ml/min/1.73m^ for diabetics with nephropathy. 
The plots of creatinine clearance rate against plasma MGdG, CEdGA.B and 
GdG concentration in control and type-2 diabetics show that the decrease in 
creatinine clearance rate in patients of type-2 diabetics (especially those with 
diabetic nephropathy) was accompanied by enhanced levels of the adducts 
in plasma (Fig. 5.5 (c)). This was estimated by comparing the median values 
of the various adducts in plasma of control and diabetics. However, the rise 
1 0 1 
Fig. 5.4 - The frequency distribution plots for the various adducts of 
nucleoside oxidation and glycation measured in urine from 
healthy controls and type-2 diabetics. The urine samples from 
control and type-2 diabetic patients were analyzed by LC-MS/MS 
and the concentration of (a) deoxyguanosine, oxidation adduct 
(b) 8-oxodG, and glycation adducts (c) MGdG, (d) CEdGA.B, (e) 
GdG was estimated and plotted against frequency of occurrence 
of those concentrations in the control and diabetic subjects. 
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[Urine2'-dG](nM) 
Subjects n Median Range p 
Control 27 2.0 1.5-9.2 — 
Diatjetic 56 25 0.70-14.8 0.180 (Mann-wtiitney) 
60 
^^ 
Qabetic 
Control 
;20 
- 0 
pne8-oxodG](nM) 
Subjects n Median Range p 
Control 27 11.6 3.7-39.0 — 
Diabetic 56 9.6 2.9-25.7 <0.05 (Mann-Whitney) 
< 6 8 10 12 
dG levels In urine (nM) 
(a) [Urine GdG](nM) 
Subjects n Median Range p 
Control 26 0.13 0.05-0.35 — 
Diabetic 48 0.83 0.12-2.5 <0.001 (Mann-Whifney) 
" 5 1" 15 20 25 V V T 
OxodG levels in urine (nM) 
(b) 
.Diabeiic ControT 
Qabetic 
Control 
P 'T 
GdG levels in urine (nM) 
(e) [Urine MGdG](nM) 
Sutijects n Median Range p 
Control 27 2.7 1.2-6.9 — 
Diabetic M 3.0 0.9^.0 0.888 (Mann-Whitney) 
pneCEdG^BK"** ) 
Subjects n Median Range p 
Control 23 0.54 0.12-1.3 -
Diabetic 54 0.55 
Diabetic 
(^ntrol 
0.14-2.4 0.469 (Mann-Whitney) 
Diabetic 
Control 
levels in urine (nM) 
(c) 
CEdGlevels in urine (nM) 
(d) 
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Table 5.1- The median levels of the DNA glycatjon and oxidation adducts in 
plasma and urine obtained from control and type-2 diabetics. 
Adduct Plasma concentration (nM) Urine Concentration (nM) 
Control Diabetic p-value Control Diabetic p-value 
2'-dG 1.1 4.2 <0.001 2.0 2.5 > 0.05 
8-oxodG 0.15 0.21 > 0.05 11.6 9.6 < 0.05 
MGdG 0.81 1.1 >0.05 2.7 3.0 > 0.05 
CEdGAB 0.18 0.2 >0.05 0.54 0.55 > 0.05 
GdG 0.07 0.31 <0.001 0.13 0.83 <0.001 
The various significance levels were p-value <0.05, p-value <0.01, p-value 
<0.001. 
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in GdG levels in the plasma from diabetics with nephropathy was statistically 
significant (p<0.001, independent t-test). 
Similarly, the median values of excretory MGdG, CEdGA.e and GdG 
concentrations in urine showed that the levels of these adducts were more 
marked in urine from type-2 diabetes than controls. Further those with 
diabetic nephropathy showed increase in the urinary levels of the nucleotide 
AGEs- CEdGA.B and GdG (Fig. 5.6 (a), (b) and (c)). The rise in urinary levels 
of CEdGA.B and GdG in case of type-2 diabetics with nephropathy was 
statistically significant to the limits of p<0.05 and p<0.001 respectively 
(independent t-test). 
In another study, various adducts of oxidative and glycation damage 
were measured in plasma from nomnal healthy controls and ESRD subjects. 
It was seen in Fig. 5.7 (a-c) that in the patients of ESRD, the plasma 
concentration of 8-oxodG, MGdG and CEdGA.B were high as compared to 
the levels of these adducts in nonnal healthy controls. However, while GdG 
concentration also appeared high in plasma of patients with ESRD, the 
values were not significant when compared to controls (Fig. 5.7 (d)). As 
evident from Table 5.2, MGdG, 8-oxodG, CEdGA.e levels increased 3, 2.8, 
2.2 fold, respectively during ESRD. 
Studies on various tumor cell lines with Glo-I overexpression and 
showing MDR characteristics, were carried out in collaboration with Dr. 
Thomas Santarius, Cancer Genome Project, Welcome Trust Sanger 
Institute, University of Cambridge, Cambridge, U.K. Dr. Santarius screened 
the different cell lines for Glo-I activity and expression, and studied them for 
Glo-I gene amplification by determining relative Glo-I mF?NA levels using real 
time PCR. A gene was called amplified if the relative quantity of that gene 
was greater than two. 
The results obtained showed that NCI-H522 lung cancer cell line 
showed highest mRNA levels which correlated with maximum Glo-I activity 
as reported by Sakamoto et al. (2001). This was followed by Osteosarcoma 
cell line MG63. The lung cancer cell lines, A549 and NCI-H460 showed 
lower Glo-I mRNA levels (Table 5.3). Further, the IC50 concentration for the 
dmg, BBGC was determined for the various cell lines as detailed in the 
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Table 5.2 - Statistical analysis of the plasma nucleotide adducts measured in 
human subjects from normal healthy controls and ESRD population. 
8-oxodG 
MGdG 
CEdGA.8 
GdG 
Mean (+S.D.) 
0.25510.100 
0.566+0.179 
0.179±0.079 
0.11810,023 
Control 
Range 
0.186-0.370 
0.440-0.880 
0.109-0.309 
0.092-0.143 
Median 
nM 
0.209 
0.510 
0.172 
0.114 
End Stage Renal Disease 
Mean (±S.D.) 
0.73410.323 
1.73410.800 
0.40410.256 
0.12410.078 
Range 
0.382-1.277 
0.620-2.680 
0.173-0.906 
0.057-0.289 
Median 
0.707 
1.725 
0.317 
0.092 
p-value 
<0.01 
<0.01 
<0.05 
>0.05 
The various significance levels were p-value <0.05, p-value <0.01, p-value 
<0.001. 
Table 5.3 - mRNA levels and enzyme activity of Glo-I in various MDR tumor 
cell lines. 
Ceil line iC 50 GL01 mRNA* GL01 activity" 
pM GL01/ p-actin mRNA Mmol/min/mg protein 
N.A. 
8.4.710.10 
0.8110.02 
0.99+0.04 
MG63 
NCI-H522 
NCI-H460 
A549 
3.8 
7.0 
19.8 
23.5 
9.5 
30 
0.9 
5.9 
Note: ^ GL01 mRNA - relative GL01 mRNA levels measured by real time 
PCR (determined by Dr. Santarius) and *^ GL01 activity - as reported by 
Sakamoto et al. (2001).The values are mean l S.D. from three independent 
experiments. N.A.- not available. 
194 
material and methods, and it was found to vary between 3.8 f.iM for MG63 to 
23..5 ^ M for A549 tumour cells (Table 5.3). IC50 represents the concentration 
of a drug that is required for 50% inhibition of cell accumulation in vitro. 
Thus, it was expected that cell types with low IC50 will be more sensitive to 
the action of the inhibitor and as a result have higher cellular MG levels, and 
consequently increased apoptotic index after inhibitor treatment while cells 
with high values of IC50 concentration would show decreased sensitivity to 
the inhibitor. 
The real time quantitative PCR studies carried out by Dr. Santarius 
showed that amplification of the Glo-I gene in the cell lines MG63 and NCI-
H522 was two fold or more whereas the cell types A549 and NCI-H460 did 
not show such enhancement in gene amplification. The study also 
concluded that there was substantial variation in sensitivity of the cell lines to 
this drug. The cell lines with the amplification were more sensitive to Glo-I 
inhibitor treatment as compared to those without amplification (Sakamoto et 
al., 2001). This is indicated in the low values of IC50 for the drug BBGC in the 
cell types- MG63 and H522 (those showing amplification of Glo-I) in 
comparison to those observed in cell types without amplification (A549 and 
NCI-H460 cell types) (Table 5.3). 
A large scale cell culture was carried out for the cells types, in 
presence or absence of 20 \iM Glo-I inhibitor, BBGC for 24 h. After 
enzymatic hydrolysis of the DNA extracted from the cultures, the hydrolysate 
was studied using the LC-MS/MS for the various mariners of DNA oxidation 
and glycation. 
Fig. 5.8 shows that cell types with amplification have higher levels of 
the adducts, MGdG, GdG, 8-oxodG. The levels of CEdGA,B were however 
somewhat higher in case of A549 and H460 cells exhibiting no amplification 
of Glo-I as compared to the MG63. CEdGA,B levels in H522 cells were 
however the highest among the cells studied. 
Cell types without amplification of the Glo-I gene showed little change 
in the levels of MGdG, GdG and 8-oxodG (Fig. 5.8 (a,c,d)), on treatment with 
the Glo-I inhibitor, except the A549 cell type that showed significant rise in 
CEdGA,B (Fig. 5.8 (b)). The cells with amplification of the Glo-I gene showed 
195 
A549 H460 MG63 H522 
(a) 
A549 H460 M063 H522 
(c) 
o 
m 
9 
2 70 
o 
a 
o 60-i 
&50 
« 40 
A549 
X 
O 
H460 MG63 H522 
(b) 
A549 H460 MG63 H522 
(d) 
197 
only a modest increase in the formation of the adducts, MGdG and CEdGA,B 
after inhibitor treatment, although the difference as compared to the controls 
was however not satistically significant. Increase in the GdG levels in MG63 
and H522 cells was observed but the rise was statistically significant only in 
case of the latter. H522 cells also exhibited a marked increase in the 
concentration of 8-oxodG in response to BBGC treatment but inspite of the 
difference of the mean value from the control, the rise was not satistically 
significant due to large variation between the samples. 
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5.3 DISCUSSION 
Glycation is a recognised contributor to diabetic nephropathy, ESRD 
and researches have focused on the pathogenic properties of various 
protein AGEs such as N£-(carboxymethyl) lysine (CML), pentosidine and 
imidazolone. Diabetic patients with renal impairment show decreased urinary 
excretion of fluorescent AGEs and CML accompaniejd by their elevated 
serum levels (Tanji et al., 2000; Wagner et al., 2001). 
Dicarbonyl compounds like MG and glyoxal are implicated in carbonyl 
stress, increased formation of AGEs and the development of diabetic 
nephropathy (Jadidi et a!., 2003). Type-2 diabetes is known to be associated 
with increased MG and glyoxal levels (McLellan et al., 1994) as well as 
oxidative stress (Ceriello et al., 2004). Hyperglycemia in diabetes results in 
excessive accumulation of glyceraldehyde-3-phosphate and 
dihydroxyacetone phosphate which are precursors of MG. Jadidi et al. 
(2003) reported that MG derived protein AGEs - methylglyoxal derived 
hydroimidazolone A/5-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine (MG-
H1) and Ns-(l-carboxyethyl) lysine (CEL) increased two-fold in glomerular 
protein of Streptozotocin (STZ) induced diabetic rats. Little work is however 
available on DNA-AGEs as a possible measure of diabetes associated 
complications and this study was therefore undertaken. 
Jakus and Rietbrock (2004) observed that Hb-AGEs represent only 
the metabolic status, whereas elevated serum AGEs correlate better with the 
complications associated with diabetes and it was proposed that the levels of 
serum AGEs may prove to be more useful as early biochemical markers of 
microangiopathy in diabetics. The increased levels of protein AGEs in the 
serum have been shown to reflect the progression of morphological changes 
in the basal membrane thickness and mesangial fraction in the kidney (Berg 
etal., 1997). 
Among the DNA-AGEs, CEdGA,B was the first to be identified as a 
major product of glycation damage to nucleotides in in vitro experiments 
(Ochs and Severin, 1994). A competitive ELISA using a monoclonal anti-
CEdG antibody was used to measure CEdGA.B levels in normal human urine 
(Schneider et al., 2004). The work suggested that glycation induced DNA 
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damage leading to the formation of the AGE indeed occurs in vivo. In a more 
recent study, Li et al. (2006) reported the accumulation of CEdGA.B in the 
kidneys of diabetics and aorta of HD patients. Synold et al. (2008), in a 
recent study measured the CEdGA,B levels in the urine of normal and 
Streptozoticin induced diabetic Sprague - Dawley rats, employing LC-MS/MS 
with ESI and using isotopic CEdGA.e standard for quantitation. The study 
showed that 77pg/ml CEdG was excreted by control rats whereas the 
induction of diabetes increased the urinary levels ~ 4 fold. 
The ability of the kidney to filter the toxic AGEs out of the body was 
affected in case of diabetic nephropathy where the glomerular filtration rate 
(as represented by the creatinine clearance rate) was decreased. As a result 
the levels of serum AGEs in diabetics with nephropathy were higher as 
compared to those of patients without the complication (Ono et al., 1998). 
Protein AGEs are also known to accumulate in plasma during ESRD 
and promote damage in vivo (Dawnay, 2003; Odani et al., 1999). Besides, a 
direct correlation was observed between plasma protein AGE levels (CML 
and imidazolone) and DNA damage in ESRD as estimated by the 
micronuclei frequency assay (Fragedaki et al., 2005). It was suggested that 
higher incidence of cancer observed in ESRD patients may result from 
increased AGE induced DNA damage and resulting mutations (Sebekova et 
al., 2007). Plasma AGEs derived from proteins are removed by the kidney, 
and decreased renal function leads to rise in plasma AGEs and their 
accumulation in various tissues (Monnier et al., 1992; Schinzel et al., 2001). 
A study was therefore carried out to measure the levels of DNA-AGEs 
in biological fluids from healthy controls and patients of type-2 diabetes and 
ESRD. All possible efforts were made to ensure specificity/accuracy in the 
analyses. The ultrafiltrates of the biological fluids were spiked with isotopic 
standards, ensuring accurate peak identification. Stable isotopic dilution 
analysis liquid chromatography with tandem mass spectrometric detection 
(SILC-MS/MS) employed for the analysis of the plasma and urine samples 
did not necessitate tedious sample processing. Artifactual oxidation was 
minimized and analysis time reduced since ultrafiltration was the only 
purification step employed in the sample processing. Switching of valves 
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where the flow was directed towards waste for the initial 4 min of the run, 
prevented impurities from entering the mass spectrometer. This was an 
improvement over the earlier procedures used for preparation and analysis 
of biological samples, wherein solid phase extraction was used for sample 
clean up (Gemiadnik et al., 1997; Ravanat et al., 1998) prior to LC-MS/MS 
quantitation. Under the conditions used the limit of detection for the adducts 
MGdG, CEdGA,B, GdG and 8-oxodG were 0.08 pmol, 0.02 pmol, 0.03 pmol 
and 0.06 pmol respectively (Table 2.1). 
The study is a first of its kind in which the major markers of oxidative 
and glycation damage to DNA have been measured in human subjects using 
stable isotopic dilution analysis liquid chromatography with tandem mass 
spectrometric detection. 
Data.in Fig. 5.3 and 5.4 (b-d) shows a remarkable increase especially 
of GdG both in plasma and urine of diabetics. Diabetes is associated with 
accumulation of MG and glyoxal (McLellan et al., 1994, Jadidi et al., 2003). 
Increased levels of 2'-dG alongwith dicarbonyls like MG and glyoxal could 
promote the accumulation of nucleotide glycation adducts like MGdG, 
CEdGA,B and GdG in plasma and excretion in urine from diabetics. Jadidi et 
al. (2003) showed that plasma levels of glyoxal in diabetic rats were 
moderately higher as compared to MG and 3-deoxyglucasone. 
It is known that hyperglycemia is the initiating event for both 
intracellular and extracellular AGE formation in diabetics (Brownlee, 2001). 
Thornalley et al. (1999) suggested multiple routes of glyoxal formation from 
glucose, which explain the enhanced fonnation of glyoxal in diabetes (as a 
result maximum generation of GdG). Besides, the intracellular autooxidation 
of glucose may also promote glyoxal fomnation that could further contribute 
towards enhanced AGE formation (Brownlee, 2001). Manini et al. (2006) 
demonstrated that removal of oxygen decreased glyoxal fomfiation. Besides, 
Murata-Kamiya et al. (1997) stated that glyoxal generated from DNA and 
DNA precursors, immediately reacts with the DNA and the precursors to 
cause base modifications resulting in even higher GdG levels. 
Fig 5.3 shows that 2'-dG levels in the plasma of type-2 diabetics were 
enhanced ~ 4 fold. This rise in nucleotide levels could be attributed to DNA 
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damage and/or its decreased renal clearance in patients with type-2 
diabetes. The enhanced levels of 2'-dG may also not relate to increased 
degradation of circulating nucleic acids/polynucleotides since nucleases 
seem to be inhibited in diabetes. Kocic et al. (2008) observed that activity of 
RNase and a specific nuclease in the plasma from diabetics was significantly 
decreased as a result of hyperglycemia. 
The reported concentrations of MG and glyoxal in human blood 
plasma from normal individuals were in the range of 100-120 nM 
(Beisswenger et al., 1999; Strzinek et al., 1972) while cellular concentrations 
of MG ranged between 1-5 ^M and that of glyoxal between 0.1-1 ^M (Dobler 
et al., 2006). Under conditions of limiting a-oxoaldehyde, prevalent in vivo, 
the major nucleotide AGEs are the imidazopurinone derivatives, MGdG 
(Schneider et al., 1998; Papoulis et al., 1995) and GdG (Kasai et al., 1998). 
The adducts are unstable at high pH and temperatures and necessitate mild 
conditions of DNA extraction and hydrolysis (Thornalley, 2008). The earlier 
researchers (Seidel and Pischetsrieder, 1998a; Frischmann et al., 2005) 
carried out the incubation reaction of DNA/deoxyguanosine with L-ascorbic 
acid, L-dehydroascorbic acid, D-glucose, D/L-glyceraldehyde, MG or 
dihydroxyacetone at temperatures (i.e. 40 and 70°C) that could promote the 
degradation of the labile cyclic adduct (MGdG). Therefore, the observation 
that CEdGAB was the major adduct fomried on glycation of DNA in vitro and 
in vivo therefore needs to be reexamined. 
The order of nucleotide adduct levels in plasma from type-2 diabetics 
was: MGdG>GdG>8-oxodG>CEdGA,B, whereas in urine samples from type-2 
diabetics it was 8-oxodG>MGdG>GdG>CEdGA,B. Artifactual 8-oxodG 
formation occuring during the 24 h time period of urine collection may 
contribute towards the high levels of the adduct which may result in 
increased 8-oxodG concentration in the urine. 
Our CEdGA,B estimates in plasma from nonnal healthy controls were 
in the range -1.37-185.39 ng / mg creatinine, whereas those in urine were in 
the range - 0.058-0.540 ng / mg creatinine (Fig. 5.3 and 5.4). An earlier 
study showed that CEdGA.s levels in the urine of normal healthy human 
subjects determined using immunoassay were higher and in the range -1.2-
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117 ng equiv./ mg creatinine (Schneider et al., 2004). The high values of the 
adduct reported in the study may have resulted from the poor specificity of 
the monoclonal antibody used. Besides MGdG maybe transfomned to 
CEdGA.B in the samples during the pre-analysis processing due to exposure 
to high pH. 
A procedure for the successful isolation of both MGdG as well as 
CEdGA,B for use as standards during quantitative studies was developed. 
There have been few quantitative estimates of nucleotide AGEs in 
mammalian cells. Thomalley (2008) showed the presenc^ e of MGdG, GdG as 
well as 8-oxodG in DNA extracted from human MNLs, with maximum levels 
being those of MGdG. Similar results were obtained in the present study on 
DNA obtained from MNLs (Fig. 4.9). 
Figures 5.3 and 5.4 show that MGdG was the major AGE both in 
plasma and urine. There was however no significant increase in MGdG 
levels either in plasma or urine of diabetic patients. Similarily, no increase 
was observed in plasma and urine CEdGA.B in diabetics. As has been 
mentioned, rats rendered diabetic with STZ excrete four-fold higher CEdG 
compared to controls (Synold et al., 2008). Apparently diabetics do not 
exhibit enhanced excretion of adducts as observed in case of diabetic rats. 
The concentration of all the adducts (Table 5.1) excreted in urine 
were higher as compared to those in plasma, presumably due to 
concentration of blood plasma by the kidney. On comparing the median 
values for the adducts, it is evident that in case of type-2 diabetics the 
urinary levels of only GdG increased a significant 6.3- fold while those of 2'-
dG, MGdG, 8-oxodG and CEdGA.e showed no such increase in diabetics as 
compared to controls. On the otherhand, the plasma concentration of 2'-dG 
and GdG increased 3.8 and 4.4 fold in case of diabetics. The levels of 
CEdGA,B and MGdG registered only a marginal rise. 
Our data in Fig. 5.3 and 5.4 shows that although in samples obtained 
from type-2 diabetics, the levels of the MGdG adduct are higher as 
compared to the other DNA glycation adducts (CEdGA,B and GdG) analysed, 
but these did not differ significantly from the levels observed in normal 
healthy controls. This maybe related to a high variation among the 
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individuals and lack of very large sample size. GdG levels in the type-2 
diabetics were significantly elevated in both plasma and urine as compared 
to the controls suggesting remarkable enhancement in the formation of GdG. 
Our data on MDR tumour cells also supports this observation. The H522 cell 
type having highest Glo-I activity also showed significant rise in GdG levels 
after the inhibitor treatment (Fig. 5.8). Therefore, this study further suggests 
that GdG maybe considered as a major biomarker for studying diabetes. 
Accumulation of AGEs in proteins has a catastrophic outcome in 
diabetes, affecting major tissues of the human body and resulting in various 
micro- and macrovascular complications associated with diabetes including 
nephropathy (Sugiyama et al., 1996; Forbes et al., 2003). The results in 
Figures 5.5 and 5.6 show that diabetic nephropathy is accompanied by 
accumulation of DNA-AGEs like GdG in the plasma with significantly 
enhanced excretory levels of GdG and CEdGA.e in the urine. This correlates 
with the findings of Li et al. (2006) who demonstrated an increased 
accumulation of CEdGA,B in the kidneys of diabetic patients with 
nephrophathy and the aortas of hemodialysis patients. The number of 
CEdG-positive cells in glomeruli was significantly increased in diabetic 
nephropathy suggesting that CEdGA,B, a DNA-linked AGE, may lead to loss 
of genetic integrity in the kidney of patients with diabetic nephropathy. 
The data in Table 5.2 suggests that there is significant accumulation 
of the DNA- AGEs - MGdG and CEdGA,B but not GdG in plasma obtained 
from patients of ESRD. These observations need to be substantiated with 
additional analysis on ESRD patients as only 13 patients were available for 
the present study. Several other causes of renal failure in ESRD have been 
stated including glomerulonephritis, polycystic kidney disease, interstitial 
nephritis, reflux nephropathy, besides diabetes (Fragedaki et al., 2005). It is 
noteworthy that the patients recruited for the present study were not diabetic. 
In these patients the DNA damage and resultant DNA-AGE formation may 
therefore be influenced by factors other than those that influence DNA 
damage in diabetes. As a result the order of nucleotide adduct level in 
plasma from patients of ESRD was different from that observed in type-2 
diabetics. 
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It has been shown that the plasma concentration of AGE precursors-
i.e. dicarbonyls like MG and glyoxal are elevated during uraemia in ESRD 
patients (Miyata et a!., 1999). Their accumulation is not due to impaired renal 
clearance, instead multiple routes channel together to increase formation of 
the cellular those phosphates, the precursors for MG formation (Dawnay, 
2003; Odani et al., 1999). Fig. 5.7 shows that plasma samples from ESRD 
patients have greatly enhanced MGdG levels (Mean +S.D.=1.734 ± 0.8 nM 
as compared to those of normal healthy controls (Mean ±S.D. = 0.566 ± 
0.179 nM), (p=0.004). Similarly the degradation product of MGdG adduct, 
the carboxyethyl derivative of deoxyguanosine (CEdGA.e) was also 
significantly elevated in the plasma samples from ESRD (Mean ±S.D. = 
0.404 ±0.256). The order of nucleoside adduct levels in plasma from ESRD 
patients was - MGdG>8-oxodG>CEdGA,B>GdG. Plasma samples obtained 
from both type-2 diabetics as well as ESRD patients showed high levels of 
MGdG (Fig. 5.7), although the difference from controls in the former was not 
statistically significant. It has also been shown in earlier studies that free 
protein-AGEs are present in blood plasma of patients with a relatively high 
renal clearance and accumulate markedly in ESRD (Meerwaldt et al., 2009). 
Therefore, significant accumulation of the DNA-AGEs - MGdG and CEdGA.B 
was observed in the plasma from ESRD patients (Fig. 5.7) 
Several of the previous researches focused on the 8-oxodG and 8-
OHdG measurements in urine from control and diabetics (Weimann et al., 
2001; Cooke et al., 2008). Our results of urinary 8-oxodG levels in controls 
(i.e. 15.2 ± 8.8 nM) are lower than the previously reported value (i.e. 28 ±2 
nM /24 h) as determined by HPLC-MS/MS with ESI (Weimann et al., 2002). 
The high values reported by Weimann et al. (2002) could arise, as discussed 
earlier, due to the additional heating step used by them during the sample 
preparation in order to dissolve the precipitate formed. 
This study provides evidence for in vivo formation of MG and glyoxal 
derived nucleotide AGEs in human subjects as well as oxidation products 
and that these adduct levels are greatly elevated during disease states like 
type-2 Diabetes and ESRD, respectively. 
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It has been shown that some MDR tumour cells use the Glo-I 
enzymatic machinery as a defense tool against glycation-mediated apoptosis 
(Tsuruo et al., 2003). Therefore, the effect of the Glo-I inhibitor (BBGC) on 
the induction of MG mediated glycation in DNA in the MDR tumour cells was 
examined. The results obtained show that cell types with amplification of 
Glo-I gene and thus, enhanced Glo-I activity were found to be more sensitive 
to the inhibitor treatment as seen in case of NCI-H522 and MG63 tumour 
cells. This was in coherence with earlier reports on MDR tumour cells 
(Sakamoto et al., 2001). The results m Fig. 5.8 show that the GdG nucleotide 
adduct levels in cell lines with Glo-I gene amplification (NCI-H522) and 
CEdGA,B levels in A549 (cell type without amplification) were significantly 
elevated after inhibitor treatment. 
MG is known to enhance cisplatin induced apoptosis by activating 
protein kinase C6 and reports also show that tumor necrosis factor (TNF) 
induces a substantial increase In intracellular levels of MG and a specific 
MG-derived AGE (Tsuruo et al., 2003). Besides MG modification was 
involved in Hsp27 oligomerizatlon to prevent cytochrome c-mediated 
caspase activation during apoptosis (Sakamoto et al., 2002). This suggests 
that MG modification of proteins could be a targeted process and that MG 
may function as a signal molecule during the regulation of cell death. Since 
inhibifion of Glo-I is likely to cause accumulation of MG, and in turn induce 
DNA modification and protein cross-links, DNA damage or inactivation of 
some anti-apoptotic proteins by MG could be an initial activator of apoptosis 
(Tsuruo etal., 2003). 
It was anticipated that levels of MGdG and CEdGA,B, and the other 
MG derived AGEs would rise after inhibitor treatment. No significant increase 
in MGdG or CEdGA,B was however observed. It is not unlikely that enhanced 
generation of MG as a result of BBGC induced inhibition of Gto-I may not 
reach DNA. Instead the generated MG may rapidly react with proteins and 
induce apoptosis through pathways not involving DNA-AGEs. 
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Wobum House. 
20-24 Ta\istock Square. 
LondoaWClH9HF. 
United Kinerdom 
C ommonwealtli Spilt-Sile scholai-ship: Miss Sabar Vimvi 
MJSS Sahar Wans completed her Commonwealth Split-Site scholarship in my research team 
at Warwick Medical School. Umversm- of WarvMck. Coventry. U K. over the penod October 
2007 - September 200S. She has now returned to her home universiW. Umversity of Aligarh. 
.Aligarfa. India 
Sahar vvoriced ou a project on •GlyTaiion of nucleotides and DNA" She perfonned 
experimental research that included srathesis of analytical standards, analytical method 
dc\elopnient. nucleotide and DNA modification by sugars and analysis of ghxated 
nucleotides m model in \itro s>-stems and in \ivo - particularly m relation to diabetes, kidney 
fiiiluie and multidrug resistance in cancer chemotherapy. This m;olved an:il>'sis of san^iles 
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Cambndge. Cambridge. U K and Health and Nutntion Centre. Umversity of Gtaz. Austna. 
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presentanoa 
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